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5Abstract 
Background and aim: The worldwide increasing prevalence of  overweight and obesity 
raises concerns for health. There is a clear need for preventive strategies, because 
current preventative interventions have proven to be unsuccessful in the long term. 
New strategies may be developed based on targets in the small intestine by activating 
satiety signals. The thesis aimed to investigate small intestinal targets contributing 
to food intake regulation. These targets included serotonin, the vagal nerve and the 
intestinal brake mechanism. 
Methods: The effects of  ileal stimulation with safflower oil (lipid mixture), casein 
(protein), sucrose (carbohydrate) and rebaudioside A (non-caloric sweetener) on GLP-
1 and PYY release were investigated by applying an porcine ex vivo intestinal segment 
model. The same model was also used to investigate if  serotonin is involved in  (non-)
nutritional-induced GLP-1 and PYY release.  
The contribution to satiation of  GLP-1 and CCK receptors at the vagal nerve, was 
studied by investigating  the effects of  GLP-1 and CCK receptor antagonists on ad 
libitum food intake in a pig model of  subdiaphragmatic vagotomy.  
Two placebo controlled randomized crossover studies were performed in healthy 
volunteers to investigate the effects of  small intestinal macronutrient delivery on ad 
libitum food intake and satiety signals. The first study compared the effects of  duodenal, 
jejunal and ileal casein delivery on ad libitum food intake and satiety signals.  The second 
study investigated if  ileal delivery of  all three macronutrients results in activation of  
satiety signals and reduction in ad libitum food intake.  In addition, it was investigated 
if  ileal delivery of  native casein is efficiently digested and absorbed and does not result 
in adverse effects. In both studies the nutrients were delivered to the small intestine by 
inserting a nasointestinal feeding tube in healthy volunteers.     
Results: All macronutrients and rebaudioside A stimulated GLP-1 and PYY release 
from ileal tissue segments. Protein and fat stimulated serotonin release. Inhibiting the 
reuptake of  serotonin resulted in enhanced nutrient induced GLP-1, PYY and CCK 
release. Serotonin stimulated GLP-1 release from enteroendocrine cells via a serotonin 
receptor mediated process. 
Results of  the in vivo pig study showed that antagonism of  the CCK receptor increased 
food intake in both vagotomized and sham operated pigs. Blocking the GLP-1 receptor 
did not affect food intake in both groups.
The human studies showed that ileal protein delivery inhibited food intake and activated 
satiety signals as compared to duodenal or jejunal protein delivery.  Also, ileal delivery of  
small quantities (51.7 kcal) of  each macronutrient decreased food intake and activated 
satiety signals. In addition, it was shown that ileal delivery of  native casein resulted in 
a  time and concentration depended increase in plasma concentrations of  amino acids 
and did not result in activation of  immune responses nor  in gastrointestinal complaints. 
6Conclusions: The data presented in this thesis show that ileal delivery of  all 
macronutrients results in activation of  satiety signals and reduction of  food intake. 
Stimulation of  the ileum resulted in the strongest activation of  satiety signals and 
inhibition of  food intake compared to duodenal and jejunal stimulation. Besides direct 
nutrient-receptor interaction, the ileum senses (non-)nutritional stimuli via serotonin 
mediated processes resulting in GLP-1 release. In conclusion, these results demonstrate 
that targeting the ileum with small amounts of  macronutrients is safe and has potential 
as a weight management strategy. 
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Worldwide, the prevalence of  obesity 
has more than doubled since 1980. In 
2014, more than 1.9 billion adults were 
overweight of  which 600 million were 
obese (1). In the Netherlands the number 
of  adults being overweight and obese 
has increased as well. Between 1985 and 
2014 the number of  overweight people 
increased from 33.1% to 43.8%, of  which 
12.2% were obese. By comparison, in 1985 
the number of  people that were obese in 
the Netherlands was only 5.1% (2). 
The excessive accumulation of  body fat is 
associated with various health risks such 
type II diabetes, cardiovascular diseases and 
cancer (3). These health risks are associated 
with increased all-cause mortality (4). 
Because of  the established health risks and substantial increases in prevalence, obesity 
has become a major global health challenge (5). 
Not surprisingly there is a clear need for preventive strategies, as well as the need for 
therapies and non-surgical strategies that lead to a reduction in energy intake, weight loss 
and remission of  diseases such as type II diabetes. To find such strategies and therapies 
it is crucial to understand how body weight is regulated and food intake is controlled. 
It is well established that when average caloric intake exceeds total energy expenditure, 
this result in a positive energy balance and finally results in excessive accumulation of  
body fat (6). Despite the fact that the rude causes of  weight gain are relatively well 
understood, it has proven difficult to find strategies for weight management.
Energy balance and appetite regulation
Energy balance is the balance between energy intake and total energy expenditure. 
When energy intake repeatedly exceeds energy expenditure, this results in weight 
gain (7).  To find targets that help people to reduce their energy intake it is important 
to understand how the process of  food intake and meal termination is regulated by 
the body. The drive for energy intake depends on both external and internal factors. 
External factors include conditioned and environmental factors of  which many are 
highly variable throughout the day the day (8). Humans do not only eat to satisfy their 
energy demand and appetite, but also for many other reasons such as sensory hedonics, 
sensory stimulation, tension reduction, social pressure and boredom. Internal factors 
for food intake include sensory, cognitive, postingestive and postabsoptive signals (7). 
What is obesity?
According to the world health 
organization (WHO) overweight 
and obesity are defined as 
‘abnormal or excessive fat 
accumulation that may impair 
health. 
A body mass index (BMI), which is 
the weight in kilograms divided by 
the square of  the height in meters 
(kg/m2), of  equal to or more than 
25 is defined as overweight, and 
a BMI equal to or more than 30 is 
defined as obese (1)
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The first event in food intake regulation, which is initiated before actual food ingestion 
starts is the so-called cephalic phase response. During this phase, physiological signals 
are generated by the sight, smell, and oromucosal sensation of  food. Cephalic phase 
responses are occurring in many parts of  the gastrointestinal tract (GI) and their 
presumed functions are to anticipate to the ingestion of  food. During food ingestion 
itself, two processes are activated that bring eating to a halt and suppress hunger. The first 
is satiation, which is the process that leads to meal termination and therefore controls 
meal size. The second is satiety. Satiety can be seen as a behavioral state including the 
post- and preprandial phase. Satiety coordinates our eating behavior and controls the 
frequency of  eating episodes (7, 9). Satiety and satiation are activated by different kinds 
of  satiety signals triggered by the ingestion of  food. In figure 1.1 the satiety cascade as 
originally proposed by Blundell in 1994 is shown, illustrating how satiation and satiety 
coordinate our eating behavior (7, 10). 
Figure 1.1 The satiety cascade, showing  the expression of  appetite by the relation between physiological 
and behavioral events  and physiological and metabolic events (Figure adapted from Blundell et al. 1994).
Various organs (e.g. the brain, adipose tissue, liver, muscles, pancreas and central nervous 
system)  contribute to the signals generated during this satiety cascade.  The GI tract is 
Ch
ap
te
r 1
GENERAL INTRODUCTION
13
one of  the main organ systems involved in the generation of  physiological signals that 
promote satiation and satiety. One of  the main functions of  the GI tract is to digest 
ingested food and to absorb nutrients, vitamins and other important building blocks for 
the body. Simultaneously, the GI tract senses the ingestion of  food and generates signals 
to activate satiation and thereafter satiety. Various chemosensory mechanisms along the 
entire GI tract are continuously monitoring the concentration of  nutrients, digestion 
products and microbial metabolites. Together with their effect on GI hormone secretion, 
these chemosensory processes are often referred to as ‘nutrient sensing’. Nutrient sensing 
involves the action of  different receptors and transporters located on membranes or 
within the cytoplasm of  enterocytes, brush cells and enteroendocrine cells (EEC) (11). 
The primary sensor of  ingested food is the enteroendocrine system. This system is 
responsible for secreting an array of  gut hormones, which act in concert to modulate 
multiple physiological responses such as gastrointestinal motility and secretion, glucose 
homeostasis, satiation and satiety (12). The GI tract represents the largest endocrine 
organ in the human body. Enteroendocrine cells are located throughout the GI tract. 
These cells constitute <1% of  the cell population in the intestinal epithelium, but play 
a critical physiological role and represent an important component of  the gut-brain axis 
(13). At least 15 types of  EECs have been described, capable of  releasing gut hormones 
that influence processes such as gut motility, gastric acid secretion and energy intake 
(13, 14).
Nutrient sensing by G-protein coupled receptors
The enteroendocrine system interacts with and reacts to individual dietary components 
and nutrients intra- and extracellular (15). Several nutrient transporters and G-protein 
coupled receptors (GPCRs) that are expressed on enteroendocrine cells sense 
macronutrients such as lipids, carbohydrates and proteins. Activation of  these 
transporters and GPCRs results in downstream signaling and several studies showed that 
activation of  these receptors results in the release of  gut hormones such as glucagon-
like peptide 1 (GLP-1), cholecystokinin (CCK) and peptide YY (PYY) (12). 
Lipids activate several GPCRs expressed on EECs which result in the release of  GLP-1 
(16, 17). EECs express GPCRs such as GPR120 (or free fatty acid receptor 4  FFAR4) and 
GRP40 (FFAR1) both activated by long chain fatty acids (18), whereas short chain fatty 
acids activate FFAR2 and FFAR3 (19, 20). Another GPCR involved in lipid mediated 
GLP-1 release is GPR119, which is known to be activated by oleoylethanolamine 
(OEA) (21).
Carbohydrates are predominantly sensed in the form of  glucose. The proposed receptor 
involved in glucose uptake is the Na+ dependent sodium/glucose cotransporter member 
1 (SGLT-1) (12). There is also evidence for a so-called sweet taste receptor, a G-protein 
coupled heterodimer (T1R2/T1R3). It has been proposed that activation of  this 
receptor by glucose and non-caloric sweeteners induces the release of  satiety hormones 
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(22). However, if  activation of  this sweet taste receptor results in GLP-1 release is also 
subject to debate. Although glucose ingestion increases GLP-1 concentrations in rats 
(23) and humans (24), the ingestion of  non-caloric sweeteners did not stimulate GLP-1 
release in vivo (23, 25). 
Proteins are digested to- and mainly sensed as amino acids or di-and tripeptides. Amino 
acid-induced gut hormone release is associated with activation of  the G-coupled calcium 
sensing receptor (CaSR) (26-28) and the umami taste receptor dimer T1R1/T1R3 (29) 
as well as GPRC6A (30). Larger protein fragments such as di-and tripeptides have been 
linked to activation of  the peptide transporter 1 (PEPT1) (31-33). 
Satiety signals released by the enteroendocrine system
Satiation depends on short term satiety signals such as stomach distension as well as on 
the release of  gut hormones such as GLP-1, CCK and PYY (8). These hormones have 
in common that they are released from enteroendocrine cells in the small intestine. They 
are referred to as satiating peptides since exogenous administration of  physiological 
concentrations of  these hormones dose dependently results in decreased food intake 
without affecting illness (34). 
GLP-1 derives from the proglucagon gene which is highly conserved among mammals. 
After transcription, GLP-11-36 is n-terminally truncated to the active forms GLP-17-
36 and GLP-17-37 by posttranslational processing in enteroendocrine L-cells(35). At 
physiological concentrations the active forms of  GLP-1 stimulate insulin secretion (36, 
37) , insulin gene transcription (38) and improve pancreatic β-cell glucose responsiveness 
(39). Once released, the bioactive forms GLP-17-36 and GLP-17-37 are very rapidly cleaved 
by dipeptidyl peptidase IV (DPPIV) into the inactive form GLP-19-36 (40).  Besides its 
incretin effects,  GLP-1 contributes to satiety and satiation. Intravenous infusion of  
GLP-17-36 decreases gastric emptying and reduces of  food intake,  suppresses hungerand 
increases the period of  postprandial satiety (41-45). GLP-1 is found in enteroendocrine 
L-cells in the jejunum, ileum and colon (46). Other hormones which contribute to 
satiation and satiety are PYY and CCK. PYY is predominantly located in the distal 
ileum and colon, whereas CCK is found in the duodenum and jejunum (14, 47).
CCK is found in EECs present in the duodenal and jejunal mucosa. Intestinal CCK 
is secreted in response to luminal nutrients such as proteins and lipids. The CCK 
prepropeptide is processed by endoproteolytic cleavage into at least six peptides, ranging 
from 8 to 83 amino acids in length. The multiple bioactive forms share a common 
carboxy-terminal octapeptide with an O-sulfated tyrosine. The major circulating 
forms of  CCK are CCK8, CCK22, CCK44 and CCK58 (34). CCK has a large variety 
of  physiological functions in the human body, such as stimulation of  gall bladder 
contraction, pancreatic enzyme secretion, intestinal motor activity and inhibition of  
gastric emptying. When CCK is secreted, the gallbladder and pancreas are stimulated to 
excrete their juices containing digestion enzymes and bile (34, 48). Besides its function 
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to stimulate pancreas juices, CCK contributes to satiation and satiety. Intravenous 
infusion of  CCK suppresses food intake (49-51). 
Similar to GLP-1, PYY is produced by enteroendocrine L-cells, most of  which co-
express GLP-1. PYY is secreted postprandially in proportion to caloric load. Once 
released from L-cells PYY1-36  is rapidly proteolyzed by DPPIV into PYY3-36,  and 
unlike GLP-1, the cleaved product PYY3-36 is bioactive. Similar  to CCK and GLP-1, 
intravenous infusion of  PYY3-36  results in decreased hunger and ad libitum food intake, 
without causing nausea, affecting food palatability or altering fluid intake (52).  
Receptors of  GLP-1, PYY and CCK are expressed in various organs including the 
pancreas, intestine and the brain (47, 53). Once released, GLP-1, CCK and PYY may 
act paracrinely, neurocrinely or endocrinely. Secreted GLP-1, CCK and PYY diffuse 
into the lamina propria and enter the systemic circulation via the hepatic portal vein. 
Systemic circulating concentrations rise within 15 minutes of  food intake. Once 
released from EECs these hormones may act neurocrine as well by interacting with 
receptors expressed at the nodose ganglion on afferent sensory vagal nerve fibers (13, 
54, 55). Vagal afferent fibers transmit information such as gastric distension, ingested 
dietary composition and water content to the nucleus of  the solitary tract located in the 
brainstem. This feedback mechanism by vagal afferent fibers is part of  the so-called 
gut-brain axis and contributes to satiation as well. 
Potential targets and strategies for weigh management
The increase in knowledge about physiological mechanisms that control eating and 
body weight is in contrast to the lack of  available nutritional and pharmacological 
therapies leading to safe efficient and long lasting body weight reduction (56).  The most 
effective treatment for severe obesity is bariatric surgery. Bariatric surgery is normally 
indicated for people who have a BMI of  ≥40 kg/m2 or a BMI of  ≥35 kg/m2 plus 
comorbid conditions that will be improved by weight loss (57).  Bariatric surgery is 
effective both in terms of  achieved and maintained weight loss and with regard to 
improvement of  obesity related comorbidities (58, 59). One of  the most frequently 
performed bariatric operation worldwide is Roux-en-Y gastric bypass. This surgery 
results in body weight reduction of  about  20% - 30% and this weight loss is maintained 
for several years after surgery (58-60). By applying this technique, nutrients bypass the 
duodenum and proximal jejunum and as a consequence nutrients are directly delivered 
into the distal small intestine (57). In addition to weight loss, a considerable advantage 
of  RYGB is the immediate improvement in insulin sensitivity, which acts in concert 
with increased release of  hormones such as GLP-1 and PYY. This immediate effect on 
gut hormone release and remission of  type II diabetes is typical for RYGB, since other 
surgeries such as gastric banding typically show these effects only after a longer period 
of  weight loss. The mechanism by which RYGB surgery decreases body weight and 
improves metabolic health is not completely understood yet. Although restrictive or 
CHAPTER 1
16
malabsorption has been often proposed to be involved in weight loss after RYGB, there 
is more evidence available showing that the underlying mechanisms are metabolic (57).
One proposed mechanism by which RYGB may have its effect is enhanced nutrient 
stimulation of  EECs in the distal small intestine, resulting in the release of  gut hormones 
such as GLP-1 and PYY (61).  Although RYGB is very effective in causing weight 
loss and immediately improves metabolic health of  obese people, there is a need for 
nonsurgical strategies that help people limiting their daily energy intake.
Similar to RYGB, a non-surgical intervention by which intact nutrients are shunted into 
the distal ileum would be by activation of  the so called ileal brake. Activation of  this 
feedback loop slows or ‘brakes’ gastric emptying and duodenal-jejunal motility. The ileal 
brake is activated when energy containing nutrients, mainly lipids, are delivered beyond 
the duodenum and jejunum into the ileum, as is the case after RYGB. Infusion of  lipids 
into the ileum results in enhanced satiety signals, satiation and a reduction in of  energy 
intake (62-64).  
Aims and outlines this thesis
Previous research shows that satiation is regulated by satiety signals released from the 
enteroendocrine system after the ingestion of  food. This system in the small intestine 
has proven to be a potential target for surgical weight management strategies. However, 
to prevent normal weight and overweight people to become obese, other nonsurgical 
weight management strategies are needed. Before such strategies can be invented several 
knowledge gaps remain to be filled. By addressing how potential targets may activate 
satiety signals, more effective nonsurgical or nutritional strategies may be invented to 
help people limiting their daily energy intake.
The aim of  this thesis is therefore: to investigate potential small intestinal targets that 
may contribute to satiation.  How the chapters contribute to this aim is shown in figure 
1.2
Small intestinal hormone release
There are studies investigating the effects of  macronutrients such as glucose on the 
release GLP-1, PYY and CCK. We were interested if  other dietary components also 
affect the release of  GLP-1 and PYY. In chapter 2 it has been investigated if  the Stevia 
rebaudiana derived non-caloric sweetener rebaudioside A also stimulates the release of  
GLP-1 and PYY. For this study a previously described ex vivo porcine model was used 
(65).
Sensing nutrients via GPCRs on EECs results in the release of  satiety hormones. It has 
been proposed by others that EECs express GPCRs which are responsible for nutrient-
induced GLP-1, PYY and CCK release. Undigested macronutrients, and other dietary 
compounds such as rebaudioside A also stimulate GLP-1 release. The exact mechanism 
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behind undigested macronutrient or rebaudioside A-induced GLP-1 release, is still 
unknown. A potential small intestinal molecular target involved in food intake regulation 
is serotonin. Approximately 90% of  serotonin is stored in enterochromaffin cells in the 
small intestine, and modulation of  the serotonergic system does affect food intake. 
In chapter 3 we investigated if  serotonin is involved in nutrient and rebaudioside A 
induced GLP-1 release. In addition, we investigated the effects of  macronutrient and 
rebaudioside A on the release of  serotonin. This was studied in the same ex vivo porcine 
intestinal segment model as which was used in chapter 2. 
Neural contribution to satiation by receptors located at the vagal 
nerve 
When GLP-1 and CCK are released from EECs they can act either endocrinely via 
the blood to activate receptors, paracrine to act on neighboring cells or neurocrine 
via receptors located at the vagal nerve endings. In chapter 4 we investigated the 
contribution of  neurocrine CCK and GLP-1 signaling to satiation. This was studied 
by investigating the effects of  CCK and GLP-1 receptor antagonist on ad libitum food 
intake in a pig model of  subdiaphragmatic vagotomy. In this study we also explored the 
effects of  subdiaphragmatic vagotomy on postprandial release of  GLP-1 and CCK.  
Figure 1.2. Schematic overview of  the aims of  this thesis and the contribution of  the chapters to these 
aims.
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Targeting the intestinal brake as a tool for weight management
Previous research has shown that ileal brake activation by intraileal lipid infusion results 
in increased satiation and decreased energy intake. This mechanism may therefore be 
considered as a potential target for weight management. Whether other macronutrients 
such as protein and carbohydrate also activate the ileal brake, and whether the ileal brake 
is more effective in reducing food intake as compared to duodenal or jejunal brake 
remains to be investigated. In chapter 5 we compared the effects of  intraduodenal, 
intrajejunal and intraileal protein infusion on satiation. In this chapter the effect of  
intraduodenal, intrajejunal and intraileal protein infusion on GLP-1, PYY and CCK 
are evaluated as well. In chapter 6 we investigated whether different macronutrients 
infused into the ileum increase satiation and decrease energy intake. In this chapter the 
effects of  intra-ileal infusion on gut hormone release and appetite ratings have been 
studied as well. In chapter 7 we investigated if  native protein infused into the ileum 
does not result in immediate reverse reactions. In this chapter it was also investigated 
if  amino acids present in this native protein infused do recover in plasma during ileal 
infusion in healthy human subjects. 
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Abstract
Glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) are hormones important for 
satiation and are involved in the process called “ileal brake”. The aim of  this study 
was to investigate the GLP-1- and PYY-stimulating efficacy of  rebaudioside A, casein, 
and sucrose. This was studied using tissue segments collected from various regions 
of  the pig small intestine. GLP-1 release was strongest from the distal ileum. There, 
control release was 0.06 ± 0.01 (GLP-1) and 0.07 ± 0.01 (PYY) pmol/cm2 of  tissue. 
Rebaudioside A (2.5, 12.5, and 25 mM) stimulated GLP-1 release (0.14 ± 0.02, 0.16 
± 0.02, and 0.13 ± 0.02 pmol/cm2 of  tissue, p<0.001) and PYY release (0.19 ± 0.02, 
0.42 ± 0.06, and 0.27 ± 0.03 pmol/cm2 of  tissue, p<0.001). Sucrose stimulated GLP-1 
release (0.08 ± 0.01 pmol/cm2 of  tissue, p<0.05) only at 10 mM. Casein (0.5%, 1%, and 
2.5%, w/v) stimulated GLP-1 release (0.15 ± 0.03, 0.13 ± 0.02, and 0.14 ± 0.01 pmol/
cm2 of  tissue, p<0.001) and PYY release (0.13 ± 0.02, 0.20 ± 0.03, and 0.27 ± 0.03 
pmol/cm2 of  tissue, p<0.01). These findings may help in developing dietary approaches 
for weight management.
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Introduction
The presence of  nutrients and other molecules in the small intestine stimulates the 
release of  satiety hormones, such as Cholecystokinin (CCK), Glucagon-Like Peptide-1 
(GLP-1), and Peptide YY (PYY) (1, 2). The release of  these hormones results in 
decreased gastric emptying and activation of  the so-called intestinal brake. This poorly 
explored mechanism refers to a physiological feedback mechanism that is triggered by 
nutrients at a specific location in the intestine resulting in reduced appetite and food 
intake (3, 4). Lipids have been widely researched and are known to activate this ileal 
brake mechanism resulting in the release of  satiety hormones and reduced food intake 
(5-8). However, whether other macronutrients such as carbohydrates and proteins could 
also activate the ileal brake mechanism is still unknown (4). Knowledge of  the satiety-
hormone-inducing properties of  macronutrients is relevant to better understanding 
the intestinal response to ingested food and may contribute to the development of  
products with satiating properties.
The efficacies of  non-caloric sweeteners to induce the release of  satiety hormones are 
also partly unknown. However, a study by Anton et al. (2010) showed that preloads 
containing the sweetener stevia reduced daily caloric intake by 301 kcal and reduced 
postprandial glucose and insulin levels compared to preloads containing sucrose (9). 
Such a reduced caloric intake as well as glucose and insulin responses may be caused 
by reduced caloric content of  the preload but may also be caused by other mechanisms 
such as GLP-1 release. The glycoside rebaudioside A is the one of  the most abundant 
sweet compound extracted from the leaves of  Stevia rebaudiana bertoni. Rebaudioside A 
is reported to be the most potent sweetener among the steviol glycosides (10) with a 
relative sweetness of  200 – 400 times greater than that of  sucrose (11). Rebaudioside 
A is increasingly used in food products as a natural noncaloric sweetener. It has been 
approved in the United States since 2008 (12), and in the European Union since 2010 
(13). 
It is unknown if  ileal delivery of  macronutrients other than lipids and sweeteners could 
also stimulate the release of  satiety hormones and consequently activate the ileal brake. 
Stimulation of  GLP-1 and PYY release from isolated ileal tissue has been demonstrated 
for lipids including unsaturated fatty acids. This was shown using a recently described 
ex vivo porcine intestinal model (14). For other macronutrients such as sucrose and 
casein such studies have not been performed yet, although their efficacy to induce gut 
hormone release has been shown in cell cultures (15-17). The pig was chosen as a model 
because the gastrointestinal tract of  the pig shows a high degree of  macroscopic and 
microscopic resemblance with that of  humans (18-20). The present study primarily 
focused on the GLP-1 and PYY inducing efficacy of  casein, sucrose and the non-caloric 
sweetener rebaudioside A at various locations of  the small intestine. We hypothesize 
that rebaudioside A, the protein casein, and the carbohydrate sucrose are effective 
CHAPTER 2
26
stimulators of  GLP-1 and PYY release from various locations of  the small intestine, 
and thus may be effective activators of  the ileal brake in vivo.
Materials and methods 
Chemicals 
Casein protein (food grade, sodium caseinate purity >82% batch number 158156) 
was obtained from Dutch Protein Services BV, Tiel, The Netherlands. Rebaudioside 
A (Figure 2.1, food grade, purity  >97% batch number  20110301, ChemSpider 
ID: 5294031) was obtained from SteviJa Natuurlijk BV, Drachten, The Netherlands. 
Sucrose (food grade, purity >99.9%) was supplied by Suiker Unie, Oud Gastel, The 
Netherlands. Safflower oil (food grade, composed of  3-8% C16:0, 2-5% C18:0, 9-15% 
C18:1 and 75-85% of  C18:2) was provided by De Wit Specialty oils, De Waal, The 
Netherlands. Xantham Gum and Guar gum were supplied by GF Supplies, Amsterdam, 
The Netherlands. Chemicals to make the Krebs Ringer bicarbonate (KRB) buffer 
(D-glucose 1.8 gram/L, Magnesium Chloride 0.0468 gram/L, Potassium chloride 0.34 
gram/L, Sodium Chloride 7.0 gram/L, Sodium Phosphate Dibasic 0.1 gram/L, Sodium 
Phosphate Monobasic 0.18 gram/L, HEPES 5,579 gram/L) were obtained from Sigma, 
Zwijndrecht, The Netherlands. The pH of  the KRB buffer was adjusted to pH 7.4. 
Figure 2.1 Chemical structure of  Rebaudioside A (Adapted from ChemSpider ID: 5294031)
Collection of  porcine intestinal tissues
Intestinal tissues were obtained from ten healthy male pigs (Sus scrofa domesticus). The 
pigs were considered healthy after evaluation by a veterinarian. The protocol for this 
study was approved by the Animal Ethics Committee Utrecht (Ethics Committee permit 
number 2012.I.09.096, Utrecht, The Netherlands). Pigs had a mean (± SEM) body 
weight of  141 ± 2 kg, and mean (± SEM) age of  6 ± 0.1 months. They were housed in 
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groups and were fed ad libitum with standard pig diet (vitaal P 003103, de Heus, Ede, The 
Netherlands) and free access to water. Within 10 minutes after the pigs were sacrificed, 
intestines were excised and segments of  different anatomical regions were stored in ice-
cold oxygenated (95% O2, 5% CO2) KRB buffer. Jejunum (4.5 meter proximal to the 
ileocecal junction) and proximal, mid and distal ileum (0.5 meter of  intestine sampled 
from 1.5, 1 and 0.5 meter proximal to the ileocecal junction, respectively) were collected 
for the experiments. Tissues were transported to the laboratory and immediately 
used for ex vivo experiments. Time between excision and start of  the experiments was 
approximately 30 minutes. 
Nutrient exposure of  intestinal tissue and viability tests
Incubation with casein (0.5, 1 and 2.5% w/v), rebaudioside A (2.5, 12.5 and 25 mM), 
sucrose (2.5, 5 and 10 mM), and safflower oil (3.35% w/v) were performed with porcine 
intestinal tissue as described previously (14) with some minor adaptations.  In brief, 
upon arrival at the laboratory, the intestine was rinsed with KRB buffer and cut open 
in a longitudinal direction. The outer muscle layers were carefully stripped off  with the 
basolateral side upwards. The mucosal tissue was placed on a gauze (pores = 250 µm, 
Sefar Nitex 03-250/50, Sefar Heiden Switzerland) with the apical side upward, and 
circles of  tissue with a diameter of  11.8 mm (about 1.0 cm2) were punched out using a 
biopsy punch. The intestinal segments were randomized, per region, in a beaker glass and 
transferred to a 24-wells plate, filled with 500 µl ice cold KRB buffer/well, and kept on 
ice until start of  the experiment. Thereafter, tissues were brought to room temperature 
within 30 min, followed by an pre-incubation step at 37°C for 1 hour in a humidified 
incubator (5% v/v CO2). To study the release of  GLP-1 and PYY, incubations were 
initiated by replacing the KRB buffer solution with 500 µl pre-warmed (37°C) KRB 
without D-glucose containing the test compounds. KRB buffer without D-glucose 
was used as a control since D-glucose might induce gastrointestinal hormone release. 
Then the tissue was put in a humidified incubator for 1 hour at 37°C at 5% v/v CO2. 
After incubation, solutions were collected, mixed with 100 µM phenylmethanesulfonyl 
floride (PMSF) (Sigma Aldrich, Zwijndrecht, The Netherlands) to inactivate dipeptidyl 
peptidase IV, aliquoted and stored at 4°C for further analysis of  lactate dehydrogenase 
(LDH), or stored at -80°C for further analysis of  GLP-1 and PYY.
Tissue viability was checked by measuring leakage of  intracellular LDH in 
supernatant. LDH, a stable cytosolic enzyme, was analyzed using a LDH kit (Sigma 
Aldrich, Zwijndrecht, The Netherlands). LDH activity in supernatant was expressed 
as a percentage of  the total LDH activity present in control tissue collected before 
incubation. Total tissue levels of  LDH were determined per region in 1.0 cm2 tissue 
samples, which were homogenized in ice-cold KRB buffer with a Potter-Elvehjem-type 
Teflon pestle tissue grinder (Braun, Melsungen, Germany) for 5 minutes at 200 rounds 
per minute. Samples were only included for further analysis when LDH leakage did not 
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exceed 10% of  the total LDH tissue content (14, 21). No samples had to be excluded 
applying this criterion.
Analysis of  satiety hormones GLP-1 and PYY 
GLP-1 active levels were analyzed using commercially available ELISA assay kits 
obtained from Millipore (Billerica, MA, USA) and used according to the manufacturer’s 
instructions using a BioTek Synergy HT fluorescence microplate reader (BioTek 
Instruments Inc., Winooski Vermont, USA). Since the GLP-1 hormone gene sequence 
is highly preserved, this kit could be applied for analyzing porcine GLP-1. The range of  
this assay is approximately 2 – 100 pM. The inter-assay coefficient of  variation is 11%, 
and the intra-assay variation is 6%. When necessary, samples were diluted in assay buffer 
from the kit to be in this range.
PYY release was measured from distal ileum only, since PYY is known to be co-
localized with GLP-1 (22). PYY concentrations were measured using a PYY ELISA 
kit for total PYY (Bachem, Penisula Laboratories, San Carlos, CA, USA) according to 
the manufacturer’s instructions using a BioTek Synergy HT microplate reader (BioTek 
Instruments Inc., Winooski Vermont, USA). This kit measures porcine PYY, which is 
identical to human PYY23. The range of  this assay is approximately 0.32 – 5 ng/ml (4.6 
– 1150 pM). The inter assay coefficient of  variation for this assay is 6% and the intra 
assay coefficient of  variation is 3%. The lower detection limit of  this kit was 20 pg/ml 
(4.6 pM) It was not necessary to dilute samples for this assay. 
Statistical analysis
Statistical analysis was performed using the SAS statistical software package (SAS version 
9; SAS institute, Cary, NC, USA). Both variables GLP-1 and PYY were compared 
with a mixed analysis of  variance model (ANOVA). GLP-1 and PYY were both log 
transformed to meet the requirements for ANOVA.  The ANOVA model included 
the fixed factors dose solution (control, sucrose 2.5, 5 and 10 mM, casein 0.5, 1 and 
2.5% w/v, rebaudioside A 2.5, 12 and 25 mM and safflower oil 3.35% (w/v), intestinal 
location (jejunum, and proximal mid and distal ileum) and the number of  incubations 
per condition (incubations were performed in triplicate). The factor pig, which specifies 
the individual pig, was added to the model as random factor. The Tukey post hoc test 
was used to correct for multiple comparisons. Data are presented as the mean ± SEM 
and considered significant at p<.05. 
Ch
ap
te
r 2
REBAUDIOSIDE A INDUCES GLP-1 AND PYY RELEASE 
29
Results
Effects of  rebaudioside A and other compounds / mixtures on GLP-1 release 
Table 2.1 shows the GLP-1 concentrations in the medium following incubation with 
the test compounds or mixtures using tissues taken from different locations. In all parts 
of  the small intestine investigated, rebaudioside A caused a significant release of  GLP-
1 already at the lowest concentration tested (2.5 mM) (p<0.01), except for the jejunum 
where the release was significant at a concentration of  12.5 mM (p<0.05). The highest 
relative increase of  GLP-1 after incubation with rebaudioside A was seen in the distal 
ileum (p<0.001). The release at 25 mM was not higher than at 12.5 mM. As also shown 
in Table 2.1, safflower oil (3.35% w/v) significantly increased GLP-1 release from the 
proximal ileum (p<0.05) and even more from the distal ileum (p<0.001). Safflower 
oil did not increase GLP-1 release from the mid-ileum and only marginally from the 
jejunum. At the concentrations tested sucrose did not stimulate GLP-1 release from 
jejunal and mid ileal tissue. The only significant stimulation was seen in tissues from the 
distal ileum at a sucrose concentration of  10 mM (p<0.05).
Casein, at 1 and 2.5 % (w/v) increased GLP-1 release (p<0.001) from tissues collected 
from the jejunum, whereas 0.5% (w/v) casein did not. Both 0.5 and 2.5% (w/v) casein 
Table 2.1 GLP-1 concentrations released from jejunal, proximal, mid and distal ileum intestinal tissue 
segments after exposure to various compounds. 
a p<0.05, b p<0.01, c p<0.001; p-values are based on comparison to control (ANOVA + Tukey correction). The 
incubations were performed in triplicate (n=6 for jejunum, n=10 for proximal, mid and distal ileum
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stimulated GLP-1 release from the proximal ileum (p<0.001). A concentration of  1% 
(w/v) casein stimulated GLP-1 release from proximal ileum (p<0.010), but exposure 
to 0.5% and 2.5% (w/v) casein caused a higher GLP-1 release. None of  the casein 
concentrations, 0.5, 1 and 2.5% (w/v), stimulated GLP-1 release from the mid ileum. All 
three casein concentrations stimulated GLP-1 release from the distal ileum (p<0.001). 
Similar to rebaudioside A, the most pronounced stimulation of  GLP-1 by casein was 
observed in the distal ileum. 
Regional differences in GLP-1 release
Exposing intestinal tissue to the control did not result in regional differences in control 
GLP-1 release. However, after exposure to the nutrients, regional differences were 
observed. For GLP-1 both an overall incubation and location effect (p<0.001), and an 
interaction effect between incubation and location was found (p<0.05). Overall GLP-1 
release from all ileal locations (distal, mid and proximal ileum), was higher than GLP-
1 release from the jejunal locations (p<0.001). Furthermore, GLP-1 release from the 
distal ileum was higher than GLP-1 release from the mid ileum (p<0.001). Neither 
hormone release from mid and proximal ileum differed, nor did release from proximal 
and distal ileum (p<0.08). 
Table 2.2 PYY concentrations released distal ileum intestinal tissue segments after exposure to various 
compounds  
a p<0.01, b p<0.001; p-values are based on comparison to control (ANOVA + Tukey correction).The incubations were 
performed in triplicate (n=10). 
Ch
ap
te
r 2
REBAUDIOSIDE A INDUCES GLP-1 AND PYY RELEASE 
31
Effects of  compounds and mixtures on PYY release
The compounds and mixtures stimulating GLP-1 release were also tested for their 
PYY releasing capacity from the distal ileum (Table 2.2). Safflower oil was found to 
stimulate PYY release, whereas sucrose at the concentrations tested did not. Casein 
stimulated PYY release from the distal ileum at all three concentrations tested. Release 
after exposure to a concentration of  1% (w/v) was higher than with 0.5% (w/v) casein 
(p<0.05). Rebaudioside A stimulated PYY release from distal ileum (p<0.001). The 
effect  at 12.5 mM rebaudioside A was higher than that at 2.5 mM (p<0.05). 
Discussion 
Our study confirmed our hypothesis that rebaudioside A and casein induce GLP-1 and 
PYY release from porcine intestinal tissue segments. Remarkably, rebaudioside A was 
found to stimulate GLP-1 release from all ileal and jejunal regions investigated, whereas 
sucrose (10 mM) only caused GLP-1 release from the distal ileum. Rebaudioside was 
effective in stimulating hormone release from more locations of  the small intestine than 
casein. Therefore, taking into account that the model and the tested concentrations 
make a direct comparison difficult, our results suggest that rebaudioside A and the 
protein casein are candidate substances that may activate the ileal brake in vivo via the 
release of  GLP-1 and PYY.
Some sweeteners including sucralose were found not to affect satiety hormone release 
in vivo (24, 25). For Stevia Anton et al. (2010) demonstrated satiating inducing properties 
which may be due to increased satiety hormone release. However, since satiety hormones 
were not measured in that study, this association cannot be made from these findings. 
To our knowledge no reports have shown the satiety hormone-inducing capacity of  the 
non-caloric sweetener rebaudioside A as was done in our study. 
Nutrients, such as casein and sucrose, could stimulate satiety hormone release following 
interaction with G-protein coupled receptors and some solute carrier transporters 
located on enteroendocrine cells in the intestinal epithelium (26). A potential mechanism 
by which rebaudioside A could stimulate GLP-1 and PYY release is via the sweet taste 
receptor. Recently, it was found that rebaudioside A has affinity for the sweet taste 
receptor TAS1R2/TASR3 (10). This receptor is involved in glucose dependent release 
of  GLP-1 and PYY in vivo (27). Furthermore, TAS1R2/TASR3 is present on brush cells 
and enteroendocrine cells (28). However, other mechanisms than via the taste receptors 
by which rebaudioside A and casein could induce satiety hormone release cannot be 
excluded and should be further studied.
Already more than 100 compounds have been identified in Stevia rebaudiana. However, 
the steviol glycosides stevioside and rebaudioside A have been found to be the most 
abundant. Steviol glycosides are metabolized into steviol upon their arrival in the colon 
and are absorbed thereafter (29). Incubation of  the murine enteroendocrine STC-1 
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cells with Stevia preparations resulted in higher GLP-1 and CCK release compared to 
incubation with sucrose (17), which is in line with our findings. The same study also 
demonstrated GLP-1 and CCK release after incubation with sucralose. However, only 
relatively high concentrations of  150 and 300 mM sucralose and of  600 mM sucrose 
were able to stimulate GLP-1 and CCK release from STC-1 cells. In our study 2.5 
mM rebaudioside A resulted in higher GLP-1 release compared to 2.5 mM sucrose 
(0.14±0.02  vs. 0.06±0.01 p<0.001, distal ileum). Concentrations of  sucrose and 
rebaudioside A in this study were in the same range (0-25 mM). Further in vitro studies 
should explore dose-effect relationships of  these compounds. 
Safflower oil was used as a positive control in our study. Safflower oil (3.35%) was found 
to activate the ileal brake in vivo and to increase satiety and gastrointestinal hormone 
concentrations (5, 7). As expected safflower oil effectively stimulated GLP-1 release 
from the ileum mainly from the distal part whereas no such stimulation occurred from 
the mid ileum. This difference may relate to the enteroendocrine cell distribution. 
Enteroendocrine L-cells are most abundant in the distal part of  the small intestine 
(30) corresponding to the intestinal tissue content of  GLP-1 (14). The protein casein 
increases satiety in vivo (31) and in vitro it stimulates GLP-1 release from enteroendocrine 
murine STC-1 and human NCI-H716 cells (15, 16, 32). In our study casein induced 
GLP-1 and PYY release which confirms these previous findings and suggests that 
casein is a candidate to induce the ileal brake in vivo.
Apart from the differences in efficacy of  various nutrients to stimulate GLP-1 and PYY 
some other questions remain. An important question is to what extent the effects on 
satiety hormone release found in our model can be reproduced in in vivo models and 
specifically in humans. Another relevant question is whether the capacity  to induce 
satiety hormone release will lead into satiation in vivo. In one study of  Veldhorst et 
al.(2009) it was shown that breakfast with higher casein content (25% vs. 10%) increased 
VAS scores in fullness and satiety whereas subsequent energy intake was not reduced 
and GLP-1 plasma concentrations did not differ per condition (33). Food intake is 
regulated by a whole cascade of  responses which have to be taken into account if  
studying satiation in vivo. Therefore, knowledge of  the satiety hormone releasing 
capacity of  macronutrients and non-caloric sweeteners could be useful to understand 
this so called ‘satiety cascade’ (34).
The current in vivo data are based on lipid infusions mainly. Those data could be extended 
into infusion studies using rebaudioside A and casein since the results from this study 
suggest that the satiety hormone releasing effect of  sweeteners and proteins might be 
at least as effective as fat. These human interventions will then further substantiate the 
relevance of  this ex vivo intestinal model. 
One could question whether the concentrations of  the selected compounds are relevant 
in view of  those reached in the gut after dietary intake. Nutrient concentrations in the 
small intestine depend on the rate of  gastric emptying of  a meal, the rate of  absorption, 
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and (or) digestion of  the nutrients the meal contained (35-37). Data on actual 
concentrations of  the selected products are very scarce. There is only one animal study 
showing that luminal glucose concentrations after a meal are varying between 0.2 and 
48 mM depending on postprandial time and the small intestinal region (38). Although 
the data are limited one could estimate intestinal concentrations on the following 
assumptions; 1 cup of  coffee or tea (200 ml) with 0.3 gram of  rebaudioside A (based 
on ADI of  0.4 mg/kg BW/day), or 1 cube of  sugar (1 gram), in a total volume of  300 
ml (100 ml gastric juice is added in the stomach) (17). These assumptions would yield 
an estimate of  approximate concentrations of   10 mM sucrose and 1 mM rebaudioside 
A for the small intestine. The estimate for casein is based on the assumption that 1 
glass of  milk is consumed (total volume including gastric juice 300 ml) with a  casein 
concentration of  80% of  total milk protein content which is approximately 35 g/L. This 
means that a concentration of  approximately 3% may initially be reached in the small 
intestine. Although these values are estimates only they suggest that the concentrations 
used in this study may be relevant from a dietary perspective. 
The hormone secreting capacity of  nutrients and other compounds is often studied 
in vitro using enteroendocrine cell lines including murine STC-1 (15, 39-41), GLUTag 
cells (42), and the human NCI-H716 cell line (43). The advantage of  the current ex vivo 
model compared to cell lines is that this model consist of  all different cell types present 
in the gut. Another model to study the GLP-1 and PYY inducing capacity of  nutrients 
is the Ussing chamber technology using animal or human biopsies (44). It is however, 
challenging to obtain human biopsies especially from the ileum which makes the ex vivo 
intestinal porcine segment system a valuable alternative. However, there are still some 
technical limitations such as tissue viability and intra-subject variation. In this study 
tissue viability was evaluated by LDH leakage as before (14) and LDH leakage did not 
exceed 10%. Also, hormone release in the control condition was low. Both conditions 
indicate a good tissue viability. However, we cannot exclude that hormone release may 
be due to aspecific processes like cell lysis. Also, a high number of  replicates was needed 
because of  a high intra-subject variation. This variation may be caused by the relatively 
low number of  enteroendocrine cells (reported to account for only 1% of  the epithelial 
cell population in the small intestine) and these cells may be unevenly distributed (2, 28). 
In conclusion, the present study showed that rebaudioside A and casein, but not 
sucrose, induced satiety hormone release at various locations of  the small intestine 
using an ex vivo model. These findings may contribute to the development of  dietary 
approaches improving weight management and glucose control. However, in vivo studies 
are necessary to confirm the potential satiety inducing properties of  rebaudioside A and 
casein in vivo.
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Abstract
Glucagon like peptide-1 (GLP-1) and serotonin are both involved in food intake 
regulation. GLP-1 release is stimulated upon nutrient interaction with G-protein 
coupled receptors by enteroendocrine cells (EEC), whereas serotonin is released from 
enterochromaffin cells (ECC). The central hypothesis for the current study was that 
nutrient-induced GLP-1 release from EECs is modulated by serotonin through a 
process involving serotonin receptor  interaction. 
This was studied by assessing the effects of  serotonin reuptake inhibition by fluoxetine 
on nutrient-induced GLP-1, PYY and CCK release from isolated pig intestinal segments. 
Next, serotonin-induced GLP-1 release was studied in enteroendocrine STC-1 cells, 
where effects of  serotonin receptor inhibition were studied using specific and non-
specific antagonists. 
Casein (1% w/v), safflower oil (3.35% w/v), sucrose (50 mM) and rebaudioside A (12.5 
mM) stimulated GLP-1 release from intestinal segments, whereas casein only stimulated 
PYY and CCK release. Combining nutrients with fluoxetine further increased nutrient-
induced GLP-1, PYY and CCK release. 
Serotonin release from intestinal tissue segments was stimulated by casein and safflower 
oil while sucrose and rebaudioside A had no effect. The combination with fluoxetine 
(0.155 µM) further enhanced casein and safflower oil induced-serotonin release.
Exposure of  ileal tissue segments to serotonin (30 µM) stimulated GLP-1 release 
whereas it did not induce PYY and CCK release. Serotonin (30 and 100 µM) also 
stimulated GLP-1 release from STC-1 cells, which was inhibited by the non-specific 
5HT receptor antagonist asenapine (1 and 10 µM). 
These data suggest that nutrient-induced GLP-1 release is modulated by serotonin 
through a receptor mediated process.  
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Introduction 
Gastro-intestinal (GI) hormones play major roles in the regulation of  food intake, 
gastric emptying and GI motility. In the small intestine hormones are secreted by 
enteroendocrine cells (EEC) (1), and are involved in modulating feelings of  satiety 
and satiation using feed-back mechanisms to reduce food intake (1, 2). Well-known 
satiety inducing hormones are cholecystokinin (CCK), peptide YY (PYY) and glucagon 
like peptide-1 (GLP-1). The release of  these hormones involves interaction between 
nutrients and G-protein coupled receptors (GPCR) or ion-dependent transporters that 
are expressed on EECs (1).
Recently it was found by our group that nutritional and non-nutritional stimuli such as 
a lipid mixture (safflower oil), carbohydrate (sucrose), protein (casein) and a non-caloric 
sweetener (rebaudioside A) induce GLP-1 and PYY release from ileal tissue segments 
(3). The mechanism of  how these different nutrients cause satiety hormone release 
remains to be investigated. 
It is known that lipids are sensed in the form of  long and short chain fatty acids by free 
fatty acid receptors. Carbohydrates are predominantly sensed as glucose, possibly via 
the Na+ dependent sodium/glucose cotransporter member 1 (SGLT-1) or by the so-
called sweet taste receptor, a G-protein coupled heterodimer (T1R2/T1R3). Proteins 
are mainly detected  after being digested into amino acids, di- and tripeptides by the 
G-coupled calcium sensing receptor (CaSR), umami taste receptor dimer T1R1/T1R3, 
GPCR6A, and peptide transporter 1 (PEPT1) (1, 4). However, not for all nutrients 
stimulating GLP-1, PYY or CCK release, a receptor is known. There may be additional 
mechanisms allowing to respond to fluctuations in intestinal nutrient levels (5). One 
such mechanism may involve paracrine cell-cell interaction via serotonin release from 
enterochromaffin cells (ECC).
Although it is known that serotonin is involved in food intake regulation (6), it is 
still unknown how serotonin stored in the small intestine contributes to food intake 
regulation. Serotonin is present throughout the gut in the duodenum, jejunum and 
ileum and stored in dense core granules located in the basal and apical part of  ECCs. 
These cells are responsible for the production and storage of  approximately 90% of  
the total pool of  serotonin in the body (3, 12, 44). The release of  serotonin from ECCs 
is stimulated by some dietary compounds in vitro (7) and several serotonin receptor 
subtypes are expressed in the small intestine. Enteric neurons and enterocytes express 
5-HT1, 5-HT2, 5-HT3, 5-HT4 and 5-HT7 receptors.  Activation of  these receptors has 
various effects such as neurotransmitter release, controlling motility, intestinal secretion 
and contraction or relaxation (8).
The present study aimed to investigate to what extent  serotonin is involved in nutrient-
stimulated GLP-1 release. It was hypothesized that nutrients stimulate serotonin release 
from ECCs, which consequently stimulates GLP-1 secretion via a serotonin receptor 
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at EECs. This was studied by analyzing serotonin,  GLP-1, PYY and CCK release 
from intestinal tissue segments after exposure to a lipid mixture (safflower oil), protein 
(casein), carbohydrate (sucrose) and a non-caloric sweetener (rebaudioside A).
Next, the role of   serotonin on GLP-1 release from intestinal segments  was studied 
using the selective serotonin re-uptake inhibitor (SSRI) fluoxetine. Fluoxetine inhibits 
serotonin re-uptake that is mediated by the membrane embedded serotonin reuptake 
transporter (9). Two different models were used; an ex vivo and in vitro model. First, 
porcine intestinal segments were applied because these conglomerates of  multiple 
cell types such as EECs, ECCs, and absorptive enterocytes offer a suitable system to 
study cellular interactions involved in serotonin and GLP-1 release. Second, serotonin-
stimulated GLP-1 release was studied using the murine enteroendocrine STC-1 cell line 
(10). STC-1 cells were exposed to serotonin and the non-specific receptor antagonist 
asenapine or the specific 5-HT3 receptor antagonist ondansetron.  
Material and Methods
Chemicals  
Casein (food grade containing sodium, purity 88%, batch number 15156) was obtained 
from Dutch Protein Services BV (Tiel, The Netherlands). Rebaudioside A (food grade, 
purity >97%, batch number 20110301, Chemspider ID 5294031) was obtained from 
SteviJa Natuurlijk BV (Drachten, The Netherlands). Sucrose (food grade, purity >99.9%) 
was supplied by Suiker Unie (Oud Gastel, The Netherlands). Safflower oil (food grade, 
composed of  3% C16:0, 2-5% C18:0, 9-15% C18:1 and 75-85% C18:2) was provided 
by De Wit Specialty Oils (De Waal, The Netherlands). Safflower oil was emulsified 
as described previously (3, 11) using potassium caseinate (2.5% w/v), xanthan gum 
and guar gum (both 0.1% w/v, GF supplies, Amsterdam, The Netherlands). Asenapine 
maleate (purity >98%), 5-hydroxytryptamine hydrochloride (serotonin, purity >98%), 
fluoxetine hydrochloride, L-ascorbic acid (purity >99%), pargyline hydrochloride 
and phenylmethanesulfonyl fluoride (PMSF) were obtained from Sigma Aldrich 
(Zwijndrecht, The Netherlands). Chemicals to prepare the Krebs-Ringer bicarbonate 
(KRB) buffer were: D-glucose (1.8 g/L), magnesium chloride (0.0468 g/L), potassium 
chloride (0.34 g/L) sodium chloride (7.0 g/L), sodium phosphate dibasic (0.1 g/L) 
sodium phosphate monobasic (0.18 g/L), and HEPES (5.95 g/L) were all obtained from 
Sigma Aldrich (Zwijndrecht, The Netherlands). Hanks’ Balanced Salt Solution (HBSS) 
was obtained from Life technologies Europe BV (Bleiswijk, The Netherlands) and was 
supplemented with 10mM HEPES (Merck Millipore, Darmstadt, Germany). Lonza 
(Verviers SPRL, Belgium) provided Dulbecco’s Modified Eagle Medium (DMEM), 
fetal calf  serum (FCS). The pH of  both the buffers was adjusted to pH 7.4 and both 
buffers contained 1 mM L-ascorbic acid and 100 µM pargyline to prevent oxidation and 
metabolism of  serotonin by monoamine oxidase as described previously (12).
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Collection of  porcine intestinal tissues
Intestinal tissues were obtained from 10 male pigs (Sus scrofa domesticus), considered 
healthy after evaluation by a veterinarian. The protocol for this study was approved by the 
Animal Ethics Committee Utrecht (Ethics Committee Permit Numbers 2014.I.01.001 
and 2014.I.06.037, Utrecht, The Netherlands). The pigs had a mean (± SEM) body mass 
of  88 ± 4 kg and a mean age of  6  months. Pigs were housed in groups, fed ad libitum 
with a standard pig diet (Vitaal P 003103, de Heus, Ede The Netherlands) with free 
access to water. The pigs were killed by a veterinarian through an intracardial injection 
of  Euthanimal (pentobarbital 40%, 30 ml per pig) (Alfasan, Woerden, NL). Within 
approximately 5 minutes after the pigs were killed, the intestines were excised, and 
intestinal tissue of  about 1 meter length of  different anatomical regions were collected 
and stored in ice-cold oxygenated (95% O2, 5% CO2) KRB buffer. Duodenal tissue was 
collected at 10 cm below the pylorus, jejunal tissue was collected 4.5 meters proximal 
from the ileocaecal junction and ileal tissue was collected at 1 meter proximal from the 
ileocaecal junction. Tissues were transported to the laboratory and immediately used for 
ex vivo experiments.
The time between excision and start of  the experiments did not exceed 30 minutes. To 
determine the intracellular concentrations of  serotonin, CCK, GLP-1 and PYY whole 
tissue segments (0.5 cm2) from duodenal, jejunal and ileal tissue were immediately snap 
frozen and stored below -70°C.
Stimulation of  intestinal segments with casein, safflower oil, sucrose and rebaudioside A
Concentrations of  the nutrient stimuli chosen are within the physiological range and 
these concentrations previously showed to stimulate GLP-1 release in the same porcine 
intestinal segment model (3).  Incubations of  porcine intestinal tissue segments with 
casein (1% w/v), rebaudioside A (12.5 mM), sucrose (50 mM), safflower oil (3.35% 
w/v), serotonin (30 µM) and fluoxetine (0.155 µM) alone, or in the presence of  fluoxetine 
(0.155 µM) were performed as described previously (3). In brief, upon arrival at the 
laboratory the intestine was rinsed with ice-cold oxygenated KRB buffer and cut open 
in a longitudinal direction. The outer muscle layers were carefully stripped off  with the 
basolateral side upward. The mucosal tissue was placed with the apical side upward, and 
circles of  tissue with a diameter of   8 mm (about 0.5 cm2) were punched out using a 
disposable biopsy punch (Medline Industries, Inc. Mundelein, Illinois, USA). Intestinal 
segments of  duodenal and ileal tissue were used for the incubation experiments. The 
intestinal segments were transferred to a 48-wells plate which was filled with 500 
µL ice-cold KRB buffer per well, and kept on ice until the start of  the experiment. 
Thereafter, the tissues were brought to room temperature within 30 minutes, followed 
by a preheating step at 37°C for 1 hour in a humidified incubator (95% O2, 5% v/v 
CO2). Within the time of  this preheating step all tissue segments exposed to the SSRI 
fluoxetine were pre-incubated with fluoxetine, 30 minutes before the actual incubation 
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started, by replacing the KRB buffer with KRB buffer in which fluoxetine had been 
dissolved. The concentrations fluoxetine (0.155 µM) and serotonin (30 µM) used were 
selected based on pilot experiments analyzing tissue uptake of  radiolabeled serotonin 
after exposure to various concentrations of  fluoxetine and serotonin, and on a previous 
study showing an IC50 for fluoxetine of  0.0155 µM in Caco-2 cells (12).
To study the release of  serotonin, CCK, PYY and GLP-1, incubations were initiated 
by replacing the KRB buffer solution with preheated (37°C) isosmotic KRB buffer 
without D-glucose containing the test compounds. KRB buffer without D-glucose was 
used as a control since D-glucose might induce gastrointestinal hormone release. Next, 
the tissue was put in a humidified incubator for either 5, 10, 20 or 60 minutes at 37°C 
(5% (v/v) CO2). After incubation (5, 10, 20 and 60 minutes) samples of  incubation 
media were collected, mixed with 100 µM  PMSF to inactivate dipeptidyl peptidase IV, 
aliquoted and either stored at 4°C for further analysis of  lactate dehydrogenase (LDH) 
or stored below -70°C for further analysis of  serotonin, CCK, GLP-1 and PYY.
Tissue viability was checked by measuring the leakage of  intracellular LDH as described 
before (3, 13) using an LDH kit (Sigma Aldrich, Zwijndrecht, the Netherlands). LDH 
activity in the supernatant was expressed as a percentage of  the total LDH activity 
present in control tissue collected before incubation. Total tissue levels of  LDH and 
intracellular serotonin, CCK, GLP-1 and PYY were determined in 0.5 cm2 tissue 
segments of  duodenum, jejunum, and ileum, which were homogenized in ice-cold KRB 
buffer containing 100 µmol/L PMSF with a Potter Elvehjem type Teflon pestle tissue 
grinder (Braun, Melsungen, Germany) for 5 minutes at 200 rounds per minute. Samples 
were only included for further analysis when LDH leakage did not exceed 10% of  the 
total LDH tissue content. No samples had to be excluded on the basis of  this criterion. 
Incubation of  STC-1 cells with serotonin 
STC-1 cells, a murine pluripotent enteroendocrine cell-line, were cultured in Dulbecco’s 
modified Eagle’s medium containing 10% fetal  calf ’s serum (Life Technologies Europe 
BV., Bleiswijk, NL) and 1% Penicillin-Streptomycin  (Lonza, Verviers, BE). For the 
GLP-1 secretion experiments the cells were grown in a 24-wells plate. Upon reaching 
80% confluence, medium was washed and replaced by Hank’s balanced salt solution 
(HBSS) (Life Technologies Europe BV., Bleiswijk, NL) with serotonin (0, 10, 30 and 
100 µM). STC-1 cells were incubated with serotonin (0, 30 µM) in the presence and 
absence of  asenapine (0, 1 and 10 µM) a non-specific serotonin receptor antagonist 
(14) and in the presence and absence of  ondansetron (0, 1 and 10 µM) a specific 5-HT3 
receptor antagonist (15, 16) to investigate whether serotonin-stimulated GLP-1 release 
is mediated through a receptor-mediated process. The concentrations asenapine and 
ondansetron were chosen based on literature data (14-16). Cells were pre-incubated 
with either asenapine  or ondansetron for  30 minutes in a humidified incubator (37°C; 
95% O2, 5% v/v  CO2). After pre-incubation, medium was replaced by HBSS containing 
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test compounds and incubated for 2 hours. Media samples were collected, PMSF (100 
µM) was added and samples were stored at -20°C for GLP-1 analysis. Cell viability 
was analyzed by measuring leakage of  intracellular lactate dehydrogenase (LDH) into 
the media, and expressed as a percentage of  total leakage induced by 1% Triton-X100 
incubation. LDH leakage did not exceed 10%.  Furthermore, cell viability was checked 
by neutral red assay (17). None of  the test conditions affected cell viability. 
Serotonin, CCK, GLP-1 and PYY analysis
Serotonin was analyzed according to instructions of  the manufacturer by a commercially 
available enzyme-linked immunosorbent assay (ELISA) (BA E-5900; Labor Diagnostika 
Nord GmbH &  Co. Germany), using a BioTek Synergy HT absorbance microplate 
reader (BioTek Instruments, Inc. Winooski, VT, USA). The detection range of  this 
assay is 0.015 – 2.5 ng/mL. The inter-assay coefficient of  variation (CV) of  this kit is 
18% and the intra-assay variation is 14%. If  necessary, samples were diluted with assay 
buffer to obtain concentrations within the detection range of  this kit.  
Concentrations of  CCK-8 (CCK 26-33) were analyzed with an optimized and validated 
commercial human RIA kit (EURIA-CCK, RB302, Euro-diagnostica, Malmö, Sweden). 
An identical sequence of  CCK-8 has been found for most mammals, among them pig 
and man. This improved assay system has been optimized to reach a high sensitivity 
of  0.05 pM and does not have cross-reactivity with gastrin-17 or sulfated gastrin. The 
intra-assay CV was 8.9% at a concentration of  0.84 pM and 4.9% at a concentration 
of  1.98 pM. Radioactivity of  [125I]-CCK-8 was measured by liquid scintillation counting 
using a gamma counter (EC&G, Breda, The Netherlands). 
Active GLP-1 (7-36) was determined using a Glucagon Like Pepide-1 (Active) 
ELISA kit (EGLP-35K, Millipore, Linco Research, Billerica, MA, USA) according to 
the manufacturer’s instructions. Since the GLP-1 hormone gene sequence is highly 
preserved, this kit can be applied for analyzing porcine GLP-1. The range of  this assay 
is 2-100 pM. The inter-assay CV is 11% and the intra-assay CV is 6%. When necessary, 
samples were diluted in assay buffer from the kit to be within the detection range of  
this assay.
PYY release was analyzed by a commercially available ELISA kit for total porcine PYY 
(Bachem, Penisula Laboratories, San Carlos, CA, USA) according to the manufacturer’s 
instructions. This kit measures porcine PYY, and the range of  this assay is approximately 
4.6 - 150 pM. The inter-assay CV is 6% and the intra-assay CV is 3%. It was not necessary 
to dilute samples for this assay.  
Statistical analysis
Statistical analysis was performed using the SAS statistical software package (SAS 
version 9; SAS Institute, Cary, NC, USA). All variables, serotonin, CCK, GLP-1 
and PYY were compared with a mixed analysis of  variance (ANOVA) model. Data 
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were visually checked on normality and on constant variance of  residuals by plots of  
residuals vs. corresponding predicted values. If  data was not normally distributed, log 
transformation was applied for further analysis of  the data as was the case for CCK, 
GLP-1 and serotonin. For the intestinal segment experiments the statistical model 
included the fixed factors time (5, 10, 20 and 60 minutes), location (duodenum and 
ileum) and treatment (control, casein, safflower oil, sucrose, rebaudioside A, serotonin, 
fluoxetine, casein and fluoxetine, safflower oil and fluoxetine, sucrose and fluoxetine, 
rebaudioside A and fluoxetine, serotonin and fluoxetine). Because all incubations were 
performed using intestinal tissue  obtained from the same pig, intervention effects 
within the intestine of  one pig were compared by including the random factor pig, 
which specifies the individual pig. For the STC-1 cell experiments the statistical model 
included fixed factors serotonin (0 and 30 µM) and asenapine (0, 1 and 10 µM). A post 
hoc test with Tukey-Kramer adjustment was used if  an significant effect occurred.  Data 
are presented as the mean ± SEM and differences are considered signifcant at p<0.05. 
Results 
Intestinal hormone concentrations in tissue segments and effects of  nutrients and rebaudioside A on 
GLP-1, PYY and CCK release 
GLP-1 tissue concentrations were highest in ileum followed by jejunum and duodenum 
(0.3±0.1, 6.7±0.7, 10.5±1.2 pmol/cm2 tissue in duodenum, jejunum, and ileum, 
respectively). PYY concentrations in tissue were highest in jejunum followed by ileum 
and duodenum (1.1±0.4, 7.7±1.0, 4.3±0.8 pmol/cm2 tissue, for duodenum, jejunum and 
ileum, respectively) and CCK intestinal tissue concentrations were highest in duodenum 
followed by jejunum and ileum (12.8±1.6, 1.5±0.3, and 0.27±0.1 pmol/cm2 tissue, for 
duodenum, jejunum and ileum, respectively).
The effects of  casein, sucrose, safflower oil and rebaudioside A on GLP-1, PYY and 
CCK release from ileal and duodenal  segments are presented in Figure 3.1. The effects 
on GLP-1 release from ileal segments were the most pronounced (Figure 3.1A). 
Casein, sucrose and rebaudioside A all induced a marked GLP-1 increase (p<0.001). 
The effect of  safflower oil was less pronounced (p<0.05). Casein and rebaudioside 
A also increased ileal GLP-1 release as compared to safflower oil (p<0.05). Nutrients 
and rebaudioside A did not stimulate GLP-1 release from duodenal segments (data not 
shown). 
None of  the nutrients stimulated PYY release from ileal segments as compared to 
control. Casein increased ileal PYY release as compared to sucrose and safflower oil 
(p<0.05; (Figure 3.1B)). Nutrients and rebaudioside A did not stimulate PYY release 
from duodenal segments (data not shown). 
None of  the nutrients stimulated CCK release from duodenal segments as compared to 
control. Casein and rebaudioside A increased CCK release (Figure 3.1C) as compared to 
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Figure 3.1 GLP-1, PYY and CCK released from intestinal tissue segments after exposure to various 
nutrients and rebaudioside A.  Ileal GLP-1 (A), ileal PYY (B) and duodenal CCK (C) released from 
intestinal segments after exposure to KRB buffer, sucrose, casein, safflower oil or rebaudioside A. 
$p<0.05 release is increased over time as compared to KRB buffer, ^p<0.05 release is increased over time 
as compared to safflower oil, !p<0.05 release is increased over time as compared to sucrose, *p<0.001 
release is increased as compared to KRB buffer at the same time point, #p<0.05 release is increased  as 
compared to safflower oil at the same time point.  
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exposure to sucrose and safflower oil (p<0.05). Nutrients and rebaudioside A exposure 
did not stimulate ileal CCK release (data not shown).
Serotonin stimulates GLP-1 release from ileal tissue segments and enteroendocrine cells 
Serotonin increased GLP-1 release from ileal segments several fold over time  (p<0.001) 
(Figure 3.2A). Incubation with serotonin did not change PYY release nor CCK released 
from both ileal and duodenal tissue segments (data not shown).
The role of  serotonin on GLP-1 release was further explored in STC-1 cells experiments. 
Serotonin (30 and 100 µM) stimulated GLP-1 release from STC-1 cells as compared to 
control and to 10 µM serotonin (p<0.001) (Figure 3.3A). Serotonin-stimulated GLP-
1 release was inhibited by the non-specific serotonin receptor antagonist asenapine 
(Figure 3.3B). Effects were significant at 10 µM asenapine (p<0.05) but not  at 1 µM 
asenapine (p=0.07).  Exposure of  STC-1 cells  to asenapine alone did not affect GLP-1 
release. Ondansetron (1 and 10 µM) a specific 5-HT3 receptor antagonist had no effect 
on serotonin-stimulated GLP-1 release (data not shown). 
Serotonin intestinal tissue concentrations and induction of  it’s release following exposure to  casein 
and safflower oil
Tissue concentrations of  serotonin showed a different distribution pattern over the small 
intestine compared to that of  GLP-1, PYY and CCK. Tissue concentrations of  serotonin 
were highest in duodenum, followed by ileum and jejunum (2463±363, 884±202, and 
1371±154 pmol/cm2 tissue for duodenum, jejunum and ileum, respectively). 
To study the effect of  (non-)nutritional stimuli on serotonin release from intestinal 
epithelium, concentrations of  serotonin secreted in the medium were analyzed after 
Figure 3.2 GLP-1 released from ileal tissue segments after exposure to serotonin.  $p<0.05 GLP-1 
release is increased over time as compared to KRB buffer. *p<0.001 significant increased GLP-1 release 
as compared to KRB buffer at the same time point. 
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exposure of  the tissues to casein, safflower oil,  sucrose and rebaudioside A. Casein and 
safflower oil caused increased serotonin concentrations in media over time (p<0.001) 
(Figure 3.4), with media concentrations from duodenum approximately 10 times 
higher as compared to media concentrations from ileum (p<0.001). Duodenal and 
ileal serotonin concentrations in medium did not change by exposure to sucrose and 
rebaudioside A (Figure 3.4). 
Figure 3.3 GLP-1 released from STC-1 cells after exposure to serotonin (A), GLP-1 released in the 
absence and presence of  the non-specific serotonin receptor antagonist asenapine (B) (n=3). 
**p<0.001 increased GLP-1 release as compared to 0 and 10 µM serotonin. *p<0.01 GLP-1 release is decreased as 
compared to 30 µM serotonin. #p=0.07 1 µM asenapine tended to inhibit serotonin-stimulated GLP-1 release. 
SERT inhibition augments casein- and safflower-stimulated serotonin release
Blocking the cellular reuptake of  serotonin with fluoxetine resulted in increased serotonin 
concentrations in the medium from duodenal segments after 60 minutes (p<0.001) 
(Figure 3.5A). Fluoxetine induced a smaller effect on serotonin concentrations in 
medium from ileal tissue segments, these concentrations being increased after 20 
minutes only (p<0.05) (Figure 3.5B).   
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The combination of  fluoxetine and casein increased serotonin medium concentrations 
from duodenal and ileal tissue incubations as compared to fluoxetine alone (p<0.001) 
and casein alone (p<0.05 at 10 minutes) (Figure 5). Combining fluoxetine with safflower 
oil increased serotonin medium concentrations from duodenum and ileum as compared 
to fluoxetine alone (p<0.001) (Figure  3.5). 
Figure 3.4 Serotonin released from duodenal (A) and ileal (B) tissue segments after exposure to various 
nutrients and rebaudioside A. Duodenal (A) and ileal (B) serotonin released from intestinal segments after 
exposure to KRB buffer, sucrose, casein, safflower oil or rebaudioside A. ***p<0.001 release is increased 
over time as compared to KRB buffer, *p<0.001  release is increased as compared to KRB buffer at the 
same time point.
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The combination of  rebaudioside A and fluoxetine increased duodenal serotonin 
concentrations in medium only after 10 minutes as compared to rebaudioside A 
(p<0.001). However, serotonin concentrations in medium of  ileum did not change after 
exposure to the combination of  rebaudioside A and fluoxetine (data not shown). The 
combination of  sucrose and fluoxetine did not change serotonin concentrations in the 
media of  both duodenal and ileal segments (data not shown). 
Figure 3.5 Serotonin released from duodenal (A) and ileal (B) tissue segments after exposure to casein 
and safflower oil in the presence and absence of  fluoxetine. Duodenal (A) and  Ileal (B) serotonin 
concentrations in incubation media after exposure to KRB, fluoxetine, casein, casein + fluoxetine, 
safflower oil and safflower oil + fluoxetine.  *p<0.001 increased as compared to KRB buffer at the same 
time point,  $p<0.001 increased as compared to fluoxetine at the same time point, ^p<0.001 increased as 
compared to casein at the same time point. 
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Figure 3.6 GLP-1, PYY and CCK released from intestinal tissue segments after exposure to casein in the 
presence and absence of  fluoxetine. Ileal GLP-1 (A), ileal PYY (B) and duodenal CCK (C) released after 
exposure to KRB buffer, fluoxetine, casein or the combination of  casein and fluoxetine. $p<0.05 release is 
increased over time as compared to KRB buffer. *p<0.001 increased release as compared to KRB buffer 
at the same time point.
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Figure 3.7 GLP-1, PYY and  CCK released from intestinal segments after exposure to various nutrients 
and rebaudioside A in the presence and absence of  fluoxetine. Area under the curves (AUCs) of  ileal 
GLP-1 (A), ileal PYY (B) and duodenal CCK (C) released after exposure to various stimuli with and 
without fluoxetine. The AUCs of  CCK, PYY and GLP-1 are increased by SERT inhibition as compared 
to stimuli exposure alone (fluoxetine effect p<0.01). #p<0.05 increased compared to KRB buffer, 
%p<0.05 increased compared to safflower oil, !p<0.05 increased compared to safflower oil + fluoxetine, 
^p<0.05 increased compared to serotonin, *p<0.05 increased compared to sucrose, $p<0.05 increased 
compared to sucrose + fluoxetine.  
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SERT inhibition increases nutrient- and rebaudioside A-stimulated GLP-1, PYY and CCK 
release
Fluoxetine alone increased GLP-1 release (p<0.001), whereas ileal PYY and duodenal 
CCK release were not changed. The combination of  casein and fluoxetine increased 
GLP-1 (p<0.01),  PYY and CCK release over time (p<0.001) (Figure 3.6). For the 
other combinations of  nutrients and sweetener with fluoxetine no time and treatment 
interactions were found. However, since the release of  GLP-1, PYY and CCK tended to 
be increased by the addition of  fluoxetine as compared to nutrient exposure alone, total 
area under the curves (AUC) were calculated. Overall, the combination of  fluoxetine 
with the nutrients tested and with rebaudioside A resulted in increased AUCs of  GLP-1 
(Figure 3.7), PYY and CCK release vs nutrients alone (p<0.01). 
Discussion 
In our study we showed that GLP-1 release from intestinal tissue following stimulation 
by different (non-)nutritional stimuli could be further augmented by adding the 
serotonin reuptake inhibitor fluoxetine. Next to this, serotonin itself  stimulated GLP-1 
release from ileal tissue segments and from STC-1 cells. The latter was inhibited by the 
non-specific serotonin receptor antagonist asenapine suggesting a receptor-mediated 
process.
All nutrients and mixtures tested as well as the non-caloric sweetener rebaudioside A 
stimulated GLP-1 release from intestinal tissues, which confirmed our previous findings 
using the same intestinal segment model (3). These data correspond to findings in 
vivo as well, since ileal stimulation with the same macronutrients resulted in increased 
satiation and satiety hormone release (11). For rebaudioside A, however, it is not known 
if  this stimulates GLP-1 release in vivo as well and hence induces satiation. Another 
study demonstrated satiating properties of  stevia in vivo (18) whereas other sweeteners 
including sucralose did not affect satiety hormone release in vivo (19, 20). 
In the experiments described here, time-dependency of  satiety hormone release was 
studied. Compared to our previous study we found a slightly higher PYY release from 
ileal segments after exposure to buffer only. It is unlikely that this effect is due to tissue 
damage, since LDH leakage was below 10%. CCK release from duodenal segments 
was analyzed for the first time using this ex vivo model. Surprisingly, rebaudioside A and 
casein stimulated CCK release only when compared to sucrose and safflower oil,  but 
not when compared to control. Safflower oil was expected to increase CCK, as it was 
shown before that intraduodenal lipid infusions resulted in increased CCK levels in vivo 
(21). In the latter study, lipid infusions of  mixtures of  linoleic, oleic and palmitic acid 
were used. 
Overall, the results of  the present study illustrate that the ex vivo model being a 
conglomerate of  multiple cell types such as EECs, ECCs and absorptive enterocytes, 
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offers a suitable system to study the cellular interactions involved in serotonin and 
GLP-1 release.
It is known that nutrient sensing GPCRs and ion-dependent nutrient transporters at 
EECs play a major role in nutrient-stimulated GLP-1, PYY and CCK release (15, 21). 
However, not for all nutrients stimulating GLP-1, PYY or CCK release, a receptor 
is known. We hypothesized that nutrient-receptor interaction results in serotonin 
release, and that this released serotonin enhances nutrient-stimulated GLP-1 release. A 
hypothetic model for this effect is depicted in Figure 3.8.
The proposed mechanism by which serotonin may contribute to receptor-mediated 
GLP-1 release is; 1) nutrients stimulate serotonin release from ECCs via interaction 
with GPCR receptors on ECCs (7), subsequently 2) this released serotonin stimulates 
the release of  GLP-1 from EECs via a serotonin receptor-mediated process. This 
hypothesis is supported by the data found in the present study. We showed that nutrients 
stimulated serotonin release from ileal tissue segments and that serotonin stimulated 
GLP-1 release from ileal tissue segments. Also in the enteroendocrine STC-1cell model, 
serotonin stimulated GLP-1 release which could be inhibited by a non-specific serotonin 
receptor agonist asenapine. 
Figure 3.8 Proposed mechanism of  serotonin modulating GLP-1 release from the ileum
This cartoon illustrates the following hypothesis; dietary compounds such as casein, safflower oil, sucrose or rebaudioside 
A may stimulate GLP-1 release from an EEC via interaction with a GPCR (A), simultaneously casein may stimulate extra-
intestinal serotonin concentrations from ECC via interaction with a GPCR (B). Consequently this induced serotonin 
release may stimulate (additional) GLP-1 release via interaction with an 5-HT receptor on EEC (C).  
Asenapine has binding affinities for various serotonin receptors including the 
5HT1a, 5-HT1b, 5-HT2a, 5-HT2b, 5-HT2c, 5-HT5, 5-HT6 and 5-HT7 receptor (14). It 
should be noted that this antagonist has binding affinities for other receptors such 
as adrenoreceptors and dopamine receptors as well (14). However, because asenapine 
inhibited GLP-1 release after  stimulation with serotonin, we believe this effect to be 
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mediated via serotonin receptors. In contrast to asenapine, ondansetron, a specific 5-HT3 
receptor antagonist did not inhibit serotonin-stimulated GLP-1 release from STC-1 
cells. This suggests that receptors other than the 5-HT3 receptor mediate serotonin-
stimulated GLP-1 release. A potential candidate may be the 5-HT1b receptor. Asenapine 
has affinity for this 5-HT1b receptor. A recent report also showed that stimulation of  
5-HT1b receptors with specific 5-HT1b agonists enhanced GLP-1 plasma concentrations 
in mice (22). Further studies are needed to identify the specific serotonin receptors 
involved in serotonin-stimulated GLP-1 release.
This study has also limitations that warrant discussion. First, the data presented support 
the idea that serotonin contributes to nutrient-stimulated GLP-1 release, whereas the 
effects on CCK and PYY were less convincing. Such an effect may relate to serotonin 
receptor distribution in the small intestine. Possibly, serotonin receptors on GLP-1 
containing L-cells in the ileum are more abundant than those on EECs containing 
PYY, or CCK in the duodenum. Remarkable though was that serotonin release and 
tissue concentrations were highest in duodenum. Therefore, more studies are needed to 
investigate serotonin receptor expression on EECs and to study the relation between 
activation of  specific serotonin receptors and GLP-1, PYY and CCK release. 
Second, sucrose and rebaudioside A both stimulated GLP-1 release and this GLP-
1 release was further stimulated after inhibition of  serotonin reuptake. However, 
serotonin release was not stimulated by these compounds. It was expected that sucrose 
and rebaudioside A would result in serotonin release since other studies showed that 
odorants and tastants other than rebaudioside A stimulated serotonin release from 
enterochromaffin cells (7, 23). Possibly, the turn-over of  serotonin is so high that 
quantities of  serotonin accumulated in the incubation media were too low to be detected. 
It would be interesting to use alternative methods to provide more insight in the timing 
and sequence of  the release of  serotonin and satiety hormones. One interesting method 
is amperometrical recording (24), which has been applied to measure serotonin release 
from rabbit ileal mucosa and from ECCs (23, 25). 
Third, the combination of  nutrients and fluoxetine further enhanced nutrient-stimulated 
GLP-1, PYY and CCK release from intestinal segments. However, the additional effect 
of  fluoxetine was only small in comparison to hormone release induced by the nutrients 
alone, possibly due to the fact that there was already a copious release of  serotonin in the 
epithelial space. Further studies are needed to investigate the magnitude of  serotonin’s 
contribution to nutrient-stimulated GLP-1 release.  
Collectively, our data suggest an additional mechanism for nutrient-stimulated GLP-1 
release via the release of  serotonin by ECCs. Serotonin present in the small intestine 
contributes to the enhancement of  GLP-1 release by responding to macronutrients, 
possibly via the activation of  serotonin receptors on EECs. This additional mechanism 
contributes to the idea that nutrient sensing in the small intestine is regulated by 
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interaction of  multiple cells that respond to nutrient fluctuations in order to optimize 
food digestion and regulation of  food intake.  
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Abstract 
The vagal nerve and gut hormones CCK and GLP-1 play important roles in the control 
of  food intake. However, it is not clear to what extent CCK and GLP-1 increase satiation 
by stimulating receptors located on abdominal vagal nerve endings or via receptors 
located elsewhere. This study aimed to further explore the relative contribution of  
the abdominal vagal nerve in mediating the satiating effects of  endogenous CCK 
and GLP-1. Total subdiaphragmatic vagotomy or sham operation was combined with 
administration of  CCK1 and GLP-1 receptor antagonists devazepide and exendin (9-
39) in 12 pigs, applying an unbalanced Latin Square within-subject design. Furthermore, 
effects of  vagotomy on preprandial and postprandial acetaminophen absorption, 
glucose, insulin, GLP-1 and CCK plasma concentrations were investigated. 
Ad libitum liquid meal intake (mean ± SEM) was similar in sham and vagotomized pigs 
(4180 ± 435 and 3760 ± 810 gram/meal). Intake increased by about 20 % after blockade 
of  CCK1 receptors, independently of  the abdominal vagal nerve. Food intake did not 
increase after blockade of  GLP-1 receptors. Blockade of  CCK1 and GLP-1 receptors 
increased circulating CCK and GLP-1 concentrations in sham pigs only, suggesting the 
existence of  a vagal reflex mechanism in the regulation of  plasma CCK1 and GLP-1 
concentrations. Vagotomy decreased acetaminophen absorption and changed glucose, 
insulin, CCK and GLP-1 concentrations indicating a delay in gastric emptying. Our 
data show that at  liquid feeding, satiation is decreased effectively by pharmacological 
blockade of  CCK1 receptors. We conclude that regulation of  liquid meal intake appears 
to be primarily regulated by CCK1 receptors not located on abdominal vagal nerve 
endings.
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Introduction
The regulation of  appetite and food intake is complex and consists of  several processes, 
each involving combinations of  different and interacting regulatory mechanisms (1). 
A better understanding of  these processes is not only relevant to prevent overweight, 
but also relevant in relation to unintentional weight loss as for example in cachexia or 
sarcopenia. Two key processes involved in limiting food intake are satiety and satiation. 
Satiety refers to the feeling of  fullness after a meal, which decreases in time and ultimately 
leads to initiation of  a new meal (2, 3). Satiation refers to processes that promote meal 
termination by which meal size is limited (4). Nutrient sensing in the gastrointestinal 
tract is one of  the processes involved in generating satiation responses. This process 
may be defined as the activation of  neural and hormonal signals in response to nutrients 
passing the gastrointestinal tract.
The vagal nerve is involved in the neural regulation of  satiation (5). The vagal nerve by 
its efferent fibers controls intestinal motility and as a consequence the intestinal transit 
time of  nutrients. As such the vagal nerve contributes to the exposure time of  the 
nutrients to the enteroendocrine cells located in the small intestine (6).
Gastrointestinal hormones such as cholecystokinin (CCK) and glucagon-like peptide 
1 (GLP-1) are playing important roles in generating satiation. These hormones are 
released when nutrients are sensed by receptors located on enteroendocrine cells which 
are distributed over the small intestine. CCK is mainly released by enteroendocrine 
I-cells which are relatively abundant in the duodenum, whereas GLP-1 is released by 
enteroendocrine L-cells mainly distributed over the distal jejunum, ileum and colon 
(7, 8). CCK is mainly secreted in response to dietary fat and protein (8). The largest 
bioactive form is CCK-83, which corresponds to the amidated sequence 1-83 of  
proCCK. This sequence is cleaved variably at four monobasic sites to release CCK-58, 
CCK-33, CCK-22 and CCK-8, all of  which have the same C-terminal heptapeptide 
amide sequence which is necessary for receptor binding (9-11). There are two types of  
CCK receptors, CCK1 receptors and CCK2 receptors. The vagal nerve expresses CCK1 
receptors. Studies where this receptor is blocked using specific CCK1 antagonists, such 
as devazepide, resulted in increased food intake (12). These results show that this CCK1 
receptor is important for the regulation of  food intake. 
The GLP-1 receptor is expressed on enteric nerves, vagal nerve endings, and in the 
pancreas, stomach, small and large intestine, adipose tissue and brain (7, 13). Similar 
to CCK, GLP-1 levels in plasma increase after a meal (14). GLP-1 exists in multiple 
forms, the majority (at least 80%) of  circulating biologically active GLP-1 in humans is 
the COOH terminally amidated form, GLP-1 (7–36) amide, with lesser amounts of  the 
minor glycine extended form, GLP-1 (7–37). Other forms of  GLP-1 are 9-36 and 9-37 
which arise after the action of   the serine protease dipeptidyl peptidase IV (DPP-IV) 
(7, 15).
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 It has been shown that peripheral administration of  exogenous GLP-1 and CCK 
reduces food intake in humans and experimental animals (16-20). Studies, mostly 
in rodents, suggest  that this effect is mediated via vagal afferent nerves (12, 21-24). 
However there is also evidence from studies using pharmacological receptor blockade 
that endogenous CCK stimulates satiety not only via vagal afferent nerves but also 
via CCK1 receptors beyond the blood brain barrier independently of  the vagal nerve 
(25, 26). For this reason in the present study it was investigated whether CCK and 
GLP-1 affect food intake via their receptors located at the abdominal vagal nerve, 
or by receptors elsewhere. In this study we have used the pig as experimental model 
for food intake regulation. Pigs resemble humans in many ways with respect to the 
omnivorous character of  food intake, digestion, endocrine regulation of  metabolism 
and neurophysiologic modulation of  food intake (27, 28).
To determine whether the effects on food intake of  endogenous CCK and GLP-
1 are mediated via receptors located at the abdominal vagal nerves, or receptors 
located elsewhere, ad libitum liquid food intake was studied after blocking the CCK1 
receptors, GLP-1 receptors or both, in a group of  sham operated and a group of  total 
subdiaphragmatic vagotomized pigs. These effects were further studied by evaluating 
pre- and postprandial hormone responses and portal-peripheral hormone gradients.
Material and methods
Ethical approval
All procedures involving animal handling and testing were reviewed and approved 
by the ASG-Lelystad Animal Care and Ethics Committee (Ethics Committee permit 
number 2011143 Lelystad, The Netherlands).
Design 
Twelve domestic 4 months old, crossbred (Yorkshire x Landrace) male pigs, weighing 49 
± 10.2 kg (Wageningen UR-Swine Innovation Centre, Sterksel, The Netherlands) were 
used in the study. Two weeks before surgery the pigs were kept in specially designed 
metabolic pens (1.15 x 1.35 m) and adapted to the light/dark cycle (lights on at 05:00 h 
and off  at 19:00 h) and the feeding schedule. During the whole study period pigs were 
fed twice a day at 08:00 AM and 04:00 PM at a restricted feeding level of  2.8 times 
maintenance requirements (MR) for metabolisable energy (MR=293 kJ/kg BW0.75). 
For a pig of  60 kg this amount is approximately 16 MJ gross energy per meal which 
is practically close to ad libitum access to food (29). The diet (Milkiwean®, Trouw 
Nutrition, Putten, The Netherlands) was based on a standard pig nutrition, containing 
all required macronutrients and vitamins (Table 4.1), but fed in a liquid form (thin 
slurry 1:2 (w:v) ratio). During the whole study period water was available overnight 
from 05:00 PM to 07:00 AM. 
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Table 4.1 Chemical composition of  Milkiwean® diet 
Pigs underwent either sham surgery (further indicated as sham pigs) (n=6) or total 
abdominal subdiaphragmatic vagotomy (further indicated as vagotomized pigs) (n=6) 
under general sevoflurane anaesthesia. Using laparoscopy, in the latter both afferent and 
efferent subdiaphragmatic vagal nerves were interrupted by removal of  approximately 3 
cm length of  both vagal nerves along the esophagus in between the diaphragm and the 
stomach, as close as possible to the diaphragm in order to bypass the interconnections 
between the dorsal and ventral trunks posterior to the heart. Vagal nerve interruption was 
confirmed at necropsy; all nerve-like tissue at the level of  the esophagus and diaphragm 
was interrupted only in the vagotomized group (Figure 4.7). In the sham group exactly 
the same procedure was done without vagal nerve interruption. During and three days 
after surgery pigs were administered flunixin twice daily (2.2 mg/kg; Finadyne 50 mg/
ml, Schering-Plough Animal Health, Brussels, Belgium) to ease postsurgical pain. The 
pigs also received an antibiotic combination (once a day 50 µl/kg pig; 200.000 IU/
ml procaïne penicillin G and neomycin 100mg/ml, Neopen, Intervet, Boxmeer, The 
Netherlands) to prevent bacterial infections. After a 7 day postsurgical recovery period, 
catheterization surgery was performed. Under general sevoflurane anaesthesia, Tygon 
catheters (i.d. 1.27 mm, o.d. 2.29 mm, length 1.25 m; Access Technologies, Skokie, 
Illinois, USA) were placed into the right carotid artery, the right external jugular vein 
and the portal vein according to a procedure described previously(1, 2) Seven days after 
catheterization surgery the first study day started.
Neural and hormonal mechanisms of  satiation and satiety were investigated in a within-
subject design. Pigs were unequally divided in six groups with different treatment orders 
according to the unbalanced Latin Square design. Allocation per treatment order was 
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randomized according to weight of  the pigs. Each treatment was studied on 4 separate 
study days with 2 day wash out periods. Total study duration period was six weeks. 
Experimental design of  a study day
At 8 AM (t = 0) a standardized liquid morning meal (1.4 times maintenance requirements 
for energy, based on metabolic weight of  the pigs) was presented to the pigs. This meal 
was mixed with acetaminophen (0.02 g/kg pig) (Sigma-Aldrich Chemie BV, Zwijndrecht, 
The Netherlands) to monitor gastric emptying(3-5). At t = 120 min, an intravenous 
infusion via the jugular vein catheter was started at a rate of  20 ml/h and continued 
for 2 hours, with either placebo (saline), exendin (9-39) a selective GLP-1 receptor 
antagonist (American Peptide Company, Sunnyval, CA, USA) at 0.5 nmol/kg.min (dose 
based on human studies(6-8)), devazepide a selective CCK1 receptor antagonist (Tocris 
Bioscience, R&D Systems, Abindon, Oxon UK) at 2 nmol/kg.min (dose based on pig 
and rat studies(9-11)), or a combination of  both exendin (9-39) and devazepide. Sixty 
minutes after initiation of  the infusion (t=180 min) an ad libitum meal was presented to 
the pigs. Food intake was measured and eating behavior and time of  meal termination 
(ingestion time) were observed. At 240 min after the standardized liquid morning meal 
the study day ended. Portal vein and peripheral blood samples were taken at t = -45, -15, 
30, 60, 90, 120, 150 and 180 min.
Necropsy
Four days after the last study day, pigs were sacrificed exactly 180 minutes after they 
received a standardized liquid morning meal (1.4 times maintenance requirements for 
energy, based on metabolic weight of  the pigs) after overnight fasting. The stomach and 
intestine were excised  and total length and food content of  the small intestine, which 
was divided  into three parts, were measured. Bladder content and liver weight were also 
measured.
Plasma analysis
Portal and peripheral blood samples were collected in cooled EDTA vacutainersR 
containing dipeptidyl peptidase IV inhibitor (DPPIV) (Millipore, Billerica, MA, USA) with 
EDTA free protease inhibitor tablets (Roche Applied Sciences, Penzberg, Germany) to 
inhibit enzymatic degradation of  the bioactive hormones. Glucose levels were measured 
instantaneously using portable glucose analyzers (Medisense Precision Xceed, Abbott 
Diabetes Care Ltd. Witney, Oxon, UK) and glucose strips (Freestyle Precision, Abbott 
Diabetes Care Ltd. Witney, Oxon, UK). Blood samples were gently shaken and kept on 
ice and centrifuged at 4°C for 10 min at 2000 g within 10 minutes. Plasma samples were 
aliquoted and kept at -80°C until further analysis. Commercially available ELISA assay 
kits for active GLP-1 were obtained from Millipore (Billerica, MA, USA) and utilized 
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according to the manufacturer’s instructions using a BioTek Synergy HT fluorescence 
microplate reader (BioTek Instruments Inc., Winooski Vermont, USA). ELISA assay 
kits to analyze porcine insulin levels were obtained from Alpco Diagnostics (Salem, 
NH, USA) and were used according to the manufacturer’s instructions. Peripheral 
CCK levels were analyzed using an validated commercial available RIA kit for human 
plasma (Euro Diagnostica Malmö, Sweden) optimized for pig plasma. This kit uses 
rabbit antiserum raised against CCK 26-33 sulphate and is found to cross react with 
CCK 26-33 sulphate (100%) and CCK-33 sulphate (134%). Peripheral blood samples 
were analyzed for acetaminophen using a commercially available kit according to the 
manufacturer’s instructions (Immunalysis, Oxfordshire, UK).  
The change in plasma concentrations after the morning meal was calculated by 
subtracting the preprandial concentrations of  glucose, insulin, CCK and GLP-1 from 
each concentration on the various time points until the drug infusion started (t=120). 
This value was statistically analysed to determine the effect of  vagotomy on postprandial 
glucose, insulin, CCK and GLP-1 responses.
The portal-peripheral gradient was calculated by subtracting the peripheral concentrations 
of  glucose, insulin and GLP-1 for each time point from the portal levels.
The drug responses were analyzed by taking the time interval beginning at the start 
point of  the infusion (t=120) until the ad libitum meal started (t=180). This interval 
was further used in the statistical analysis to determine the effect of  the CCK and 
GLP-1 receptor blockade on circulating blood concentrations. The changes in plasma 
concentrations after drug infusion were calculated by subtracting the concentrations of  
glucose, insulin, GLP-1 and CCK at the start of  the drug infusion (t=120) from the 
time points at the start of   the ad libitum meal (t=180). 
Data and statistical analysis
Statistical analyses were performed using the SAS statistical software package (SAS 
version 9; SAS institute, Cary, NC, USA). Proc Gplots were used to test outcome 
variables for normality of  distribution. If  data were not normally distributed, log 
transformation was applied for further analysis of  the data as was the case for insulin, 
GLP-1, CCK and acetaminophen.
A mixed model (ANOVA) with a co-variance structure, was used to analyze the effects 
of  vagotomy and receptor blockade on food intake. Fixed factors in this model are 
vagotomy (yes/no) , devazepide (yes/no), exendin (9-39) (yes/no), combination (yes/
no) and treatment order to correct for possible treatment order effects. No treatment 
order effects were observed. Time curves of  plasma parameters were compared with 
a mixed analysis of  variance model using a co-variance structure, that included the 
fixed factors treatment (sham vs vagotomy), drug (placebo, exendin 9-39, devazepide or 
combination) and the interaction of  drug treatment and vagotomy. To exclude possible 
treatment order effects, the treatment order was added to the model. No treatment order 
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effects were observed. For the plasma parameters, time and the interaction between 
treatment and time, drug and time, and the interaction time, treatment and drug were 
added to the model. The factor entry number, which specifies the pig number, was 
added to the model as a random factor. A post hoc Tukey’s test was used to analyze 
differences between groups. Data is presented as the mean ± SEM and considered 
significant at p<0.05. Necropsy data was analyzed by using the two-tailed independent 
samples t-test.
Results
All 12 pigs rapidly recovered from surgery and showed normal pig behavior as judged 
by feed intake, weight gain and the absence of  any clinical symptoms. Weight of  the pigs 
at the start of  the study period was 49 ± 10.2 kg. Weight gain during the 6-week study 
was comparable between groups (20 ± 1.7 kg sham vs 19 ± 1.9 kg vagotomy). Data 
obtained during the last study day of  one vagotomized pig was excluded from analysis 
because the pig did not eat the standardized liquid morning meal. 
Effects of  vagotomy and CCK, GLP-1 receptor blockade on ad libitum liquid food intake
Vagotomy did not affect food intake (4180 ± 440 and 3760 ± 810 g/meal p= 0.794) 
(Figure 4.1). As compared to placebo, blocking CCK receptors using devazepide 
resulted in a significant increase (p<0.01) in food intake in both groups (Figure 4.1). 
Administration of  exendin (9-39) to block GLP-1 receptors did not affect food intake 
in both groups. The combination of  a CCK and GLP-1 receptor antagonist resulted 
in an increased meal size (p<0.05). There was no interaction between vagotomy and 
devazepide, vagotomy and exendin (9-39) or vagotomy and combination, suggesting 
Figure 4.1 Ad libitum liquid food intake for both groups after various treatments. The results are shown 
as the mean ± SEM. *p<0.05 food intake increased as compared to placebo.
Ch
ap
te
r 4
VAGOTOMY
69
that the effect of  devazepide and combination treatment was independent of  the 
vagotomy. Ingestion time was unaffected by vagotomy (6.9 ± 0.8  min sham vs 6.8 ± 
0.9 min vagotomized) and the various drug treatments (7.0 ± 0.7 min exendin (9-39) vs 
6.7 ± 0.8 min devazepide vs 7.6 ± 0.4 min combination). 
Effects of  vagotomy on preprandial plasma glucose, insulin, CCK and GLP-1 concentrations
Plasma concentrations of  glucose, insulin, CCK and GLP-1 in sham and vagotomized 
pigs were analyzed after overnight fasting on four separate study days. Preprandial 
peripheral and portal plasma concentrations of  insulin, glucose and CCK were 
significantly higher in vagotomized pigs compared to sham pigs (Table 4.2), but 
preprandial peripheral and portal GLP-1 concentrations did not differ between the two 
groups. The preprandial portal-peripheral glucose gradient was elevated in the vagotomy 
group (0.01 ± 0.1 mmol/L sham vs 0.56 ± 0.12 vagotomized p<0.01). Preprandial 
portal-peripheral gradients of  insulin and GLP-1 were not affected by vagotomy.
Table 4.2. Preprandial plasma concentrations of  glucose, insulin, GLP-1 and CCK. The effects on 
preprandial plasma concentrations are based on 48 observations per group (6 pigs, 4 study days, 2 time 
points). ND not determined
Effects of  vagotomy on postprandial glucose, insulin, CCK and GLP-1 responses
Plasma levels of  glucose, insulin, CCK and GLP-1 were analyzed to monitor the effects 
of  vagotomy on postprandial responses after a standardized liquid morning meal. The 
effects of  vagotomy on postprandial peripheral glucose and insulin levels are shown 
in Figure 4.2A and 4.2C. An overall time effect (p<0.01 peripheral, p<0.01 portal) 
and an interaction between time and vagotomy (p<0.01 peripheral, p<0.01 portal) was 
found for postprandial glucose and insulin levels. Peak levels for glucose and insulin 
were reached 30 minutes after the standardized liquid morning meal. Vagotomy did not 
affect peak peripheral glucose level (7.39 ± 0.25 mmol/L sham vs 7.22 ± 0.22 mmol/L 
vagotomy) but portal peak glucose tended to be decreased after vagotomy (10.65 ± 
0.49 mmol/L sham vs 8.68 ± 29 mmol/L vagotomy p<0.08). Peak peripheral insulin 
level was decreased after vagotomy (1.39 ± 0.23 ng/ml sham vs 0.53 ± 0.06 ng/ml 
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vagotomy p<0.05). Portal peak insulin did not differ significantly between the sham 
and vagotomized pigs (1.09 ± 0.11 ng/ml sham and 0.81 ± 0.12 ng/ml vagotomy). 
The change in peripheral glucose and insulin after a standardized liquid morning meal 
was greater in the sham group as compared to the vagotomy group (p<0.007) (Figure 
4.2B, 4.2D). 
The plasma concentrations for peripheral CCK and GLP-1 are shown in Figure 
4.3 and 4.4. A time effect (p<0.001) and an interaction between time and vagotomy 
(p<0.001) were found for postprandial peripheral CCK, however individual time points 
did not differ significantly between sham and vagotomized pigs. For postprandial GLP-
1 concentrations a time effect (p<0.001 peripheral and portal) and interaction between 
time and vagotomy (p<0.05 peripheral p<0.01 portal) were found, however individual 
time points did not differ significantly between sham and vagotomized pigs.
Figure 4.2 Peripheral glucose (A) and insulin (C) concentrations and changes (Δ) in peripheral glucose 
(B) and insulin (D) concentrations after a standardized morning meal. The results are shown as the 
mean ± SEM. The solid line represents the sham group (24 observations per time point) the dotted line 
represents the vagotomy group (24 observations per time point). *p<0.05 specific time point is significant 
different between the sham and vagotomy group. 
Effects of  CCK and GLP-1 receptor blockade in combination with vagotomy on CCK and GLP-1 
plasma concentrations
Both peripheral and portal insulin and glucose concentrations were not affected by 
the various drug treatments. An overall drug (devazepide and exendin (9-39)) effect 
(p<0.001) was found for both CCK (Figure 4.3) and GLP-1 concentrations (Figure 
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4.4). Peripheral CCK concentrations were increased after blockade of  the CCK receptor 
by devazepide in the sham group (p<0.01) and tended to be increased after combination 
treatment in the sham group (p = 0.06). The effect of  devazepide and combination 
treatment on peripheral CCK concentrations was absent in the vagotomized pigs. The 
change in peripheral CCK concentrations after the various drug treatments is shown 
in Figure 4.3B. For the change in CCK concentrations an overall vagotomy effect 
was found (p<0.05) as well as an overall drug effect (p<0.001).  CCK concentrations 
increased more after devazepide (p<0.05) as compared to placebo treatment in the 
sham operated group.
Peripheral GLP-1 was increased after blocking the GLP-1 receptor using exendin (9-
39) in the sham group (p<0.01). Vagotomy abolished the effect of  exendin (9-39) 
on peripheral GLP-1 concentrations. Combined drug treatment resulted in increased 
GLP-1 in the sham group (p<0.001) and in the vagotomized group (p<0.05). The 
Figure 4.3A Peripheral CCK  responses in the sham group (A) and the vagotomized group (B), after a 
standardized morning (t=0 min) meal and various drug treatments (t=120 min). The CCK concentrations 
(mean ± SEM) of  the sham group (A) and the vagotomy  group  (B) after a standardized liquid morning 
meal (0 minutes) and concentrations after the drug infusions started (t=120 minutes). *p<0.05 specific 
time point is significant different as compared to placebo treatment within the group. 
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change in both peripheral and portal GLP-1 concentrations is shown in Figure 4.4B. 
For both peripheral and portal GLP-1 concentrations an overall time effect (p<0.05) 
and an overall drug effect (p<0.001) was found. Vagotomy did not affect the changes 
in peripheral and portal GLP-1 concentrations. The changes in peripheral GLP-1 
concentrations were larger after the exendin (9-39) (p<0.05)  and combination (p<0.05) 
treatment as compared to placebo. The changes in portal GLP-1 concentrations were 
larger after exendin (9-39) (p<0.05) and combination (p<0.05)  treatment in the sham 
group only. 
Figure 4.3B Changes (Δ) in peripheral CCK concentrations in the sham group (A) and the vagotomized 
group (B), after  various drug treatments (t=120 min). The changes in CCK concentrations (mean ± 
SEM) of  the sham group (A) and the vagotomy  group  (B) after the drug infusions started (t=120 
minutes). *p<0.05 The change in CCK concentration is significant different compared to placebo 
treatment within the group.
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Portal-peripheral gradients 
The portal – peripheral gradients for glucose and GLP-1 are shown in Figure 4.5. For 
glucose a time effect (p<0.001) and interaction between time and vagotomy treatment 
(p<0.001) were found, with a decreased glucose gradient in the vagotomized pigs. Also 
for GLP-1 a time effect (p<0.001) and interaction between time and vagotomy treatment 
(p<0.05) were found, however individual time points did not differ significantly between 
sham and vagotomized pigs. The GLP-1 gradient was decreased after vagotomy. The 
portal-peripheral insulin gradient was not affected by vagotomy and portal CCK was 
not analyzed.
Figure 4.4A Peripheral GLP-1 responses in the sham group (A) and the vagotomized group (B) after 
a standardized morning (t=0 min) meal and various drug treatments (t=120 min).The GLP-1 plasma 
concentrations are shown as the mean ± SEM. The GLP-1 concentrations (mean ± SEM) of  the 
sham group (A) and the vagotomy group (B) after a standardized liquid morning meal (0 minutes), and 
concentrations after the drug infusions started (t=120 minutes). *p<0.05 specific time point is significant 
different as compared to placebo treatment within the group.
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The various drug treatments did not affect peripheral and portal glucose and insulin 
levels in both sham and vagotomized pigs (data not shown). Portal-peripheral GLP-1 
gradient was increased after combination treatment in both groups (p<0.05), single 
drug treatments did not affect the portal-peripheral GLP-1 gradient. 
Effects of  vagotomy on small intestinal motility and gastric emptying 
The peripheral plasma acetaminophen concentrations (µg/ml) were measured over 
time to monitor gastric emptying after the standardized liquid morning meal (Figure 
4.6). A time effect (p<0.001), vagotomy effect (p<0.001) and interaction between time 
and vagotomy (p<0.001) were found. The acetaminophen concentration was higher 
in the sham group 30 minutes after the standardized liquid morning meal (4.1 ± 0.6 
µg/ml sham vs 1.7 ± 0.2 µg/ml vagotomy p<0.01), and the maximum acetaminophen 
plasma concentrations (Cmax) was higher in the sham group (11.6 ± 1.0 µg/ml sham 
vs 4.1 ± 0.5 µg/ml vagotomy p<0.001). The time that the maximum acetaminophen 
concentrations were reached (Tmax) did not differ between groups (154 ± 8 min sham 
vs 146 ± 9 min vagotomy). 
Stomach content 180 minutes after a standardized liquid morning meal (postmortem 
examination) was larger (p<0.001) in vagotomized pigs (5320 ± 430 g) as compared 
to the sham group (1770 ± 750 g). Content of  the first 1/3 part of  the small intestine 
Figure 4.4B Changes (Δ) in peripheral and portal GLP-1 concentrations in the sham group (A and C) 
and the vagotomized group (B and D), after various drug treatments (t=120 min). Changes in GLP-1 
concentrations (mean ± SEM) of  the sham group (peripheral A, portal C) and the vagotomy  group  
(peripheral B, portal D) after the drug infusions started (t=120 minutes). *p<0.05 The change in GLP-1 
concentration is significant different compared to placebo treatment within the group.
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was larger in vagotomized pigs as compared to sham pigs (325 ± 65 g sham vs 430 ± 
85 g vagotomy, p<0.001). Length of  small intestine in vagotomized pigs was greater as 
compared to small intestinal length in sham pigs (13 ± 0.2 meter sham vs 15 ± 0.5 meter 
vagotomy, p<0.001). Content of  the second and third part of  the small intestine did not 
differ between groups, neither did liver weight nor bladder content.
Figure 4.5 Preprandial and postprandial portal-peripheral gradients of  glucose (A) and GLP-1 (B). The 
portal – peripheral gradients are shown for glucose and GLP-1. The sham group is represented by the 
solid line (24 observations per time point) and the vagotomized group is represented by the dotted line 
(20 observations per time point).
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Discussion 
The present study showed that blockade of  CCK1  receptors using devazepide, and a 
combination of  CCK1  and GLP-1 receptor blockade resulted in increased liquid food 
intake. This was observed both in the sham and vagotomized pigs which indicates that 
this effect was independent of  CCK1 receptors located on the abdominal vagal nerve. 
These results suggest that under the test conditions CCK mainly induces satiation via 
central CCK1   receptors and not via CCK1 receptors located at the abdominal vagal 
nerve. Simultaneous blocking of  both CCK1 and GLP-1 receptors did not enhance 
the effect on food intake compared to CCK1 receptor blockade alone, suggesting the 
absence of  synergy between the CCK and GLP-1 pathways. Interruption of  abdominal 
vagal signal transduction by subdiaphragmatic vagotomy did not affect ad libitum liquid 
meal size in pigs.
Figure 4.6 Appearance of  acetaminophen in plasma after standardized acetaminophen containing liquid 
morning meal in the sham (A) and vagotomized group (B). Plasma concentrations of  acetaminophen 
(µg/ml) in time in peripheral blood is shown.
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Our results on CCK are in line with previous studies in which the intravenous 
administration of  devazepide (17.5-140 µg/kg) in pigs resulted in a dose dependent 
increase in food intake (38), and also confirm rat studies showing that satiety in rats 
is mediated in part by an endogenous CCK action that is independent of  the vagal 
nerve (25). In a more recent study (26) it was concluded that endogenous CCK acts 
through CCK1 receptors beyond the blood brain barrier and through CCK1 receptor-
mediated mechanisms involving abdominal vagal nerves. This was studied in rats by 
using two antagonists of  which one does not cross the blood brain barrier, whereas 
the other devazepide does. This rat study showed that CCK increases food intake via 
CCK1  receptors beyond the blood brain barrier. This finding  was confirmed in our 
pig study showing that devazepide is effective in increasing food intake in vagotomized 
pigs. Furthermore, Reidelberger et al.(26) found that endogenous CCK can also act 
on mechanisms involving abdominal vagal nerves to inhibit food intake. The latter 
mechanism seems to play no major role in the regulation of  liquid food intake in pigs 
because vagotomy did not alter the efficacy of  devazepide in our study.
In our study GLP-1 receptor blockade with exendin (9-39) did not affect food liquid 
food intake. This is in line with another rat study in which the intravenous administration 
of  10 or 30 nmol/kg body weight exendin (9-39) failed to increase spontaneous meal 
size (40).
However, the effects of  GLP-1 receptor blockade on food intake are inconsistent. In 
a study of  Williams et al.(41) blockade of  the GLP-1 receptor by exendin (9-39) in rats 
increased food intake. This effect was only observed when food intake was normally 
low. In another rat study food intake decreased after administration of  another GLP-1 
receptor antagonist (exendin-4[desHis-1, Glu-9]) prior to a premeal peak of  GLP-1 
(42). In this rat study food intake increased when the antagonist was administered after 
the GLP-1 premeal peak but prior to food presentation (42). These results suggest 
that studying the effects of  GLP-1 receptor blockade on food intake depend on the 
timing of  the antagonist administration. In our pig study the timing of  antagonist 
administration and ad libitum food intake was optimized to avoid any anticipatory or 
conditioned release of  GLP-1 prior to the ad libitum meal. Pigs were normally fed 
around 8:00 AM and 4:00 PM whereas during the study days they were fed at 08:00 
AM (morning meal) and at 11:00 AM (ad libitum meal). Although the time between the 
morning meal and the ad libitum meal at the study days was only 3 hours, the drive of  
the pigs to consume the (second) ad libitum meal might have overruled the effect of  
the GLP-1 receptor blockade.  
Another reason for the lack of  effect of  exendin (9-39) might be the high ingestion rate 
of  liquid feeding. Liquid feeding does not require chewing and the rate of  ingestion 
is therefore high. Solid food is usually ingested in about 30 minutes, whereas in this 
study the liquid meals were completed within 6.9 ± 0.6 min. It is known that CCK is 
produced by enteroendocrine I cells which are most abundant in proximal part of  the 
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small intestine located at duodenal and jejunal mucosa (14) whereas GLP-1 is released 
from enteroendocrine L-cells which show a maximum density in the ileum for most 
species (7, 14). It is therefore conceivable that the more pronounced effect of  CCK 
receptor blockade is due to the short period of  eating and rapid passage of  nutrients 
into the duodenum. Also, there was a large variability in food intake. Therefore the 
power of  this study might be a limitation. 
Total subdiaphragmatic vagotomy was conducted by endoscopic laparoscopy which 
has been used before (43, 44). By using this technique, pigs recovered rapidly without 
complications  from their surgery. Total subdiaphragmatic vagotomy was achieved by 
removal of  approximately 3 cm length of  both vagal nerves and confirmed by inspection 
at necropsy (Figure 4.7).  
Figure 4.7 Confirmation of  subdiaphragmatic abdominal vagotomy at necropsy in the sham showing the 
intact vagal nerves (A) and vagotomized group showing the interrupted vagal nerves (B).
Although liquid food was chosen to avoid effects on gastric emptying in the vagotomized 
pigs, an effect on gastric emptying cannot be excluded, since the acetaminophen Cmax 
was lower in the vagotomy group as compared to the sham group. Plasma acetaminophen 
concentrations were determined by small intestinal absorption of  acetaminophen, 
which is dependent on gastric emptying rate (32, 33, 45, 46). The decreased plasma 
acetaminophen concentrations in the vagotomized pigs thus indicate a delay in gastric 
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emptying. A decreased gastric emptying rate is supported by the observation that 
animals from the vagotomy group showed a larger stomach content at autopsy. 
In our study vagotomy did neither affect food intake, nor body weight. The reports on 
the effects of  vagotomy on food intake in previously conducted studies are contradictory 
(20, 25, 26, 47). This may be the result of  types and characteristics of  food and(or) 
feeding regimens, different vagotomy techniques and species differences. Liquid meals 
used in other vagotomy studies were often provided as sucrose solutions which lack 
other essential nutrients and possibly sucrose intake is more related to taste than to 
dietary satiation. In the present study we have used a complete liquid diet containing all 
macronutrients required for pig food.
The present study showed the effects of  total subdiaphragmatic vagotomy on basal 
and postprandial responses of  glucose, insulin, GLP-1 and CCK. It was found that 
postprandial responses of  glucose, insulin and CCK were decreased after vagotomy, 
whereas basal levels were increased. A difficulty in the interpretation for these findings 
is the delay in gastric emptying which might have caused the differences in both the 
basal and postprandial responses of  the measured plasma parameters in the vagotomy 
group. Despite the effect of  gastric emptying, the vagal  nerves are involved in detecting 
the presence and volume of  ingested food (48-53). This may also have contributed to 
the increased basal and decreased postprandial concentrations in the vagotomy group. 
In the present study we investigated the role of  CCK and GLP-1  by blocking their 
receptors which is expected to interrupt the action of  endogenously released hormones. 
Studies in which CCK and GLP-1 are exogenously administered lead to concentrations 
outside the normal physiological range, locations which do not correspond to their 
endogenous sites of  secretion and time profiles which may be out of  balance with 
the fasting – feeding cycles. Blocking the receptors as is done in the present study, 
allows to study the effects of  physiologically released CCK and GLP-1 at their normal 
sites of  action, since both antagonist are able to penetrate the blood brain barrier (26, 
54). Some other studies using receptor blockade have been done in rats, but to the 
best of  our knowledge we are the first to report the effects of  the abdominal vagal 
nerve interruption in combination with GLP-1 and CCK receptor blockade on food 
intake regulation. Also effects of  vagotomy on postprandial responses of  plasma 
acetaminophen, glucose, insulin, CCK and GLP-1 have not been reported elsewhere. 
The novel finding of  increased CCK and GLP-1 concentrations after receptor blockade 
in our study mostly in sham pigs suggests the existence of  a feed-back mechanism 
involving a sensing and/or regulatory role of  the vagal nerve in CCK and GLP-1 
plasma concentrations. This vagal feed-back mechanism may consist of  the vago-vagal 
reflex, as described previously (55).
In our study CCK1 receptor blockade resulted in increased food intake. For pharmaceutical 
applications, this would argue for the further development of  CCK1 receptor agonists 
or antagonists to either inhibit or stimulate food intake. In practice the exogenous 
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administration of  CCK1 receptor agonists has been hampered by difficulties in dosing, 
route of  administration and timing with respect to feeding. Indeed, CCK agonists have 
not delivered any useful weight management drugs so far. While human trials with 
such compounds indeed often showed lower food-intake during meals, participants 
tended to compensate with increased intake in between meals (56). On the other hand, 
pharmaceutical or dietary intervention strategies to increase the endogenous release of  
CCK may not suffer from the drawbacks of  exogenously administered CCK and could 
therefore still provide interesting approaches for weight reduction. At the same time, 
pharmaceutical and dietary interventions aiming at a reduction of  endogenous CCK 
secretion or CCK receptor blockade may stimulate (liquid) food intake and thereby 
offer novel therapeutic possibilities for patients suffering from delayed gastric emptying 
or disease related malnutrition (57).
In conclusion, our data contribute to a better understanding of  the balance between 
neural and humoral regulation of  satiation by CCK and GLP-1. They underline the 
importance of  the vagal nerve in regulating the gastric emptying, and meal transit which 
are important determinants for blood glucose, insulin, CCK and GLP-1 concentrations. 
Remarkably, in case of  CCK, CCK1 receptors elsewhere in the body appear to be 
more important than the CCK1 receptors located at the abdominal vagal nerve for the 
regulation of  liquid meal size.
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Abstract
Background: Protein infusion in the small intestine results in intestinal brake activation: 
a negative feedback mechanism that is mediated by the release of  GI peptides and 
results in a reduction in food intake. It has been proposed that duodenum, jejunum and 
ileum may respond differently to proteins. 
Objective: To investigate differences in ad libitum food intake, feelings of  hunger and 
satiety and the systemic levels of  cholecystokinin (CCK), glucagon-like peptide-1 (GLP-
1), peptide YY (PYY), glucose and insulin after intraduodenal, intrajejunal and intraileal 
protein infusion.
Methods: Fourteen subjects (4 male, mean age: 23 ± 2.1 years, mean body mass index: 
21,6 ± 1,8 kg/m2) were intubated with a naso-ileal catheter and participated in this 
double blind, randomized, placebo-controlled crossover study. Test days started with 
the ingestion of  a standardized breakfast, followed by the infusion of  15 g of  protein 
in either the duodenum, jejunum or ileum over a period of  60 minutes. Food intake 
was measured by offering an ad libitum meal and Visual Analogue Scale (VAS) scores 
were used to score feelings of  hunger and satiety. Blood samples were drawn at regular 
intervals for CCK, GLP-1, PYY, glucose and insulin analyses. 
Results: Intraileal protein infusion resulted in a decrease in ad libitum food intake 
compared with both intraduodenal and placebo infusion (Ileum: 628.5 ± 63 kcal vs. 
Duodenum: 733.6 ± 50 kcal at p<0.01 and Placebo: 712.2 ± 53 kcal at p<0.05). GLP-
1 concentrations were increased after ileal infusion compared with duodenal, jejunal 
and placebo infusion, while CCK concentrations were only increased after intraileal 
protein infusion compared with placebo. None of  the treatments affected VAS scores 
for hunger and satiety nor plasma concentrations of  PYY and glucose.  
Conclusion: Protein infusion in the ileum results in a more potent increase in the release 
of  GLP-1 and a decrease in food intake compared with infusion into the duodenum or 
jejunum, or compared with placebo, respectively.
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Introduction
Protein is known to be more satiating than an isocaloric amount of  either fat or 
carbohydrate (1, 2). An increase in the amount of  dietary protein results in satiating 
effects with significant long-term weight loss (3). It has been suggested that increasing 
protein ingestion is an effective weight management tool (2). The mechanisms underlying 
the satiating effect of  protein are multifactorial, but it has been well established that the 
gastrointestinal (GI) tract plays an important role in generating signals that mediate 
satiety.
It has been shown previously that intraduodenal infusion of  protein results in a more 
pronounced increase in plasma cholecystokinin (CCK) levels and decrease in food intake 
compared with oral ingestion of  the same amount of  protein (4). This difference may be 
explained by the activation of  the so-called duodenal brake. Undigested nutrients in the 
duodenum activate this negative feedback mechanism that modulates not only proximal 
gastrointestinal motility, secretion and mucosal peptide release but also feelings of  
satiety and food intake (5). In recent years, several human studies provided evidence for 
the inhibitory effects of  intraduodenal infusion of  protein on satiety and food intake 
(6-9). However, it has been suggested that infusion of  nutrients into the ileum results in 
an even greater effect on satiety and food intake when compared with infusion into the 
more proximal parts of  the small intestine (10). 
Under physiological conditions, only small amounts of  undigested nutrients reach the 
distal small intestine (11, 12). Most evidence for a more pronounced ileal versus duodenal 
or jejunal brake effect is derived from surgical procedures such as the Roux-en-Y Gastric 
Bypass (RYGB) and ileal transposition (IT). RYGB is one of  the procedures that bypass 
the proximal intestine, herewith increasing the exposure of  the distal small intestine to 
undigested nutrients (13). Also, intraileal fat infusion applying intestinal feeding catheters 
results in a significant reduction in appetite, a significant increase in fullness and a more 
delayed GI motility as compared with intraduodenal fat infusion (14). Human studies 
comparing the responsiveness of  different parts of  the small intestine to protein are still 
lacking. Aim of  the present study was therefore to investigate differences in ad libitum 
food intake, feelings of  hunger and satiety and the systemic levels of  cholecystokinin 
(CCK), glucagon-like peptide-1 (GLP-1), peptide YY (PYY), glucose and insulin after 
intraduodenal, intrajejunal and intraileal protein infusion, respectively. We hypothesized 
that intraileal protein infusion results in a more potent decrease in food intake and a 
stronger increase in both feelings of  satiety and plasma GI peptide levels as compared 
with intraduodenal and intrajejunal protein infusion.
Materials & Methods
This study was approved by the Medical Ethics Committee of  the Maastricht University 
Medical Center+ (MUMC), Maastricht, the Netherlands, and performed in full 
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accordance with the Declaration of  Helsinki (latest amendment by the World Medical 
Association in 2013). All participants gave their written informed consent prior to 
participation. The study has been registered in the US National Library of  Medicine 
(http://www.clinicaltrials.gov, NCT02500069). 
Subjects
Healthy, lean volunteers were recruited by local advertisement. Subjects were screened 
using a standard health questionnaire and a physical examination. Exclusion criteria 
included: medical or surgical history that could have affected study outcome, medication 
use (except contraceptives), smoking and excessive alcohol consumption (>2 units per 
day). All participants were weight stable for at least two months prior to participation, 
and were not following any energy restriction- or food supplementation diets. Power 
calculation showed that fourteen study completers were needed, to reach sufficient 
statistical power. 
Study design
In this double-blind randomized placebo-controlled crossover study, subjects were 
studied on 4 randomly assigned consecutive test days. On these occasions, 15 g of  
casein was infused using a naso-ileal feeding catheter over a period of  60 minutes into 
one of  the three different locations of  the small intestine: 1) the duodenum, 2) the 
jejunum and 3) the ileum, or no protein was infused (placebo). During each intervention, 
protein infusion was accompanied by simultaneous infusion of  tap water in the 
other two locations. For example, intraduodenal protein infusion was accompanied 
by simultaneous tap water infusion in jejunum and ileum, respectively. The placebo 
treatment consisted of  tap water infusion in all three locations. 
Naso-ileal catheter
Subjects were intubated with a 290 cm long silicon 9-channel (8-lumen, 1 balloon inflation 
channel, outer diameter of  3.5 mm) custom-made catheter (Dentsleeve International, 
Mui Scientific, Missisauga, Canada). The catheter contained three sideholes per channel 
with 3-cm interspacing between consecutive side holes, and had an inflatable balloon 
(maximum inflation capacity 10mL) integrated into the distal tip. After local anaesthesia 
of  a nostril (xylocaine 10% spray; AstraZeneca, Zoetermeer, The Netherlands), the 
catheter was introduced into the stomach. Subsequently, the tip of  the catheter was 
positioned in the duodenum under intermittent fluoroscopic control. Progression 
of  the catheter into the ileum was performed as described previously (15). Correct 
positioning of  the catheter was checked under fluoroscopy before starting each test 
day. The catheter includes radio-opaque markers at all sideholes, which enabled us to 
accurately determine the position of  the catheter. The radio-opaque markers made it 
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possible to select the infusion channel from this multi-lumen catheter that was located 
at the infusion location (duodenum, jejenum or ileum). Infusion into the duodenum 
took place 5 cm distal to the pylorus, while infusion into the jejunum took place 40-50 
cm distal of  the pylorus. Intraileal infusion was performed at least 120 cm distal to the 
pylorus.
Protein and placebo infusions
Casein (energy density: 3.4 kcal/g, Dutch Protein Services, the Netherlands) was used 
as the protein source in this study. Fifteen gram of  casein was dissolved in 180 mL of  
tap water and infused at a speed of  3 mL/min over a 60 min period. During placebo 
treatment, tap water was infused simultaneously in all three locations.
Protocol
During four consecutive test days, subjects arrived at our laboratory at 8:00 AM after 
an overnight fast. After checking correct positioning of  the catheter as described above, 
test days started with the insertion of  an intravenous catheter in a forearm vein for 
collection of  blood samples. At 8:30 AM basal blood samples and VAS scores for 
hunger and satiety were taken. Hereafter, subjects consumed a standard fixed sized 
liquid breakfast meal (150 kcal, Goedemorgen Drink Yoghurt, Friesland Campina, 
the Netherlands). One hundred fifty minutes after the ingestion of  the breakfast meal 
(11:00 AM), infusion of  protein or placebo into the small intestine was started. Intestinal 
infusion took place over 60 min, at a rate of  3 mL/min. Thirty minutes after ending 
the infusion, volunteers received a standard ad libitum pasta lunch (Lasagne Bolognese, 
t=240 min). After ingestion of  the meal, the test day was finished (see Figure 5.1 for 
design of  test day)
Figure 5.1 Timeline of  test day.  Intestinal infusion started 150 minutes after ingestion of  the breakfast 
and took sixty minutes (until t=210 min). Blood samples and VAS scores were collected at several time 
points.
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Gastrointestinal peptides
Venous blood samples were drawn at regular intervals (baseline (0), 60, 120, 150, 165, 
180, 195, 210, 240 min). For GLP-1 (7-36), PYY and CCK measurements blood was 
collected in ice chilled EDTA aprotonin coated tubes (Becton & Dickinson, New 
Jersey, USA) and 10 µL Dipeptidyl peptidase-4 inhibitor (DPP4-010, Merck Millipore, 
Massachusetts, USA) per 1 mL of  whole blood was immediately added after blood 
collection to prevent proteolytic cleavage. Tubes were centrifuged at a rate of  3000 
revolutions per minutes (rpm), 4° C for 15 minutes and plasma was transferred into 
aliquots and stored at -80° C.  Active GLP-1 (7-36) was determined using a Glucagon 
Like Peptide-1 (Active) ELISA kit with a range of  2-100 pmol/L, an inter-assay 
coefficient variation (CV) of  11%, and an intra-assay CV of  6% (EGLP- 35K, Merck 
Millipore, Massachusetts, USA). Total PYY (includes both peptide YY 1-36 and peptide 
YY 3-36) was measured using a human PYY (Total) ELISA kit with a range of  10-2000 
pg/ml, an inter-assay CV of  6% and an intra-assay CV of  3% (EZHPYYT66K, Merck 
Millipore, Massachusetts, USA). Plasma cholecystokinin-8 (cholecystokinin 26–33) 
concentrations were measured with an optimized and validated commercial human RIA 
kit (EURIA CCK, RB302, Euro-Diagnostica, Malmö, Sweden) (14). This improved 
assay system has been optimized to reach a high sensitivity of  0.05 pmol/L and to have 
no cross-reactivity to gastrin-17 or sulfated gastrin. The intra-assay CV was 8.9% at a 
concentration of  0.84 pmol/L and 4.9% at a concentration of  1.98 pmol/L. 
 
Glucose and insulin
Sodium fluoride- and SST II Plus gold tubes (Becton & Dickinson, New Jersey, USA) 
were used for determination of  glucose and insulin, respectively. SST II Plus gold 
tubes were stored at room temperature for 30 minutes before centrifugation at 3000 
rpm, 20° C for 15 minutes. Glucose measurements were performed on a Roche Cobas 
C701 analyzer (GLUC3, Roche, Mannheim, Germany) with an inter-assay variation 
of  0.02 mmol/L at glucose concentration 3.27 mmol/l. Serum insulin was measured 
using the Immulite 1000 Insulin Kit (LKIN5) on the Immulite 1000 (Siemens Medical 
Solutions Diagnostics, Los Angeles, CA) with an inter-assay variation of  4.09 pmol/L 
at insulin concentration 51.23 pmol/L.
Visual Analogue Scales (VAS) for hunger and fullness
Feelings of  hunger, satiety, fullness and prospective food consumption were measured 
using Visual Analogue Scales (VAS, 0 to 100 mm) anchored at the low end with the 
most negative or lowest intensity feelings (e.g., extremely unpleasant, not at all), and 
with opposing terms at the high end (e.g., extremely pleasant, very high, extreme) (15). 
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Statistical analyses 
Statistical analyses were performed using the SAS statistical software package (SAS 
version 9; SAS institute, Cary, NC, USA). Data were visually checked for normality and 
for constant variance of  residuals by plots of  residuals vs. corresponding predicted 
values. If  data were not normally distributed, log transformation was applied for further 
analysis of  the data, as was the case for CCK, GLP-1 (7-36), and PYY. Regarding food 
intake, statistical analysis was performed on the amount of  food eaten in kcal. VAS 
scores for hunger and satiety were corrected for the values obtained at the onset of  
infusion and are displayed from the start of  the substrate infusion (t=150 min) until 
the start of  the ad libitum meal (t=225 min). CCK, GLP-1 (7-36) and PYY are displayed 
from the start of  the test day (t=-15 min) until the last blood sample collected before 
the start of  the ad libitum meal (t=240 min). The effects of  each intervention on the 
levels of  GI peptides were determined by analyzing the peptide levels from the start of  
the test day until ingestion of  the ad libitum meal.
All variables were compared with a mixed analysis of  variance model that included 
the fixed factors treatment (ileum, jejunum, duodenum and placebo). For the VAS and 
plasma parameters, time and the interaction between treatment and time were added to 
the model. Because of  the crossover design, intervention effects within subjects were 
compared by including the random factor subject. If  an intervention effect occurred, a 
post hoc Dunnett test was used to analyze differences in ad libitum meal intake. A post 
hoc Tukey-Kramer test was used to analyze differences in VAS scores and GI peptides 
(CCK, GLP-1 and PYY). Data are presented as the mean ± SEM (unless specified 
otherwise) and considered significant at p<0.05. 
Results
Sixteen healthy volunteers were included. Two volunteers dropped out because of  
discomfort induced by the feeding catheter; fourteen volunteers  (4 male, mean age: 23 
± 2.1 years, mean BMI: 21,6 ± 1,8 kg/m2) completed the study.
Food intake 
Intraileal protein infusion decreased ad libitum meal intake compared with placebo 
infusion and compared with duodenal protein infusion (ileum: 628.5 ± 63 kcal vs. 
placebo: 712.2 ± 53 kcal; p<0.05 and duodenum: 733.6 ± 50 kcal; p<0.01) (Figure 
5.2). Food intake did not differ between jejunal and ileal protein infusion.
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Figure 5.2 Food intake in kcal (mean+SEM) of  an ad libitum lunch ingested 30 min after ending the 
protein infusion into the ileum, jejunum, duodenum or placebo, respectively, over a 60 min period (n=15). 
A significant reduction in food intake was observed after ileal protein infusion compared to duodenal 
protein infusion (p<0.01, **) and placebo infusion (p<0.05, *) based on a mixed analysis of  variance 
model with a post-hoc Dunnett correction.
Figure 5.3 VAS Desire to eat, hunger, fullness and satiety (mean+SEM) during and after protein infusion 
in the ileum, jejunum, duodenum and placebo, respectively. Intestinal infusion started 150 minutes after 
breakfast ingestion and lasted for 60 minutes. No differences in VAS scores were observed. These results 
were analyzed with a mixed analysis of  variance model with a post-hoc Tukey-Kramer correction. 
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Figure 5.4 Plasma concentrations of  GLP-1, CCK and PYY (mean+SEM) and GLP-1, CCK and 
PYY areas under the curve (AUC 150-240 min) during and after protein infusion in the ileum, jejunum, 
duodenum and placebo infusion, respectively. Intestinal infusion started 150 minutes after breakfast 
ingestion and lasted for 60 minutes. A) Significantly higher GLP-1 levels were observed after intraileal 
infusion of  protein versus intrajejunal, intraduodenal and placebo infusion (all p<0.001 **). Intrajejunal 
and intraduodenal protein infusion increased GLP-1 concentrations compared with placebo infusion 
(both p<0.02, *) and # B) AUC (150-240 min) for GLP-1 was significantly increased after ileal protein 
infusion compared to jejunal (p<0.05, **) duodenal (p<0.05, **) and placebo infusion (p<0.01, *). C) 
Significantly higher CCK levels were observed after intraileal and intrajejunal infusion of  protein versus 
placebo infusion; (p<0.001, *). Intrajejunal infusion resulted in an increase in CCK levels compared with 
duodenal infusion; (p<0.05, #). D) AUC (150-240 min) of  CCK during ileal and jejunal infusion was 
significantly increased compared with placebo infusion (p<0.05, * and P<0.001, **, respectively). E+F) 
No differences in the release of  PYY were observed. These results were analyzed with a mixed analysis 
of  variance model with a post-hoc Tukey-Kramer correction.
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Appetite
Mean VAS scores for desire to eat, hunger, fullness and satiety are presented in Figure 
5.3. Consumption of  the liquid breakfast at time t=0 min resulted in a decrease in 
desire to eat and hunger and an increase in fullness and satiety in all treatments (data not 
shown). VAS scores for desire to eat, hunger, fullness and satiety were not different after 
ileal protein infusion compared with duodenal or jejunal protein infusion or compared 
with placebo. 
GLP-1, CCK and PYY 
The effects of  ileal, jejunal and duodenal infusion on plasma concentrations of  
GLP-1, CCK and PYY and AUCs (150-240 min) are presented in Figure 5.4. Fasted 
plasma concentrations of  CCK, GLP-1 and PYY did not differ between test days. 
CCK concentrations increased after ingestion of  the liquid breakfast, whereas GLP-
1 and PYY concentrations did not change. Ileal protein infusion increased GLP-1 
concentrations compared with duodenal, jejunal and placebo infusion, respectively 
(p<0.001, Figure 5.4A). Both jejunal and duodenal protein infusion increased GLP-
1 concentrations compared with placebo infusion (both p<0.01, Figure 5.4A). The 
AUC (150-240 min) for GLP-1 was increased after ileal protein infusion compared with 
jejunal, duodenal and placebo infusion, respectively (Figure 5.4B)  CCK concentrations 
were also increased after intraileal and intrajejunal protein infusion compared with 
placebo (p<0.05). Furthermore, an increase in CCK was observed after intrajejunal 
infusion compared with duodenal infusion (p<0.05, Figure 5.4C). Ileal and jejunal 
protein infusion increased the AUC (150-240 min) for CCK compared with placebo 
Figure 5.5 Glucose and insulin concentrations (mean+SEM) during and after protein infusion in the 
ileum, jejunum, duodenum and placebo infusion, respectively. Intestinal infusion was started 150 minutes 
after breakfast ingestion and lasted  for 60 minutes. Intraileal, intrajejunal and intraduodenal infusion of  
protein resulted in an increase in insulin levels compared to placebo infusion (p<0.0001*). No differences 
in glucose concentrations were seen.  These results were analyzed with a mixed analysis of  variance 
model with a post-hoc Tukey-kramer correction.
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infusion (Figure 5.4D)  None of  the treatments affected plasma concentrations of  
PYY (Figure 5.4E+F).
Glucose and insulin
Ingestion of  the breakfast resulted in an increase in plasma insulin concentration, 
followed by a decrease in plasma glucose in all treatments (Figure 5.5). Insulin levels 
increased after intraileal, intrajejunal and intraduodenal protein infusion compared with 
placebo infusion (p<0.0001). No differences in glucose levels were observed.
Discussion
This is the first study to demonstrate that ileal protein infusion significantly reduces 
food intake compared with intraduodenal infusion of  protein and placebo, while no 
differences between intraileal and intrajejunal infusion were observed. Herewith we 
confirm our hypothesis and show differences in responsiveness to undigested protein 
infusion between the duodenum, jejunum and ileum.
It has been suggested that increasing the exposure of  the distal small intestine to 
nutrients may result in the most potent brake effect. However, the mechanism of  
action for such an  effect is not completely understood. Here we show an increase in 
the release of  the GI peptide GLP-1 after intraileal infusion compared with duodenal 
and jejunal infusion of  protein, respectively. Interestingly, an increase in GLP-1 is also 
seen after RYGB and IT procedures (16-18). Based on the changes seen after these 
procedures, it was hypothesized that a higher density of  L-cells, found in the mucosa of  
the distal small intestine could account for such a GLP-1 increase (19). These variations 
in density and absolute number of  L-cells over the small intestine, may also serve as an 
explanation for the observed differences in food intake and GI peptide release between 
the duodenum, jejunum and ileum in the current study (10).
In the present study we found a mean decrease in food intake of  90 kcal after intraileal 
infusion. In another study by our group, we showed that infusion of  a similar amount (15 
g) of  casein into the ileum resulted in a reduction in food intake of  130 kcal (15). This 
difference may be explained by differences in study design. The set-up of  the present 
study was based on the ingestion of  a liquid breakfast in the morning, whereas a solid 
breakfast was consumed in the previous study. The current design was chosen to ensure 
that the stomach had emptied any food residues and that the breakfast would have 
been absorbed at the start of  the infusion. As such we excluded intestinal exposure to 
breakfast-originated nutrients and were able to assess the effects of  intestinally infused 
protein only. Consequently, subjects had an empty and non-distended stomach during 
the intestinal nutrient infusion in the present study, whereas subjects had a partially filled 
stomach at the time of  intestinal infusion in the previous study. Since it is known that 
gastric distension plays an important role in the regulation of  appetite and food intake, 
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this may explain the differences in mean reduction of  food intake between the two 
studies (20-22). Furthermore, it has been shown that intestinal infusion of  nutrients, 
with simultaneous distension of  the stomach, more potently increases feelings of  
satiety compared with intestinal infusion alone (22). This may also have contributed to 
the absence of  differences in VAS scores for satiety and fullness in the current study, 
which were present in the previous study. 
The increase in GLP-1 after ileal protein infusion compared with jejunal, duodenal and 
placebo infusion was unexpected since GLP-1 is primarily stimulated by carbohydrates 
and fats (23). However, this is not the first study to show the GLP-1 stimulating ability 
of  protein. Ryan et al. showed the load-dependent effect of  intraduodenal whey infusion 
on GLP-1 release and found that a protein load as little as 0.5 kcal/min transiently 
stimulated the release of  GLP-1 (6). In our study, GLP-1 did not increase after 
intraduodenal or intrajejunal infusion, while protein was infused at a higher rate (0.85 
kcal/min). This difference could be explained by the type of  protein infused, since Ryan 
et al used whey protein while we used casein. Casein and whey both contain all essential 
amino acids but they differ in digestion and absorption (24). Some studies propose 
that whey is more satiating and results in a greater release of  GI peptides than casein 
(25-28). However, these data are mainly based on studies looking into oral ingestion of  
casein and whey. We chose casein because we previously established significant effects 
of  intraileal infusion of  casein on food intake (15). 
GLP-1 is known to increase insulin sensitivity (29). Postprandial GLP-1 levels were 
previously shown to increase after RYGB and to enhance insulin secretion (30). In the 
current study, we found an increase in insulin after ileal, jejunal and duodenal protein 
infusion compared with placebo. However, no differences with regard to insulin secretion 
between the ileum and other locations were found. These results were not in line with a 
recent study by Salinari et al. in which bypassing the duodenum and proximal jejunum, 
hereby infusing a mixed meal (Nutrison, 524 kcal) in the mid jejunum, enhanced insulin 
sensitivity and decreased insulin levels in glucose-tolerant obese subjects (31). It is not 
clear why, despite the increase in GLP-1, no differences in insulin levels were seen 
after intraileal protein infusion compared with the other locations in the current study. 
Several factors may be involved. First, our study was performed in lean, healthy and 
young adults, while studies investigating RYGB often include morbidly obese diabetics. 
The difference in glucose homeostasis between these groups might account for the 
discrepancy in insulin secretion. Second, the incretin effect on insulin secretion after 
glucose ingestion was shown to be dose-dependent (32). As we only infused 15 g of  
protein (50 kcal) in the current study, it is possible that this amount was too small to 
establish effects on insulin levels.
 We found an increase in plasma CCK concentrations over time after intestinal protein 
infusion compared with placebo, while this increase was shown to be independent of  
the location of  protein infusion (duodenum, jejunum or ileum). CCK is considered to 
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be a peptide hormone originating from the proximal gut, but CCK-secreting I-cells are 
also expressed in the distal small intestine (33). Our group previously showed CCK 
release after intra-ileal fat infusion and the current study adds to this evidence that the 
same holds true for ileal protein infusion (34).
Distal L-cells secrete PYY in proportion to caloric load, with the lowest macronutrient 
potency for protein. Ryan et al infused protein in the duodenum and found that a 
threshold for the infusion rate of  protein exists in order to induce PYY release. A 
load of  0.5 and 1.5 kcal/min did not result in the release of  PYY whereas a load of  
3 kcal/min did. We infused protein at a rate of  0.85 kcal/min in several parts of  the 
small intestine and found no increase in the release of  PYY. It is therefore reasonable 
to postulate that protein infusion in the distal small intestine may have a higher PYY-
inducing threshold compared with that of  duodenal infusion. 
Our study has some limitations that need to be addressed. First, volunteers were 
intubated with a naso-ileal catheter for five consecutive days and this could have induced 
feelings of  discomfort, hereby possibly affecting study outcome parameters despite the 
randomized design of  this study. Second, we infused protein directly into the distal 
small intestine, hereby bypassing regions that are important for protein digestion. It 
is not clear whether distal protein infusion could lead to protein malabsorption and 
subsequently to increased colonic protein fermentation. If  this would be the case, this 
could have detrimental effects for the host’s physiology and health, possibly affecting 
outcome parameters in this study (35). Noteworthy, in the current study we did not 
observe adverse effects in any of  the subjects after distal protein infusion. A recent 
study by Bojsen-Møller et al also showed that protein digestion was not impaired after 
RYGB (36). This suggests that the distal small intestine is capable of  effectively digesting 
and subsequently absorbing protein and its metabolites.
This study provides evidence for location specific responsiveness in the small intestine 
to protein infusion with regard to intestinal brake activation. These results have 
implications for the design of  future nutritional and/or surgical strategies for overweight 
and obesity. These strategies should aim to deliver nutrients to the distal small intestine 
in order to exert the most potent brake effect.
In conclusion, this study shows the effects of  a protein infusion into different locations 
in the gastrointestinal tract. Ileal protein infusion results in the most pronounced and 
potent increase in GLP-1 and decrease in food intake.
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Abstract
Background: Activation of  the ileal brake, by infusing lipid directly into the distal part 
of  the small intestine, alters gastrointestinal motility and inhibits food intake. The ileal 
brake effect on eating behavior of  the other macronutrients is currently unknown.    
Objective: The objective of  this study was to investigate the effects of  ileal infusion of  
sucrose and casein on food intake, release of  gastrointestinal peptides, gastric emptying 
rate and small bowel transit time with safflower oil as positive control. 
Design: This randomized, single-blind, crossover study was performed in 13 healthy 
subjects (6 male; mean age 26.4±2.9 years; mean BMI 22.8±0.4 kg/m2) who were 
intubated with a naso-ileal catheter. Thirty minutes after the intake of  a standardized 
breakfast participants received an ileal infusion, containing control (saline[C]), safflower 
oil (51.7 kcal[HL]), low-dose casein (17.2 kcal[LP]) or high-dose casein (51.7 kcal[HP]), 
low-dose sucrose (17.2 kcal[LC]), high-dose sucrose (51.7 kcal[HC]), over a period of  
90 min. Food intake was determined during an ad libitum meal. VAS questionnaires for 
hunger and satiety and blood samples were collected at regular intervals.  
Results: Ileal infusion of  lipid, protein and carbohydrate resulted in a significant 
reduction in food intake compared to control (HL: 464.3±90.7 kcal p<0.001, HP: 
458.0±78.6 kcal p<0.005, HC: 399.0±57.0 kcal p<0.0001 vs. control: 586.7±70,2 kcal 
respectively, p<0.001). A reduction in energy intake was still apparent when the caloric 
amount of  infused nutrients was added to the amount eaten during the ad libitum meal.
Secretion of  CCK and PYY but not of  GLP-1 (7-36) was increased during ileal perfusion 
of  fat, carbohydrates and protein. During ileal perfusion of  all macronutrients a delay in 
gastric emptying and intestinal transit was observed, but differences were not significant 
compared to control.
Conclusion: Apart from lipids also sucrose and casein reduce food intake upon ileal 
infusion, thereby activating the ileal brake. In addition to food intake, also satiety and 
gastrointestinal peptide secretion were affected. 
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Introduction
Worldwide the incidence of  overweight and obesity is rapidly expanding with tremendous 
negative impact on health and health care costs (1, 2). Up to now various nutritional and 
pharmacological strategies for overweight have failed and new treatment modalities in 
the battle against obesity are urgently needed. An interesting but still poorly explored 
mechanism is to reduce caloric intake via activation of  the so-called intestinal brake, 
in particular the ileal brake. The brake refers to an intestinal feedback mechanism that 
is triggered by nutrients at a specific location in the intestine, resulting not only in 
modulation of  gastrointestinal secretions and motility but also of  food intake and 
hunger (3, 4). This concept was first seen in ileal transposition (IT) studies performed in 
rats. Koopmans and Sclafani were the first to describe this model in 1981 and together 
with several others it was shown that IT in rats resulted in a reduction in food intake and 
weight loss on the long term (5, 6). 
A few years later, Welch et al demonstrated in humans that ileal infusion of  a high 
amount of  lipid delayed gastric emptying, induced satiation and also reduced food 
intake (7, 8). Recently, several studies have confirmed these findings with much smaller 
amounts of  intact lipids (9-12).
While ‘ileal brake’ inducing effects on satiety and food intake have been explored in more 
detail with respect to lipids, little is known about ileal brake induced satiating effects of  
the other macronutrients, carbohydrates and proteins. Ileal infusion of  carbohydrates is 
known to delay gastric emptying rate, decrease intestinal motility and enhance release of  
PYY and GLP-1 (13-15), gut peptides associated with induction of  satiation and food 
intake. When administered intraduodenally, potent inhibitory effects of  carbohydrates 
on energy intake have been demonstrated (16-18) but effects of
carbohydrates on food intake and satiety in humans upon intra-ileal infusion have not 
been assessed.
Dietary proteins are commonly regarded as the most satiating macronutrients (19). 
However, data on effects of  intestinal protein infusion on satiety are scarce. It has 
been demonstrated that ileal protein infusion resulted in a delay in gastrointestinal 
motility (20). Intraduodenal administration of  pea protein was shown to induce a more 
pronounced inhibitory effect on food intake compared to oral ingestion of  the same 
amount of  pea protein (21). 
Up to now, human data on effects of  ileal exposure to carbohydrates and proteins on 
food intake and satiety are lacking. This study was undertaken to investigate effects 
of  ileal infusion of  different doses of  carbohydrates and proteins on ad libitum food 
intake in comparison to placebo (control) and to ileal infusion of  an equicaloric amount 
of  lipids, as positive control. In addition to food intake also satiety, gastric emptying, 
small intestinal transit time and gastrointestinal (GI) peptide secretion were measured. 
Previous studies with duodenal infusion of  macronutrients did not show major 
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differences in satiety and food intake between macronutrients (18, 22). We therefore 
hypothesized that ileal infusion of  carbohydrates and proteins will result in an equal, 
dose dependent reduction of  food intake, and in equally enhanced satiety compared to 
ileal infusion of  equicaloric amounts of  lipids. 
Methods
Participants
Healthy men and women, aged between 18 and 55 years with a BMI between 18 and 
25 kg/m2 were recruited by local advertisement to participate in this study. Smoking, 
consumption of  >100 g alcohol/wk, medical history, active symptoms, medication use 
(apart from oral contraceptives) were exclusion criteria. All participants reported to be 
weight stable for at least two months prior to participation, to be unrestrained eaters 
(assessed by the Dutch eating behavior questionnaire) and were on a normal caloric diet 
(23). Written informed consent was obtained from each individual before inclusion in 
the study. This study was approved by the Medical Ethics Committee of  the Maastricht 
University Medical Center+ (MUMC), Maastricht, the Netherlands, and performed in 
full accordance with the Declaration of  Helsinki. The study has been registered in the 
US National Library of  Medicine (http://www.clinicaltrials.gov, NCT01509469). 
According to our power calculation thirteen subjects were needed to complete the 
study. This number was based on the difference in food intake observed in previous 
work (7, 10). Fifteen subjects met the inclusion criteria. Due to discomfort induced by 
the ileal catheter, two subjects did not complete all experiments and dropped out of  the 
study. Thirteen healthy subjects (6 male, age 26.4 ± 2.9 yrs, BMI of  22.8 ± 0.4 kg/m2) 
completed the study.
Study outline 
This single-blind randomized placebo controlled study compared the effects of  six 
different interventions: 1) saline (control [C]); 2) lipid emulsion (6 g safflower oil [HL], 
51.7 kcal); 3) protein low dose (5 g casein [LP], 17.2 kcal); 4) protein high dose (15 g 
casein [HP], 51.7 kcal); 5) carbohydrates low dose (4.3 g sucrose [LC], 17.2 kcal); 6) 
carbohydrates high dose (12.9 g sucrose [HC], 51.7 kcal), respectively. Each of  the 
substances was infused directly into the ileum over a 90 min period, on separate test days. 
Test days were randomly assigned (by using Research randomizer, www.randomizer.org) 
and subjects were tested in two consecutive weeks, with three test days planned in each 
week. 
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Catheter positionning 
We used a 270 cm long silicon 9-channel (8-channels, 1 balloon inflation channel, outer 
diameter 3.5 mm) custom-made catheter (Dentsleeve international, Mui scientific, 
Mississauga, Canada). The catheter contained three sideholes per channel with 3-cm 
interspacing between consecutive side holes, and had an inflatable balloon (maximum 
inflation capacity 10 ml) integrated into the distal tip. Nutrients were directly infused 
into the ileum.
On the day of  catheter introduction (Monday), subjects were allowed to consume a light 
breakfast in the morning (ingested before 08.00 AM). After local anaesthesia of  the 
nasal mucosa (xylocaine 10% spray; AstraZeneca, Zoetermeer, The Netherlands), the 
catheter was introduced transnasally into the stomach. Under intermittent fluoroscopic 
control, the catheter was positioned with the tube tip located in the proximal small 
intestine. Further progression of  the catheter into the ileum was attained as described 
previously (11). Participants returned to the department at 8:00 AM the next three 
days for test days 1, 2 and 3 (Tuesday, Wednesday and Thursday) and a week later for 
test days 4, 5 and 6, respectively. Before the start of  each test day the position of  the 
catheter was checked by fluoroscopy. In all subjects the tip of  the catheter was placed at 
least 120cm distal to the pylorus (24).  
Nutrient infusions
In this study we infused protein, carbohydrate and lipid directly into the ileum. Casein 
(energy density: 3.45 kcal/g, Dutch Protein Services, the Netherlands) was used as protein 
source. Sucrose (energy density: 4 kcal/g, van Gilse Automatensuiker, the Netherlands) 
was used as carbohydrate source. Safflower oil (6 g; energy density: 8.6 kcal/g, de Wit 
Specialty Oils, the Netherlands) was used as positive control, as it was shown repeatedly 
that safflower oil appears to be the most potent lipid in ileal brake activation (9). All 
nutrients were dissolved in a total volume of  180 ml water and administered at a rate of  
2 ml/min (total infusion time 90 min).
Experimental design
Each subject participated in six test days. On all test days an intravenous catheter was 
placed in a forearm vein for collection of  blood samples. At 8.30 AM a basal blood sample, 
Visual Analogue Scores (VAS) for hunger and satiety and breath samples were obtained. 
Subsequently a standardized breakfast meal, consisting of  a sandwich and an egg (sunny 
side up, 210 kcal), was consumed. Since intraileal infusion of  nutrients is known to 
delay gastric emptying and intestinal transit, gastric emptying rate of  the breakfast meal, 
determined by using the 13C stable isotope breath test (25), and duodenocecal transit 
time, measured by hydrogen breath testing were included as GI transport parameters 
(26). At the start of  the ileal infusion (at t=30), 6 g of  lactulose was administered 
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directly into the duodenum to enable measurement of  the small bowel transit time. Ileal 
substrate infusion was scheduled from t=30-120 min after breakfast ingestion. One 
hour after ending the infusion, the volunteer received a standardized ad libitum lunch 
meal (sandwiches with egg salad (energy density: 2.2 kcal/g), t=180). Sandwiches were 
randomly cut in different sized pieces, to mask the number of  sandwiches eaten.  After 
ingestion of  the lunch meal, the test day was finished and subjects could return home. 
Gastrointestinal peptides
Venous blood samples were drawn at regular intervals. For Glucagon-like Peptide-1 
(GLP-1 (7-36)), Peptide YY (PYY) and Cholecystokinin (CCK) measurements blood 
was collected in ice chilled aprotinin-coated tubes (Becton & Dickinson, New Jersey, 
USA). Immediately after blood collection, 10 µl of  DPP-IV inhibitor (Millipore, 
Massachusetts, USA) per 1 ml of  whole blood was added to the tubes to prevent 
proteolytic cleavage. Tubes were immediately centrifuged at a rate of  3000 rpm and 4° 
C for 15 min. Plasma was transferred into aliquots and stored on dry ice for the rest of  
the test day. At the end of  the test day samples were stored at -80° C. 
Active GLP-1 (7-36) was determined using a Glucagon Like Peptide-1 (Active) ELISA 
kit with a range of  2-100 pM, an inter-assay coefficient variation (CV) of  11%, and an 
intra-assay CV of  6% (EGLP- 35K, Millipore, Linco Research). Total PYY (includes 
both peptide YY1-36 and peptide YY3-36) was measured using a Human PYY (Total) 
ELISA kit with an inter-assay CV of  6% and an intra-assay CV of  3% (EZHPYYT66K, 
Millipore, Linco Research). Plasma cholecystokinin-8 (cholecystokinin 26–33) 
concentrations were measured with an optimized and validated commercial human 
RIA kit (EURIA CCK, RB302, Euro-Diagnostica, Malmö, Sweden). This improved 
assay system has been optimized to reach a high sensitivity of  0.05 pmol/L and to have 
no cross-reactivity to gastrin-17 or sulfated gastrin. The intra-assay CV was 8.9% at a 
concentration of  0.84 pmol/L and 4.9% at a concentration of  1.98 pmol/L. 
The effects of  each intervention on peptide secretion were determined by analyzing the 
peptide levels at the onset of  ileal infusion until ingestion of  the ad libitum meal. All data 
were corrected for the values obtained at the onset of  infusion. 
Satiety and hunger scores
Scores for hunger and satiety feelings (e.g., satiety, fullness, hunger, desire to eat, desire to 
snack) were measured using Visual Analogue Scales (VAS, 0 to 100 mm) anchored at the 
low end with the most negative or lowest intensity feelings (e.g., extremely unpleasant, 
not at all), and with opposing terms at the high end (e.g., extremely pleasant, very high, 
extreme) (27).
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Gastric emptying
13C-octanoic acid (100 mg, Campro Scientific bv, Veenendaal, the Netherlands) was 
mixed into the standardized breakfast meal ingested at t=0. Breath samples of  13CO2 
were obtained as described previously (12). Samples were analyzed by using Isotope 
Ratio Mass Spectometry (IRIS, Wagner, Bremen, Germany). 
Small bowel transit time
Duodenocecal transit time was determined by the lactulose hydrogen breath test, as 
described by Ledeboer et al (26). Via an opening of  the catheter located in the duodenum, 
6 g of  lactulose (Legendal, Inpharzam, Amersfoort) was administered at the start of  ileal 
infusion of  the substrates. Breath samples were taken at 15 min intervals and analyzed 
using a handheld hydrogen breath test unit (Gastyrolyzer, Bedfont Scientific, Kent, 
United Kingdom). Small bowel transit time was defined as the time between lactulose 
administration and the onset of  a sustained rise in breath hydrogen concentration of  at 
least 10 parts per million (ppm) above basal level.
Statistical analyses
Statistical analyses were performed using the SAS statistical software package (SAS 
version 9; SAS institute, Cary, NC, USA). Proc Gplots were used to test outcome 
variables for normality of  distribution. If  data were not normally distributed, log 
transformation was applied for further analysis of  the data, as was the case for CCK, 
GLP-1 (7-36), and PYY.
Regarding food intake, statistical analysis was performed on the amount of  food eaten 
in kcal. CCK, GLP-1 (7-36) and PYY are displayed from the start of  the infusion 
(t=30 min) until the last blood sample collected before the start of  the ad libitum meal 
(t=180 min). All variables were compared with a mixed analysis of  variance model 
that included the fixed factors treatment (C, HL, LP, HP, LC and HC). For the plasma 
parameters, time and the interaction between treatment and time were added to the 
model. The factor subject was added to the model as random factor. A post hoc Tukey 
test was used to analyze differences between treatments. Data are presented as the mean 
± SEM (unless specified otherwise) and considered significant at p<0.05.
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Results
Food intake
Ileal infusion of  lipid, high-dose protein and high-dose carbohydrates resulted in a 
significantly lower energy intake during the ad libitum meal compared to control (HL: 
464.3 ± 90.7 kcal p<0.001, HP: 458.0 ± 78.6 kcal p<0.005, HC: 399.0 ± 57.0 kcal 
p<0.0001 vs. control: 586.7 ± 70,2 kcal respectively). (Figure 6.1) There were no 
statistically significant differences in food intake between the different nutrient infusions 
HL, HP and HC. No effect of  LP and LC over control on food intake was observed 
(LP: 528.4 ± 86.1 and LC: 491.4 ± 77.5 kcal). Even after adding the caloric amount of  
infused nutrients to the amount eaten during the ad libitum meal (in kcal), the reduction 
in energy intake was significant  (HL and HC vs. C, p<0.05 and p<0.005 respectively). 
Figure 6.1 Food intake in kcal (mean+SEM) of  the ad libitum lunch ingested 60 min after ending the 
intraileal infusion of  control (C), safflower oil (HL), low-dose casein (LP), high-dose casein (HP), low-
dose sucrose (LC) and high-dose sucrose (HC), respectively. *p<0.005 and #p<0.0001.
Satiety and hunger scores 
Fasting scores for hunger and fullness at the start of  the experiments did not differ 
among the six interventions. Ingestion of  the breakfast meal resulted in a significant 
decrease in hunger and an increase in fullness scores in all six treatments (data not 
shown). Significant differences in hunger scores were observed only after start of  intra-
ileal infusion of  high-dose protein (from 30-180 min) (p<0.0001), but not of  the other 
interventions compared to control (Figure 6.2A+B). After ingestion of  the breakfast, 
fullness scores increased in all experiments. Figure 6.2C+D shows the integrated 
fullness scores from the start of  ileal infusion up to the intake of  the ad libitum meal. No 
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significant differences were observed in fullness scores between the various treatments 
and control (Figure 6.2C+D). 
Figure 6.2 Hunger (mean+SEM) (A+C) and Fullness (mean+SEM) (B+D). VAS Hunger 
concentrations (B) and areas under the curve (AUC 30-180 min A) and VAS Fullness concentrations (D) 
and areas under the curve (AUC 30-180 min C) during intra-ileal infusion of  control (C), safflower oil 
(HL), low-dose casein (LP), high-dose casein (HP), low-dose sucrose (LC) or high-dose sucrose (HC). 
Ileal infusion was started at t=30 (30 min after breakfast consumption) and continued for 90 minutes. An 
ad libitum lunch was offered at t=180 min. AUCs were calculated by using the trapezoid rule. *Significantly 
different from C (p<0.005), #Significantly different from HL (p<0.05), $Significantly different from LC 
(p<0.05).
Gastrointestinal peptides 
CCK
Plasma CCK levels were measured for the C, HL, HP and HC interventions but not for 
LP and LC. Baseline plasma CCK concentrations did not differ between interventions. 
The breakfast meal, ingested 30 min prior to starting the ileal infusions, induced an 
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increase in CCK concentration in all four measured treatments from 0.30 ± 0.06 
pmol/L at baseline to 0.74 ± 0.05 pmol/L at 30 min after breakfast intake (p<0.0001) 
(Supplementary table 1). Data are corrected for the CCK levels at t=30 min, when 
ileal infusions started. Figure 3A shows that, after an initial postprandial increase, the 
plasma CCK levels decline from 45 or 60 minutes after breakfast intake onwards. Ileal 
infusion of  lipid, high-dose protein and high-dose carbohydrates all resulted in higher 
CCK levels following ileal infusions compared to control. Consequently, the negative 
AUC of  CCK concentrations over time, corrected for the CCK levels at the start of  
ileal infusions, was smaller after lipid and high-dose protein intervention (p<0.05 and 
p<0.005, respectively) (Figure 3B), while this did not reach statistical significance for 
the high-dose carbohydrate treatment.
Figure 6.3 CCK (mean+SEM). Δ CCK concentrations (A) and areas under the curve (AUCs) (B). 
Intraileal infusion of  control (C), safflower oil (HL), high-dose casein (HP), or high-dose sucrose 
(HC) was scheduled from 30-120 min. AUCs were calculated by using the trapezoid rule. *Significantly 
different from C (p<0.0005), #Significantly different from HL (p<0.05), $Significantly different from HC 
(p<0.0005). 
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GLP-1 (7-36)
Baseline plasma GLP-1 (7-36) concentrations did not differ between study days. The 
breakfast meal induced an increase in GLP-1 (7-36) concentration in all six treatments 
from 2.63 ± 0.26 pmol/L at baseline to 3.84 ± 0.25 pmol/L at 30 min after breakfast 
intake (p<0.005) (Supplementary table 1)
The AUC GLP-1 (7-36) (30–180 min) from start of  ileal infusion to onset of  meal 
intake did not significantly differ between any of  the treatments (Figure 6.4B). Ileal 
infusion of  high-dose protein resulted in a larger increase in plasma GLP-1 (7-36) when 
compared to low-dose carbohydrates (Figure 6.4A). 
Figure 6.4 GLP-1 (7-36) (mean+SEM) Δ GLP-1 (7-36) concentrations (A) and areas under the curve 
(AUCs) (B). Intraileal infusion of  control (C), safflower oil (HL), low-dose casein (LP), high-dose casein 
(HP), low-dose sucrose (LC) or high-dose sucrose (HC) was scheduled from 30-120 min. AUCs were 
calculated by using the trapezoid rule. *Significantly different from LP (p<0.005), #Significantly different 
from LC (p<0.005).
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PYY
Baseline plasma PYY concentrations did not differ between study days. The breakfast 
meal induced an increase in PYY concentration in all six treatments from 51.36 ± 2.98 
pmol/L at baseline to 60.66 ± 2.98 pmol/L at 30 min after breakfast intake (p<0.05) 
(Supplementary table 6.1)The 30-180 min AUCs from the start of  ileal infusion 
to onset of  meal intake did not significantly differ between any of  the treatments 
(Figure 6.5B). Infusing high-dose carbohydrates and lipid into the ileum resulted in a 
significantly larger increase in plasma PYY when compared to control, and of  high dose 
carbohydrates versus low-dose carbohydrates, respectively (Figure 6.5A). The same 
was true for high-dose protein vs low dose of  protein but not vs control. 
Figure 6.5 PYY (mean+SEM). Δ PYY concentrations (A) and areas under the curve (AUCs) (B). 
Intraileal infusion of  control (C), safflower oil (HL), low-dose casein (LP), high-dose casein (HP), low-
dose sucrose (LC) and high-dose sucrose (HC) was scheduled from 30-120 min. AUCs were calculated 
by using the trapezoid rule. * Significantly different from C (p<0.005),  #Significantly different from LP 
(p<0.005), $ Significantly different from LC (p<0.005).
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Gut peptides and food intake
Energy intake during the ad libitum meal intake (in addition to the amount of  kcal 
infused) was inversely related to plasma GLP-1 (7-36) AUC (r=-0.4, p<0.0005) and 
CCK AUC (r=-0.4, p<0.005), respectively. No significant correlation between food 
intake and PYY was found.
GI transport
Ileal nutrient infusion resulted in a tendency to a slower gastric emptying half  time (t1/2) 
however differences were not statistically significant vs control. This was also true for 
small bowel transit time (SBTT) compared to control (saline infusion); non-significant 
differences (Table 6.1).
Table 6.1 GI transport. All values are means ± SEM. Gastric emptying half  time (GE ½) of  the 
breakfast meal ingested 30 min prior to, and small intestinal transit time during intraileal infusion of  
control (C), safflower oil (HL), low-dose casein (LP), high-dose casein (HP), low-dose sucrose (LC) and 
high-dose sucrose (HC), respectively. 
Discussion
We have shown that ileal infusion of  proteins and carbohydrates in healthy volunteers 
suppresses food intake to the same extent as an equicaloric amount of  lipids. Lower 
doses of  proteins and carbohydrates did not affect food intake or satiety/satiation. 
Thus, the three macronutrients all affected the ileal brake and associated eating behavior 
to the same extent, while low concentrations may not reach the sensing threshold to 
induce such effects.
Macronutrients and its metabolites are sensed by various receptors in the gastrointestinal 
tract. Each macronutrient activates different receptors, mainly present on I- and L cells. 
Lipids trigger the release of  CCK, GLP-1 and PYY primarily via activation of  several 
fatty acid receptors (FFARs, GPR120) while recent evidence suggests that carbohydrates 
exert their effects on GI peptide release via a possible interaction between the sweet 
taste receptor (T1R2-T1R3) and the sodium-glucose cotransporter 1 (SGLT1) (28, 29). 
Proteins and their metabolites are able to trigger the peptone (LPAR5) or the umami 
receptor (T1R1-T1R3). Activation of  these receptors by macronutrients results in 
the release of  a variety of  GI peptides, which exert their actions through endocrine, 
paracrine and neurocrine pathways (30). 
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Welch et al were the first to demonstrate that infusion of  lipid in the form of  corn 
oil in the ileum caused a significant reduction in food intake in healthy volunteers (7). 
We infused a much smaller amount of  lipid but still observed a significant decrease in 
food intake, confirming results of  previous studies from Welch et al and others (7, 10). 
However, in other studies applying ileal intubations no effects of  safflower oil on food 
intake could be demonstrated (9, 11, 12). This lack of  effect may have been caused by 
differences in study design, leading to a longer time interval between the end of  the 
infusion and start of  the ad libitum test meal (31). 
Effects of  intra-ileal infusion of  carbohydrates or proteins on food intake and appetite 
have not been studied previously. Intraduodenal glucose infusion was shown to induce a 
reduction in food intake (16-18, 32). The caloric content of  infused carbohydrates varied 
from 180-480 kcal in these studies and was not added to the total energy intake during 
the ad libitum meal. None of  these studies showed a significant reduction in energy 
intake when intraduodenal infused calories were added to the ingested calories during 
the ad libitum meal. With regard to intraduodenal protein infusion, comparable amounts 
of  calories, 180-210 kcal, were used. It was shown that activation of  the duodenal brake 
by pea or whey protein infusion resulted in a significant decrease in food intake (21, 22, 
33). Compared to these previously mentioned studies we have infused far less calories 
(52 vs. 180-210 kcal) but still found a significant decrease in food intake. Furthermore, 
we showed that adding the amount of  ileal delivered calories to the calories ingested 
during the ad libitum meal after ileal brake induction still resulted in a significant decrease 
in overall energy intake.  This decrease in overall net energy intake may seem rather 
small (HL: 70 kcal, HC: 135 kcal). However, it should be noted that this acute effect 
was achieved with a single infusion. Furthermore, it was shown that a positive energy 
balance may become negative already with very small daily reductions in energy intake 
of  approximately 100 kcal/day (34). 
With respect to satiety feelings, only infusion of  high-dose protein resulted in a 
significant decrease in hunger. Infusions of  lipids or high dose carbohydrates did not 
significantly affect feelings of  hunger and satiety. The absence of  such effects may 
have been caused by certain aspects in our study design, such as feeding status prior to 
intestinal brake induction and timing of  substrate infusion. However, a significant effect 
was found in the high-dose protein treatment. This was not unexpected since it is well 
established that protein is more satiating than carbohydrates or lipid (35).  Furthermore 
it is possible that certain amino acids contribute to the perception of  satiety (36). 
We observed a significant increase in the release of  gastrointestinal peptides to the 
systemic circulation after ileal infusion with safflower oil, casein and sucrose. While 
release of  CCK after intraduodenal protein, carbohydrates and lipid infusion has been 
well documented (18, 22, 33), less is known on CCK release in response to ileal infusion 
of  macronutrients. CCK was regarded as proximal GI peptide (37).We and others 
have shown that CCK is also released upon distal, ileal nutrient infusion. We cannot 
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differentiate between a direct effect of  ileal nutrient on I cells or an indirect effect via 
paracrine or neurocrine mechanisms, by feed back signaling to the more proximal parts 
of  the small intestine (38).
GLP-1 release by distal L-cells after ileal infusion of  triolein, sodium oleate, starch 
and maltose, but not after peptone infusion was previously reported (14). Here, we 
demonstrate a clear increase in GLP-1 (7-36) release after infusion of  casein. In fact we 
confirm previous data, as it has been reported that intestinal exposure to intact proteins 
induces a stronger effect on GLP-1 release compared to protein hydrolysates (39). In 
our study food intake was inversely correlated to both CCK and GLP-1 (7-36) plasma 
levels, confirming the hypothesis that indeed these GI peptides are involved in the 
regulation of  food intake (22).
We also observed an increase in PYY secretion following lipid- and carbohydrates 
infusion, which is in line with previous observations on ileal exposure to lipid or rice 
starch with glucose infusion (40, 41). Infusion of  the low dosages of  casein and sucrose 
did not result in enhanced GLP-1 (7-36) or PYY release. 
Ileal infusion of  lipids and carbohydrates is known to delay gastric emptying and small 
bowel transit time (8, 11, 15, 20, 24). The nutrient dependent delays in GI transit data 
found in this study was of  the same magnitude as found in other studies but was not 
statistically significant, due to study design with activation of  ileal brake 30 min after 
onset of  gastric emptying and transit time measurement (42). Some limitations of  our 
study should be acknowledged. First, effects of  macronutrients were studied applying 
naso-intestinal intubations in healthy individuals. The intubation with a naso-ileal 
catheter for several consecutive days may have induced discomfort and changes in total 
wellbeing, thus affecting study outcome parameters. However, sequence of  test days 
did not influence food intake during the ad libitum meal. Second, the various nutrients 
were infused during three consecutive days, resulting in a possible carry-over effect 
between infusions, although the randomized control design prevented that this effect 
did influence study outcome. Third, only healthy lean men and women were included 
in this study. Therefore, these results cannot directly be applied to overweight or obese 
individuals, since some studies showed a less pronounced suppression of  food intake 
after intraduodenal lipid infusion in obese subjects compared to lean individuals (43, 
44). However it is not clear whether this reduced gastrointestinal sensitivity also applies 
for different infusion locations and more importantly other macronutrients.
We are the first to demonstrate that ileal infusion of  all three macronutrients induces a 
decrease in food intake. Furthermore, we showed that this effect was dose-dependent. 
The reduction in food intake confirms the findings in IT in rats and shows the potential 
of  the ileal brake as a target for food-based strategies in the prevention or treatment of  
overweight and obesity (3, 45). Conducting a proof  of  principle study in overweight/
obese individuals would contribute to a better understanding of  the effect of  ileal brake 
activation on food intake in obese subjects. Therefore, reliable dietary encapsulation- or 
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slow release strategies are needed to investigate the application of  ileal brake activation 
in weight management strategies.
In conclusion, we have shown that an ileal brake satiating effect leading to a decrease 
in food intake is obtained with small amounts of  lipid, protein and carbohydrates. 
Ileal infusion of  equicaloric amounts of  these macronutrients modulates food intake, 
gastrointestinal peptide release (CCK, GLP-1 (7-36) or PYY), and feelings of  hunger.
Supplementary table 6.1 GI peptides before and after breakfast. All values are means ± SEM. 
CCK (pmol/L), GLP-1 (pmol/L) and PYY (pmol/L) levels, baseline (before) and 30 minutes after the 
ingestion of  the breakfast meal (after) . 
Before After p 
CCK (pmol/L) 0.30 ± 0.06 0.74 ± 0.05 p<0.0001 
GLP-1 (pmol/L) 2.63 ± 0.26 3.84 ± 0.25 p<0.005 
PYY (pmol/L) 51.36 ± 2.98 60.66 ± 2.98 p<0.05 
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Abstract 
Background: Activation of  the ileal brake by casein induces satiety signals and reduces 
energy intake. However, adverse effects of  intraileal casein administration have not 
been studied before. These adverse effects may include impaired amino acid digestion, 
absorption and immune activation. 
Objective: To investigate the effects of  intraileal infusion of  native casein on plasma 
amino acid appearance, immune activation and gastrointestinal (GI) symptoms.
Design: A randomized single-blind cross over study was performed in 13 healthy 
subjects (6 male; mean age 26 ± 2.9 years; mean body mass index 22.8 ± 0.4 kg m-2), 
who were intubated with a naso-ileal feeding catheter. Thirty minutes after intake of  a 
standardized breakfast, participants received an ileal infusion, containing either control 
(C) consisting of  saline, a low-dose (17.2 kcal) casein (LP) or a high-dose (51.7 kcal) 
of  casein (HP) over a period of  90 min. Blood samples were collected for analysis of  
amino acids (AAs), C-reactive protein (CRP), pro-inflammatory cytokines and oxylipins 
at regular intervals. Furthermore, GI symptom questionnaires were collected before, 
during and after ileal infusion. 
Results: None of  the subjects reported any GI symptoms before, during or after ileal 
infusion of  C, LP and HP. Plasma concentrations of  all AAs analyzed were significantly 
increased after infusion of  HP as compared to C (p<0.001), and most AAs were 
increased after infusion of  LP (p<0.001). In total,  12.49 ± 1.73 and 3.18 ± 0.87 g 
AAs were found in plasma after intraileal infusion of  HP and LP, corresponding to 
93 ± 13% (HP) and 72 ± 20% (LP) of  AAs infused as casein, respectively. Ileal casein 
infusion did not affect plasma concentrations of  CRP, IL-6, IL-8, IL-1β and TNF-α. 
Infusion of  HP resulted in a decreased concentration of  11,12-dihydroxyeicosatrienoic 
acid whereas none of  the other oxylipins analyzed were affected.
Conclusions:  A single intraileal infusion of  native casein results in a concentration 
and  time dependent increase of  AAs in plasma, suggesting an effective digestion and 
absorption of  AAs present in casein. Also, ileal infusion did not result in immune 
activation nor in GI symptoms. 
Ch
ap
te
r 7
AMINO ACID DIGESTION AND ABSORPTION AFTER INTRAILEAL CASEIN INFUSION? 
125
Introduction
The increasing prevalence of  overweight causes increased concerns for health and health 
care costs worldwide. There is a clear need for therapeutic and preventive strategies, as 
current strategies has not proven to be successful on the long term.
One potential strategy to reduce energy intake is activation of  the so-called ileal brake. 
The ileal brake is a feedback mechanism that slows or ‘brakes’ the process of  proximal 
gastrointestinal digestion and absorption, and food intake. The ileal brake is activated 
when energy-containing macronutrients reach the ileum. Ileal brake activation induces 
enhanced satiety signals, satiation and reduction of  energy intake (1, 2). Recently, we 
have shown that not only ileal appearance of  lipid but also of  the other macronutrients, 
carbohydrate (sucrose) and protein (casein), results in increased satiation and a reduction 
of  food intake (3). This reduction in food intake underlines the relevance of  the ileal 
brake as potential food based strategy in the prevention or treatment of  overweight and 
obesity. Despite its potential, it should be investigated whether undigested native protein 
infused into the ileum does not result in adverse effects such as protein malabsorption 
or immune activation. 
Intraileal infusion bypasses the proximal parts of  the gastro-intestinal (GI) tract as is also 
achieved by bariatric surgery. One of  the most frequently applied bariatric procedures 
worldwide is the Roux-en-Y gastric bypass (RYGB). RYGB effectively results in weight 
loss and improvement of  type II diabetes (4). Although the mechanism is not completely 
understood yet, the proposed mechanism by which RYGB may exert its beneficial 
effects is enhanced stimulation of  enteroendocrine cells in the distal small intestine 
by undigested nutrients, resulting in the release of  the L-cell products glucagon-like 
peptide 1 (GLP-1) and peptide YY (PYY) (5). It has been suggested that weight loss 
after RYGB may be attributable to limited food intake which can be partly explained by 
gastric restriction and malabsorption. However, evidence has increased that the positive 
health effects induced by RYGB may be due to altered GI physiology (4) and not due 
to gastric restriction and malabsorption. RYGB results in rapid emptying of  gastric 
content with prolonged small intestinal transit times (6) and only a small proportion of  
the reduction in energy intake after RYGB is due to malabsorption (7). Malabsorption 
may result in an increased risk of  developing nutritional deficiencies, such as protein 
deficiency (8). Under physiological conditions, gastric acid activates the conversion of  
pepsinogen into the proteolytic enzyme pepsin which denatures orally ingested protein. 
Protein is further digested by trypsin in the small intestine. In response to orally ingested 
protein, amino acids in the form of  peptides or free amino acids are found in the 
intraluminal content of  the jejunum and ileum (9). 
Recently it was found by Bojsen-Møller et al. (2015) that RYGB accelerates caseinate 
digestion and amino acid absorption, and it was suggested that protein digestion is 
not impaired after RYGB (10). However, it remains to be investigated whether native 
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casein, directly infused into the ileum and thus bypassing the proximal parts of  the small 
intestine results in malabsorption. If  this is the case, protein may be available for colonic 
fermentation resulting in potential harmful effects for the host’s health (11). Such effect 
could manifest itself  by immune activation (12). This might be shown by the production 
and release of  pro-inflammatory cytokines such as interleukin-1β (IL-1β), IL-6, IL-8 
and tumor necrosis factor-α  (TNFα) (12), or other pro-inflammatory mediators such 
as c-reactive protein (CRP) and eicosanoids, a subset of  oxylipins. The release of  these 
lipid mediators can be triggered by a variety of  stimuli. They have been associated to be 
involved in pain and fever and are known to be potent regulators of  the host immune 
response (13, 14). 
The aim of  this study was to investigate the effects of  intraileal native protein infusion 
on digestion, AA absorption and immune activation. This was done in a study evaluating 
the effects of  intraileal infusion of  native protein on food intake previously performed 
by our group (3). It was hypothesized that ileal infusion of  native casein results in 
plasma appearance of  AAs in casein and does not result in acute adverse effects such 
as incomplete digestion of  casein protein or inflammation. This was investigated by 
analyzing plasma AAs at several time points after intraileal infusion of  both a low-dose 
and high-dose of  casein in a randomized single-blind cross over study as reported by 
Avesaat et al. (2014) (3).  Inflammatory mediators such as pro-inflammatory cytokines 
and oxylipins were analyzed to investigate acute adverse inflammatory effects.  
Material and methods 
Study design
In the present study plasma samples from a previously published single blind randomized 
placebo controlled cross over study were analyzed to investigate the effects of  intraileal 
protein infusion on plasma profiles of  AAs and inflammation markers (3). Thirteen 
subjects (6 male, 7 female, age 26 ± 2.9 years, BMI of  22.8 ± 0.4 kg m-2) completed the 
study.
The effects on AAs and inflammation markers of  the following interventions were 
investigated 1) saline infusion (control (C)), 2) low dose protein infusion (5 g casein 
(LP), 17.2 kcal) and 3) high dose protein infusion (15 g casein (HP), 51.7 kcal). Each 
treatment was infused into the ileum over a 90-min period, on separate test days. 
Order of  interventions were randomly assigned to each participant and based on a 
randomization protocol (via randomizer.org) defined prior to the start of  the study. 
Casein (energy density: 3.45 kcal g-1, Dutch Protein & Services, Tiel, The Netherlands) 
was used as protein source. The AA composition of  casein is shown in Table 1 (Eurofins 
food testing Netherlands B.V., Heerenveen, The Netherlands).  Casein was dissolved in 
a total volume of  180 ml tap water and infused into the ileum a rate of  2 ml min-1 (0.6 
kcal/min; total infusion time 90 min).
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Experimental design
Each subject participated in all three test days. On all test days an intravenous catheter 
was placed in a forearm vein for blood collection. At 8.30 AM, a basal blood sample 
was obtained. Subsequently, a standardized breakfast meal consisting of  a sandwich and 
an egg (sunny side up, 210 kcal), was consumed.  Ileal substrate infusion was performed 
from t=30 to t=120 minutes after breakfast ingestion. Participants were blinded to the 
infusion treatment. One hour after ending the infusion (t=180 minutes), the volunteer 
received a standardized ad libitum lunch meal (sandwiches with egg salad (energy density: 
2.2 kcal g-1). At t=240 the last blood sample was taken and the test day was finished. 
Table 7.1 Amino acid composition of  native casein expressed as % (w/w)  
*The amino acid composition of  casein was analyzed by acid protein hydrolysis followed by amino acid analysis using 
ninhydrin according to ISO13903:2005, This analytical method is unable to separate  aspartic acid from asparagine 
and glutamic acid from glutamine. Tryptophan and cysteine were analyzed according the EU152/2008 (F) and ISO 
13903:2005 protocol.
Questionnaires
GI symptoms were evaluated using a questionnaire  addressing complaints such as 
headache, nausea, stomach-ache, diarrhea, and other symptoms. Symptoms were graded 
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on a 4-point scale with the grade 0 representing ‘not present’ to 4 ‘strongly present’. 
Subjects were asked to mark how they felt at the moment before (t=15 and t=30), 
during (t=60 and t=90) and after the infusion stopped (t=120 and t=240). 
Sample collection
Venous blood samples were drawn 15 minutes before breakfast (t=-15 min), and at 
30, 45, 60, 90, 120, 150, 180, 210 and 240 minutes after breakfast, respectively. Blood 
was collected in ice-chilled EDTA coated tubes (Becton & Dickinson, Franklin Lakes, 
NJ, USA). Immediately after blood collection, tubes were centrifuged at a rate of  3000 
revolutions per minute at 4°C for 10 minutes. Plasma was transferred into aliquots and 
stored on dry ice for the rest of  the test day. At the end of  the test day, samples were 
stored at -80°C until further analysis of  AAs, cytokines and oxylipins. 
Plasma amino acid profiles
Plasma AA profiles were analyzed including the AAs present in casein (Table 1, except 
cysteine), as well as other AAs and amines, i.e. 1-methylhistidine, 3-methylhistidine, 
asymmetric dimethylarginine, citrulline, DL-3-amino isobutylene, glycyl-glycine, homo-
arginine, hydroxyl-lysine, amino adipic acid, α-amino-n-butyric acid, kynurenine, 
L-4-hydroxy-proline, L-glutamic acid, homo-serine, trimethylamine, phosphor-
ethanolamine, putrescine, symmetrical dimethylarginine, sarcosine, serotonin, taurine, 
gamma-aminobutyrine, gamma-l-glutamyl amine, glycine, ethanol, glutamine, o-acetyl-
l-serine. AAs and amines were analyzed using a LC-MS method as described previously 
(16).
Plasma profiles of  pro-inflammatory cytokines and C-reactive protein
Plasma profiles of  CRP, TNF-α,  IL-1β, IL-6, IL-8 were analyzed using an in-house 
developed and validated multiplex immunoassay based on Luminex technology (xMAP, 
Luminex, Austin TX USA). The assay was performed as described previously(17, 18). 
Aspecific heterophilic immunoglobulins were pre-absorbed from all samples with 
heteroblock (Omega biologicals Bozeman MT, USA). Acquisition was performed with 
the Biorad FlexMAP3D (Biorad laboratories, Hercules USA) in combination with 
xPONENT software version 4.2 (Luminex). Data was analyzed by 5-parametric curve 
fitting using Bio-Plex Manager software, version 6.1.1 (Biorad). 
For TNF-α  the range was 1.2-5000 pg/ml and the limit of  detection (LOD) for TNF-α 
was 0.7 pg/ml, with an inter-assay coefficient of  variation (CV) of   3.0 ± 1.8% and an 
intra-assay CV of  7.6 ± 0.6%.  For IL-1β the range of  the assay was 1.2-5000 pg/ml 
and the LOD was 0.4 pg/ml with an intra-assay CV of  3.4 ± 2.9 % and an inter-assay 
of  3.5 ± 2.5%. For IL-6 the range of  the assay was 2.4 – 10000 pg/ml and the LOD 
for IL-6 was 0.9 pg/ml, with an intra-assay CV of  4.4 ± 2.7% and an inter-assay CV of  
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11.0 ± 4.6%. For IL-8 the range of  the assay was 2.4-10000 pg/ml and the LOD was 
1.3 pg/ml with an intra-assay CV of   5.8 ± 3.6% and inter-assay CV of  13.7 ± 6.8%. 
For CRP the range was 12.2 – 50000 pg/ml and the LOD was 11.7 pg/ml whereas the 
upper limit of  detection was 42691.6 pg/ml. The samples were diluted to be within the 
range of  the assay.
Not all cytokine concentrations were above the lower limit of  quantification (LLOQ) 
of  the assay. For TNF–α , 63% of  the samples was below the LLOQ (1.2 pg/ml). For 
IL-1β, 25% of  the samples was below the LLOQ (2.2 pg/ml). For IL-6, 11% of  the 
samples was below LLOQ (2.8 pg/ml). For IL-8, 46% of  the samples was below LLOQ 
(4.5 pg/ml). Since these samples were below the detection range of  the assay, they were 
excluded from the data analysis. 
Plasma profiles of  oxylipins 
The oxylipin platform (Table 2) covers classical and non-classical eicosanoids from 
different polyunsaturated fatty acids, including ω-6 and ω-3 PUFAs such as linoleic 
acid, arachidonic acid and dihomo-γ-linoleic acid (all ω-6), eicosapentaenoic acid and 
docosahexaenoic acid (both ω-3). The samples were analyzed by liquid chromatography 
tandem mass spectrometry as described previously (19).    
Data analysis 
Intervention effects on plasma AA concentrations, pro-inflammatory cytokines and 
oxylipins were analyzed within participants with a mixed model analysis of  variance 
(ANOVA) including the fixed factors treatment (infusion of  C, infusion of  LP and 
infusion of  HP), time and the interaction between treatment and time. Because of  the 
crossover design, intervention effects within subjects were compared by including the 
random factor subject. 
All statistical analyses were performed using the SAS statistical software package (SAS 
version 9; SAS institute, Cary, NC, USA). Data were visually checked on normality and 
on constant variance of  residuals by plots of  residuals vs. corresponding predicted 
values. All data met the criteria for ANOVA assumptions. If  an intervention effect 
occurred post hoc comparisons were made using Tukey-Kramer adjustment to correct 
for multiple testing. Data are presented as the mean ± SEM (unless specified otherwise) 
and considered significant at p<0.05.
Since infused amounts of  native casein (5 gram LP vs. 15 gram HP) were known, the 
amount of  AAs infused as casein was calculated based on the AA composition of  the 
native casein infused (Table 1). To calculate the absolute amount of  AA in gram, plasma 
AA concentrations (µmol/L) were corrected for the total blood volume (female 65 ml/
kg, male 75 ml/kg (20)). To estimate the increase in AAs due to LP and HP infusion, 
the total area under the curves (AUCs) during the infusion period (t=30 until t=180) 
were calculated by applying the trapezoid method. The AUC after C treatment was 
subtracted from AUCs after LP and HP infusion per individual to correct for control 
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AA concentrations. In case the AUC was negative after placebo correction, the value 
was excluded from further analysis (n=3 for LP and n=1 for HP).   
Results
Questionnaires 
Subjects did not report any feelings of  nausea, intestinal cramps, diarrhea, headache, 
heartburn, belching or other parameters of  impaired wellbeing before, during or after 
infusion of  C, LP or HP.   
Table 7.2. Overview of  oxylipins analyzed assigned to their precursor fatty acids 
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Amino acid plasma concentrations 
Baseline AA concentrations were not different between treatments. Overall, a treatment 
and time interaction effect was found (p<0.001);  AAs present in native casein increased 
after LP and HP over time as compared to C (p<0.001), whereas amines or metabolites 
not present in casein such as taurine did not  (Figure 1 and supplemental data Table 
1 and 2). Post-hoc analysis showed that both LP and HP resulted in increased plasma 
concentrations over time as compared to C of  15 out of  19 analyzed AAs in casein, 
namely alanine, arginine, asparagine, histidine, isoleucine, leucine, lysine, methionine, 
phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine (p<0.001). 
Aspartic acid was only increased after HP (p<0.0001). Concentrations of  glutamic 
acid could not be assessed due to high plasma glutamic acid concentrations. Therefore 
these results are shown in relative peak areas as compared to an internal standard of  
glutamic acid concentration (Figure 1C).  Glutamic acid was increased after HP and LP 
as compared to C (p<0.005). Plasma concentrations of  glutamine and glycine did not 
change after LP and HP infusion.
HP resulted in a further increase of  the following AAs as compared to LP; aspartic 
acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, tyrosine, 
tryptophan and valine (p<0.001). After infusion of  LP and HP the AAs present in native 
casein increased when the infusion started (t=30), and peak plasma concentrations were 
reached at the time the infusion stopped (t=120) (Figure 1A, 1B). All other amines 
and AAs not present in casein, such as taurine (Figure 1D), did not show a change in 
plasma concentrations after LP, HP or C.  
In Table 3 the mean AUCs (g) are shown per AA for LP and HP. Also the total amount 
of  AAs found in plasma after intraileal infusion of  LP and HP was calculated as a 
percentage of  amount of  AAs  infused as casein (4.44 g for LP and 13.38 g for HP). In 
total, 3.18 ± 0.87 g and 12.49 ± 1.73 g AAs were found in plasma after intraileal infusion 
of  LP and HP, respectively. These numbers correspond to 72 ± 20% (LP) and 93 ± 
13% (HP) of  the amount of  AAs infused as casein. 
Cytokines and CRP
Plasma concentrations of  IL-6, IL-8, IL-1β, TNF-α  and CRP were not affected by 
either LP, HP or C (Figure 2). Plasma concentrations of  the cytokines analyzed did 
not change over time and no interaction effect between time and protein infusion was 
found. 
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Figure 7.1 Plasma profiles of  proline (A), leucine (B),  glutamic acid (C) and taurine (D) after intraileal 
infusion (infusion time t= 30-120 min) of  control (C), low-dose casein protein (LP) or high-dose casein 
(HP) (n=13). An interaction effect (treatment*time) for proline (A) and leucine (B) was observed. 
Proline and leucine concentrations increased after HP infusion (p<0.0001) and LP infusion (p<0.0001). 
Glutamic acid (C) increased after HP infusion ($! treatment effect p<0.005) as compared with both 
placebo and LP infusion (this panel represents ratios of  the peak area’s/ internal standard peak areas). 
Taurine concentrations (D) were not affected by HP or LP infusion. *p<0.05 compared with placebo 
at the same time point, **p<0.0001 compared with placebo at the same time point, !p<0.001 compared 
with LP at the same time point. Note: in supplemental data Table 1 the results of  all amino acids are 
presented.
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Figure 7.2 Plasma concentrations of  IL-6 (A), IL-8 (B), IL-1β (C),TNFα (D) and CRP after intraileal 
infusion (infusion time t=30-120 min) with control (C), low-dose casein (LP) or high-dose casein (HP)
None of  the treatments affected plasma concentrations of  the cytokines analyzed. For IL-6, 2 subjects plasma 
concentrations were below the LLOQ (n=11). For IL-8, 8 subjects plasma concentrations were below the LLOQ 
(n=5). For IL-1β, 3 subjects had plasma concentrations below the LLOQ (n=10) and for TNFα 8 subjects had plasma 
concentrations below the LLOQ (n=5).
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Oxylipins
Only an effect of  infusion (p<0.001), time (p<0.001) and interaction between infusion 
and time was found for 11,12-DiHETrE (p<0.05) (Figure 3). Concentrations of  
11,12-DiHETrE decreased after HP (p<0.001) and LP (p<0.01) as compared to C. 
Plasma concentrations of  11,12-DiHETrE did not differ between LP as compared to 
HP.  
An infusion and time effect (p<0.05) was found for 5,6-DiHETrE and 19,20-DiHDPA. 
These oxylipins decreased after HP as compared to C, and LP (p<0.05). However, 
no interaction between time and treatment was found. None of  the other oxylipins 
presented in Table 2 were affected by ileal infusion of  either LP, HP or C. 
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Figure 7.3 Results of  11,12-DiHETre after intraileal infusion (infusion time t=30-120 min) with control 
(C), low-dose casein (LP) or high-dose casein (HP) (n=13)
An effect for time (p<0.001), infusion (p<0.001) and interaction between time and infusion (p<0.001) was found for 
11.12-DiHETre.  *p<0.05 both LP and HP resulted in decreased 11.12-DiHETre.
Discussion 
To our knowledge this is the first study showing that intraileal infusion of  native 
casein results in AA plasma recoveries of  approximately 72-93%. These results suggest 
that ileal infusion of  native protein casein at 5 and 15 g may result in near complete 
digestion and absorption of  its AAs. Pro-inflammatory mediators or GI symptoms did 
not increase in response to intraileal protein infusion, indicating that intraileal casein 
infusion does not induce adverse effects in healthy subjects.  
The present study aimed to investigate adverse effects of  intraileal protein infusion. 
This was done by 1) estimating AA digestion and absorption after LP and HP reducing 
the possibility of  casein malabsorption and 2) evaluating immune activation after ileal 
protein infusion. 
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For casein specific AAs, plasma recoveries of  72 ± 20% and  93± 13% were estimated 
after LP and HP. It cannot be excluded that part of  the increased AA concentrations 
after LP and HP result from endogenous protein breakdown. However the following 
arguments suggest that the increase in casein specific AAs was due to intraileal casein 
infusion; 1) data of  the present study show reproducible and dose-dependent AA 
concentration patterns after infusion of  both LP and HP for all AAs present in casein. 
In contrast, plasma concentrations of  amines (e.g. taurine) not present in casein did 
not change after infusion of  both LP and HP; 2) Starting ileal protein infusion resulted 
in an immediate increase in plasma AA concentrations, whereas these concentrations 
decreased immediately after ending the infusion; 3) Effects on AA plasma concentrations 
were studied within subjects making direct comparisons between undigested casein and 
saline possible. 
In this study we showed that pro-inflammatory markers were not affected by protein 
infusion, nor were GI symptoms. Subjects did not report any feelings of  nausea, 
intestinal cramps, diarrhea, headache, heartburn, belching or other overall GI symptoms 
before, during or after C, LP or HP.  The results on subjective feelings of  wellbeing 
during intestinal protein infusion are in line previous studies. In studies of  Geraerts 
(2011) and Ryan et al.(2013) it was shown that intraduodenally infused protein did not 
result in any GI complaints (21),(22).
Recently Neurath et al., proposed that factors in the diet such as dietary protein may 
contribute to an impaired intestinal barrier function, resulting in the release of  pro-
inflammatory cytokines (12).  Another possible trigger for pro-inflammatory responses 
when protein is not efficiently digested may be protein fermentation in the colon (11). 
Therefore, it was reasonable to postulate that ileal protein infusion could induce an 
inflammatory response. However, in our study none of  the pro-inflammatory cytokines 
evaluated were affected by ileal infusion of  5 or 15 g casein. Furthermore, almost the 
total amount of  AAs infused as casein was found in blood plasma suggesting that 
casein was already digested before entering the colon. Additionally, none of  the 
oxylipins analyzed were induced by protein infusion, except for 11,12-DiHETrE, which 
plasma concentrations decreased after infusion of  HP. Recently, increased plasma 
concentrations of  11,12-DiHETrE have been found in patients with nonalcoholic 
steatohepatitis (NASH), making it a candidate biomarker for the non-invasive detection 
of  NASH (23). However, in our study the decrease of  11,12-DiHETrE was rather small 
and the exact function of  this oxylipin is still unknown. Therefore we believe this effect 
is has little, if  any, biological significance. 
Several proteolytic enzymes, as well as the expression of  peptide- and amino acid 
transporters (e.g. peptide transporter 1 and B0AT1) are known to be present in the 
ileum (24-27). These enzymes and transporters may be involved in the digestion and 
absorption of  casein in the ileum. It was hypothesized that intraileal infusion of  native 
casein results in efficient casein digestion and absorption of  casein specific AAs. It was 
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found that LP and HP resulted in recoveries of  72 ± 20% and  93 ± 13% for casein 
specific AAs, suggesting that these AAs were indeed efficiently digested and absorbed. 
To our knowledge, this is the first study investigating the effects of  undigested proteins 
in the human ileum on its digestibility. Previous studies evaluated postprandial kinetics 
and digestibility of  oral protein intake in healthy volunteers (9, 28-30), as well as casein 
digestibility after RYGB surgery(10). Our estimated AA recoveries after ileal protein 
infusion are in line with AA recoveries reported by Mahé et al. In that study orally 
ingested [15N] casein was recovered in the jejunum mainly in the form of  peptides 
and subsequently efficiently absorbed in the upper part of  the small intestine (28). 
Luminal jejunal recovery of  orally ingested casein was 82.6 ± 9.5%. In another study 
by Gaudichon et al. (2002) ingestion of  a meal containing milk protein resulted in 
calculated true digestibility percentages of  AAs between 90 and 100% (30). Although 
the recovery percentages in these studies are in the same range as our findings on AA 
recoveries, direct comparisons are difficult. Both studies investigated the ingestion of  
oral protein loads containing more protein as compared to the amounts of  protein 
infused in the present study e.g. 30 g milk protein (30) and 368 mmol casein (28) as 
compared to 5 or 15 g of  casein in the present study. Although the AA recovery of  15 
g of  ileal casein infusion was approximately 80%, more studies are needed to confirm 
efficient protein digestion and subsequent AA absorption after intraileal delivery of  
higher amounts of  protein.   
This study has limitations that need to be considered. First, the present study design was 
not optimal to draw conclusions on amino acid digestion and absorption.  Since we did 
not used labeled casein protein we cannot prove that the increased AAs concentrations 
were due to digestion and absorption of  ileal infused casein. Also we cannot exclude a 
possible interaction effect between breakfast ingestion and casein infusion.  Therefore, 
we can only conclude that it is highly likely that the increased amino acid plasma 
concentrations originated from casein digestion. Secondly, data of  the present study 
only concern acute responses. The effects of  repeatedly targeting the ileum with protein 
on adverse effects remain to be investigated. However based on available literature of  
patients undergoing RYGB it seems unlikely that repeatedly targeting the ileum results 
in adverse effects or protein malabsorption. A recent report showed that ingestion of  
caseinate by RYGB patients results in efficient and even accelerated protein digestion 
and absorption as compared to protein ingestion before RYGB (10). Furthermore, 
it has been proposed that malabsorption contributes only a small proportion to the 
reduction in net energy absorption which is observed after RYGB (4, 7). These data 
suggest that it is not very likely that repeatedly targeting the ileum with native casein 
results in adverse effects in healthy subjects.  Thirdly, the present study was performed 
with healthy subjects with a normal BMI and may not give the same results in other 
groups, such as subjects with comorbidities or overweight individuals. Fourthly, we 
CHAPTER 7
138
only measured a selection of  inflammation parameters and  therefore it is possible that 
effects could have been missed. 
Our group previously showed that intra ileal infusion of  casein, sucrose and safflower 
oil results in increased satiation and decreased food intake (3).  A reduction in food 
intake by ileal protein infusion indicates that the ileal brake may be a target in the 
prevention of  overweight and obesity. The data of  the present study show that ileal 
casein infusion results in high plasma recoveries of  casein specific AA and does not 
induce acute adverse effects. These data provide evidence that targeting the ileal brake 
may not only be a potent but also a safe target for weight management.
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The research presented in this thesis adds to our knowledge on the role of  the small 
intestinal tract in the development of  satiation. Potential targets that were studied 
included intestinal brake activation, GLP-1 and CCK signaling via the vagal nerve 
and the role of  mediators such as serotonin that may be involved in nutrient-induced 
GLP-1 release. An important question addressed was whether  stimulation of  the distal 
small intestine with macronutrients other than lipids, such as undigested native protein 
(casein) and carbohydrate (sucrose) would result in the release of  satiety hormones 
and reduction of  food intake. Additionally, the hypothesis of  a serotonin mediated 
mechanism for (non-)nutritional induced GLP-1 release was investigated. This final 
chapter starts with summarizing the main findings presented in this thesis. Next, these 
results are discussed in relation to other studies and implications and suggestions for 
future research are presented. 
Main findings
The data presented in this thesis show that 
of  the potential strategies investigated, 
ileal delivery of  (non-)nutritional stimuli 
is likely to present the best approach for 
weight management. It was found that ileal 
stimulation with relatively small amounts of  
macronutrients increases satiety signaling 
and reduces energy intake. In addition, the 
effects of  ileal brake activation on satiation 
were stronger in comparison to activation 
of  the duodenal and jejunal brake (chapter 
5). Activation of  the ileal brake was 
found to be independent of  the type of  
macronutrient, since ileal stimulation with 
all macronutrients tested; lipids (safflower 
oil), protein (casein) and carbohydrate 
(sucrose) effectively increased satiety 
signals and reduced energy intake (chapter 
6).
It was found that the same macronutrients, 
as well as rebaudioside A also stimulated 
the release of  GLP-1 and PYY from ileal 
tissue segments (chapter 2). There are 
several mechanisms in the ileum which 
sense (non-)nutritional stimuli, resulting in 
GLP-1 release. It was found that serotonin 
Ileal macronutrient delivery 
has potential as a weight 
management strategy because:
The ileum senses all nutrients 
efficiently; all macronutrients delivered 
to the ileum stimulate GLP-1 release 
resulting in satiation via at least two 
processes 1) nutrient interactions with 
GPCRs and 2) via serotonin-mediated 
processes  
It does not result in adverse effects
Macronutrients are efficiently digested 
in-, and absorbed from the ileum
Ileal stimulation more effectively  
activates satiation in comparison to 
jejunal or duodenal stimulation
A small amount of  macronutrients 
(51.7 kcal) already results in a  
significant reduction of  energy intake 
(80-130 kcal)
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released from enterochromaffin cells (EECs) mediates nutrient-induced GLP-1 release 
from enteroendocrine cells (EECs) via the activation of  serotonin receptors on EECs 
(chapter 3). Furthermore, the data presented in this thesis show that ileal delivery of  
native undigested protein does not result in acute adverse effects since ileal delivered 
Figure 8.1 Overview main findings this thesis 
(A) Ileal exposure results in the most effective reduction in food intake as compared to jejunal or duodenal release. 
(B) Stimulation of  ileal tissue segments with casein, sucrose, safflower oil and rebaudioside A results in GLP-1 release. 
Serotonin contributes to this (non-)nutrient-induced GLP-1 release possibly via serotonin receptors on enteroendocrine 
cells. 
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casein is efficiently digested and absorbed, does not activate immune responses, and 
does not result in gastrointestinal complaints by healthy subjects (chapter 7).  
Additionally it was found that the vagal nerve does not contribute to satiation in pigs, 
and that CCK regulates satiation independently of  CCK receptors located on the vagal 
nerve. Complete interruption of  the abdominal vagal nerve in pigs did not affect food 
intake, and antagonism of  the CCK receptor increased food intake in both sham and 
vagotomized pigs (chapter 4). Therefore, the contribution of  endocrine and paracrine 
CCK and GLP-1 signaling to satiation seems to be more important than signaling via 
CCK and GLP-1 receptors located on the vagal nerve. 
Internal validity
For this thesis, a translational approach was used, involving different models and 
methods. Studies performed in animals or with animal tissues used the pig as model 
species. Pigs show a high degree of  resemblance to human beings in terms of  their 
intestinal anatomy and physiology and the regulation of  appetite and energy metabolism. 
Like humans, pigs are omnivorous animals (1-4). The research strategies and techniques 
used were based on an ex vivo porcine intestinal segment model, an STC-1 cell line, an in 
vivo porcine model of  subdiaphragmatic vagotomy, and an in vivo intubation technique 
in healthy volunteers (figure 8.2). In this paragraph the consistency of  the data derived 
from the various methods will be discussed. 
In vivo porcine model of  subdiaphragmatic vagotomy 
To study the role of  the abdominal vagal nerve in food intake regulation, total 
subdiaphragmatic vagotomy was applied by blocking both the efferent and the 
afferent vagal nerves via endoscopic laparoscopy. Pigs recovered rapidly and without 
complications from their surgery. The vagal nerve was interrupted by removal of  
approximately 3 cm length of  both afferent and efferent vagal nerves, as was confirmed 
with inspection at necroscopy. The advantage of  total subdiaphragmatic vagotomy is 
that all vagal nerve signaling under the diaphragm was excluded, making it possible to 
investigate the contribution of  the total abdominal vagal nerve to food intake regulation. 
By using the pig for this model we were also able to control the feeding regime during 
the whole study period, thereby reducing variation in food intake between individual 
animals. 
For interpretation of  the results of  this study, the limitations of  total subdiaphragmatic 
vagotomy should be considered as well. First, care should be taken with the interpretation 
of  the results since this model does not represent healthy physiology. Second, vagotomy 
decreased the intestinal transit time of  food. It resulted in a decreased gastric emptying 
rate and attenuated postprandial responses of  glucose and insulin. At necropsy stomach 
contents were found to be increased. These results make it difficult to pinpoint whether 
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the effects of  vagotomy on food intake and postprandial hormone responses are 
caused by vagal nerve interruption or whether they are a consequence of  the decreased 
gastrointestinal transit time. Despite the differences in gastrointestinal transit time no 
effects on food intake between vagotomy or sham operated pigs were found, suggesting 
that in pigs the vagal nerve does not contribute to satiation. To analyze the contribution 
of  neural signaling via the vagal nerve to satiation other, more precise technologies 
able to measure real time vagal nerve activity should be applied. Others applied vagal 
electrodes to minipigs and rats to stimulate vagal nerve activity. These authors showed 
that stimulation of  the vagal nerve resulted in decreased weight gain and reduced food 
intake (5, 6). It would thus be very interesting to develop technologies to analyze real 
time local vagal nerve activity in vivo. 
Figure 8.2 Overview of  the research and different research models presented in this thesis  
The STC-1 cell line was used to study the effects of  serotonin induced GLP-1 release from enteroendocrine cells. The 
ex vivo intestinal segment model was applied to study the effects and mechanisms of  intestinal nutrient stimulation 
on the release of  satiety hormones. An in vivo porcine model of  subdiaphragmatic vagotomy was used to study the 
contribution of  the vagal nerve and CCK and GLP-1 receptors located at the vagal nerve to satiation. In vivo studies with 
healthy volunteers were conducted to study the effects of  intestinal macronutrient delivery on satiation. Future studies; 
Applications for nutrient delivery, other than intubation, should be developed in order to study the effects of  daily ileal 
nutrient delivery on body weight and satiation. If  the latter is successful, it should be investigated if  ileal nutrient delivery 
before a meal helps people to maintain their healthy body weight.
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Third, due to different vagotomy techniques, species differences and types and 
characteristics of  food and (or) feeding regimens, it was difficult to compare the results 
from our study with data from other studies (7-10). 
Despite the limitations of  this model of  total subdiaphragmatic vagotomy, it was shown 
that interruption of  the total vagal nerve in pigs does neither affect food intake nor 
body weight. Overall, the results of  this study show that the vagal nerve is involved in 
regulation of  intestinal transit of  food, but does not contribute to the regulation of  
satiation, whereas other targets such as CCK receptors did show to affect satiation. 
Ex vivo and in vitro models to study (non-)nutrient-induced GLP-1, PYY and CCK release 
Another model used for the research presented in this thesis was the ex vivo porcine 
intestinal segment model. This model was applied to investigate the effects of  intestinal 
macronutrient stimulation on GLP-1, PYY and CCK release. Additionally, this model 
was used to study the role of  intestinal serotonin in nutrient-induced GLP-1 release. The 
intestinal segment model previously showed to be a suitable tool to study compound- 
and location-specific effects on the release of  GI hormones (11, 12). The advantage of  
this model is that the segments mimmic the intestinal epithelium as a relatively intact 
tissue containing multiple cell types such as EECs, ECCs and absorptive enterocytes. 
The segments can be obtained from various anatomical regions of  the small intestine 
(e.g. duodenum, jejunum, ileum and colon) making it possible to study location-specific 
effects. Since more segments can be obtained from one pig, effects can be studied 
within the same animal. Furthermore, by analyzing media that have been exposed to 
the segments, paracrine effects of  nutrient stimulation can be studied. Although this 
model offers a suitable system to study cellular interactions involved in serotonin and 
GLP-1 release, it has also some limitations that warrant consideration. First, it should be 
noted that care should be taken with interpreting the findings from this ex vivo model, 
since it is unknown if  all the findings resemble physiology of  the human situation in 
vivo. For the research presented in this thesis the intestinal segment model was used to 
get an indication which macronutrients may be potent activators of  the ileal brake in 
vivo. Second, this method does not distinguish between intestinal exposure to the apical 
or basolateral side. It is therefore also not possible to distinguish if  GLP-1, PYY and 
CCK are released to the apical or basolateral side. A more advanced method which 
can be applied to study the effects of  nutrient transport is the Ussing chamber (13). 
Third, since the segments contain multiple cells it is difficult to study which cell type 
is responsible for the effects on for example GLP-1 release. To study which cell types 
are responsible for the effects found ex vivo, cell-lines can be applied. For the research 
presented in this thesis, the secretin tumor (STC-1) cell line was applied to study if  
serotonin-induced GLP-1 release was stimulated from EECs and if  this was receptor 
mediated. This mouse derived tumor cell line is widely used to study the effects of  
dietary compounds on CCK, GLP-1 and PYY secretion (14, 15).
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Small intestinal delivery of  macronutrients in healthy volunteers
To study the effects of  the type of  macronutrient(s) and location of  their release along 
the small intestinal tract on energy intake and the release of  satiety hormones, naso-
intestinal catheters were applied to healthy human volunteers. 
This technique has previously been applied to study the effects of  duodenal delivery of  
lipids and proteins, as well as those of  ileal lipid delivery  (16-21). These studies have the 
advantage that energy intake in human volunteers can be included as primary outcome 
parameter. Also the effects of  intestinal nutrient delivery on plasma concentrations of  
GLP-1, PYY and CCK can be studied.  Although this technique is suitable to study effects 
of  intestinal nutrient delivery on satiation, it comes with its own limitations that warrant 
consideration. First, intubation with a naso-ileal catheter for several consecutive days 
may induce discomfort and changes in overall well-being, or induce possible carry-over 
effects, thereby affecting outcomes of  the study parameters. However, the contribution 
of  the latter effect was minimized by applying cross-over study designs and random 
assignment of  treatments. Second, in the human intubation studies presented in this 
thesis only acute effects on food intake were investigated. The effects of  repeatedly 
targeting the ileum with macronutrients on food intake and on adverse effects remain 
to be investigated. Taken together, the naso-intestinal intubation technique offers a 
suitable method to study the effects of  intestinal nutrient delivery on satiation, energy 
intake and release of  satiety hormones in vivo.
   
Consistency of  data derived from in vivo intubation and ex vivo intestinal segment studies  
Intestinal macronutrient stimulation was performed ex vivo and in vivo  to investigate 
underlying mechanisms behind and effects of  stimulation on activation of  satiety signals 
and satiation. The ex vivo intestinal segment studies and in vivo intubation experiments 
have in common that effects of  undigested native macronutrient exposure to the 
intestinal epithelium are studied, whereas the proximal parts (e.g. mouth and stomach) 
of  the GI tract are bypassed. By applying these methods the intestinal epithelium is 
directly stimulated with macronutrients.
The results of  the ex vivo study showed that ileal simulation with all macronutrients and 
mixtures tested, sucrose, safflower oil and casein, resulted in an increased GLP-1 and 
PYY release. Ileal stimulation in vivo with the same preparations resulted in reduction of  
energy intake and increased activation of  satiety signals. Although these results all point 
towards the direction that ileal delivery of  different macronutrients results in increased 
release of  satiety hormones and activate satiation, it should be noted that the effects on 
nutrient-induced GLP-1, PYY and CCK release were somewhat contradictory. 
Stimulation ex vivo of  ileal tissue segments with safflower oil, sucrose and casein increased 
GLP-1 and PYY release in all cases. However, in vivo the effects of  macronutrient-
induced increases in GLP-1 and PYY plasma concentrations were less pronounced. 
GLP-1 plasma concentrations increased after delivery of  casein, whereas ileal delivery 
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of  sucrose and safflower oil did not. In contrast, delivery of  sucrose and safflower oil 
increased plasma concentrations of  PYY, whereas casein did not. An explanation for 
this may be that in the in vivo studies concentrations of  GLP-1 and PYY are analyzed 
in plasma, whereas in the ex vivo studies release from tissue segments was analyzed, 
which probably reflects paracrine effects. Once released from enteroendocrine 
L-cells, the active form of  GLP-1 is very rapidly degraded by dipeptidyl peptidase IV 
(DPPIV). It is therefore conceivable that paracrine and neurocrine effects on GLP-1 
and PYY release are missed by analyzing plasma concentrations after ileal delivery of  
macronutrients. The results on CCK were somewhat contradictory as well. CCK release 
was unaffected after exposure of  ileal tissue segments to casein, sucrose and safflower 
oil. In contrast, plasma concentrations of  CCK increased after ileal delivery of  casein, 
sucrose and safflower oil to volunteers. Although a previous study showed increased 
CCK plasma concentrations after ileal delivery of  safflower oil as well (19), this was 
somewhat surprising since CCK is present in the ileum only in very low amounts. Most 
CCK is present in the duodenum, which is bypassed in the ileal intubation studies (22). 
The differences in CCK release between ex vivo and in vivo may due to a paracrine or 
neurocrine feedback loop in vivo. Hypothetically, serotonin and/or GLP-1 released from 
ileal cells can activate serotonin- or GLP-1 receptors on vagal nerve endings or EECs in 
the more proximal parts of  the small intestine resulting in CCK release from cells in the 
duodenum. In the ex vivo model such a feedback loop would not function since isolated 
ileal segments were exposed to the stimuli. 
Taken together, the effects on satiety hormone release were not always comparable 
between the two different research models, which possibly may be due to the paracrine 
effects analyzed ex vivo vs. endocrine effects analyzed in vivo. Results show that the ex 
vivo model is a suitable tool to screen the effects of  various stimuli on local release of  
GLP-1 and PYY, and investigate the contribution of  other mediators such as serotonin. 
Furthermore, it was found that the macronutrients that induced GLP-1 and PYY release 
ex vivo, activated the ileal brake in vivo. Together these ex vivo and in vivo data support the 
idea of  the ileal brake as a potent mechanism for weight management.  
The ileal brake; a target for weight management?
The data presented in this thesis show that ileal delivery of  different macronutrients 
activates the ileal brake and results in increased satiation and the release of  satiety 
hormones. The ileal brake is the primary inhibitory feedback mechanism to control 
transit of  a meal through the GI tract in order to optimize nutrient digestion and 
absorption (23). Under physiological circumstances this mechanism is activated when 
macronutrients arrive in the ileum, resulting in inhibition of  gastric emptying and the 
transit of  nutrients through the duodenum and jejunum (24). The ileal brake concept 
was first discovered in humans when ileal fat perfusion in man was shown to result in 
an inhibition of  jejunal motility (25) and an increased transit time of  a solid meal (26). 
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Although nutrients infused into the duodenum and jejunum also activate an intestinal 
brake (17, 18, 27), intraileal lipid infusion results in stronger inhibitory effects as 
compared to intraduodenal lipid infusion (28). Whether ileal delivery of  macronutrients 
other than lipids would result in more pronounced inhibitory effects as compared to 
nutrient delivery to the duodenum and jejunum was still unknown. Our data showed 
that activation with undigested native protein has stronger effects on satiation and 
release of  GLP-1 and CCK as compared to duodenal and jejunal activation. Stimulation 
of  the ileum may have stronger braking effects since under physiological conditions, 
only small amounts of  undigested nutrients reach the distal small intestine (29, 30). 
Once undigested nutrients reach the ileum this may be a sign of  inefficient digestion 
and absorption by the proximal parts of  the small intestine. As a consequence, the 
ileum generates signals such as GLP-1 to inhibit further eating, resulting in more time 
to digest and absorb the nutrients before new food enters the GI tract. 
In the small intestine there are several mechanisms allowing to respond to fluctuations 
in nutrient levels (31), to make digestion and absorption as efficient as possible. One of  
these mechanisms is by  activation of  the so-called nutrient sensing receptors (32, 33). A 
large number of  G-protein coupled receptors (GPCRs) and ion-dependent transporters 
have been identified as enteroendocrine nutrient sensors. Glucose sensing receptors, 
protein sensing receptors, fatty acid sensing receptors and sweet taste receptors all have 
been identified and shown to be activated by specific macronutrients and tastants such 
as sweet, sour, salt  and umami (33-35). In addition to this nutrient receptor mediated 
hormone release, we found that serotonin released from ECCs contributes to (non-)
nutritional stimulated GLP-1 release from EECs in the ileum. We were able to study 
local small intestinal effects of  serotonin on GI hormone release by applying the ex 
vivo intestinal segment model. These data showed that serotonin is involved in nutrient 
sensing and that it stimulates GLP-1 release from the ileum via serotonin receptor-
mediated processes. Additionally, when the reuptake of  serotonin was inhibited 
by exposure to casein and safflower oil, GLP-1 release increased. These results all 
underline that serotonin is involved in nutrient-induced GLP-1 release. Previous studies 
also showed that serotonin stored in ECCs is involved in nutrient sensing. Interactions 
of  nutrients with GPCRs on these ECCs resulted in serotonin release (36-38). Taken 
together, these results support the idea that there may be more than one mechanism 
in the ileum involved in nutrient-induced GLP-1 release which consequently may 
contribute to satiation in vivo. 
Other studies already showed that serotonin is involved in food intake regulation (39). 
It is generally thought that increased availability of  serotonin or serotonin receptor 
activation inhibits food intake, whereas reduced availability of  serotonin or inhibition 
of  serotonin receptors induces feeding (40). Recently, it was shown that intraduodenal 
infusion of  tryptophan, the precursor of  serotonin, increases satiation and plasma 
concentrations of  CCK and GLP-1 (41). The authors of  this paper suggested that 
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L-tryptophan may increase brain availability of  serotonin and thereby increase satiation. 
However, most studies that investigate the role of  serotonin do not take into account 
that the vast majority (95%) of  our serotonin resides in the GI tract instead of  the brain 
or blood. Of  this serotonin approximately 90% is stored in the enterochromaffin cells 
(ECCs) and the other 10% is present in the serotonergic neurons of  the enteric nervous 
system (42). Serotonin located in the GI tract does not reach the brain, since it cannot 
cross the blood brain barrier (39). It is therefore highly likely that serotonin in the ileum 
may have a local effect on food intake regulation as well. Although it is known that 
serotonin released from ECCs activates intrinsic and extrinsic primary afferent neurons 
resulting in activation of  the peristaltic reflex (38, 43), there is a lack of  knowledge 
about the relation between serotonin released from ECCs and food intake regulation. 
One reason for this may be that it is very difficult to study the role of  serotonin on 
food intake regulation in the small intestine in humans as a separate process. Serotonin 
is involved in many different pathways which can lead to side-effects when these are 
experimentally manipulated. 
Ileal nutrient sensing; efficient and safe? 
Ileal delivery of  all macronutrients tested decreased energy intake to the same extent, 
although there were some differences in the effects on GLP-1, PYY and CCK release. 
The issue whether dietary intake of  lipid, protein and carbohydrate stimulates satiation 
and satiety to the same extent has received growing attention the past decade. Some 
investigators claim that dietary intake of  all macronutrients contribute to satiety to the 
same extent (44), whereas others suggested that calories derived from proteins have 
more satiating properties as compared to calories derived from carbohydrates and lipids 
(45-47). Although it was shown that high protein diets effectively reduce weight  (48), 
it has proven difficult to comply to these high protein diets for longer than 1 year 
(49, 50). We did not find differences in the satiating properties of  lipid, protein or 
carbohydrate in our models. The main difference compared to studies showing more 
satiating properties for protein, is that we investigated the effects of  small intestinal 
protein delivery, instead of  oral protein intake. When protein is ingested under 
physiological circumstances, gastric acid activates the conversion of  pepsinogen into 
the proteolytic enzyme pepsin which denatures orally ingested protein. Protein is then 
further digested by trypsin in the small intestine. Most of  the orally ingested protein is 
digested into peptides or free amino acids before entering the ileum (51). By intra-ileal 
nutrient infusion these proximal parts of  the gastrointestinal tract (e.g. mouth, stomach, 
duodenum and jejunum) are bypassed and undigested nutrients are delivered to the 
ileum. It was unknown thus far whether undigested casein delivered to the ileum results 
in efficient digestion and absorption as well. It was hypothesized that if  ileal casein is 
not efficiently digested and absorbed it may enter the colon. In the colon this protein 
can then be fermented by microorganisms which may result in production of  harmful 
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metabolites (52). We showed that ileal delivery of  undigested native macronutrients 
did not result in gastrointestinal complaints in healthy subjects, and did also not result 
in activation of  pro-inflammatory responses. Additionally, it was shown that ileal 
delivery of  native undigested casein resulted in efficient digestion and absorption of  
all amino acids present in casein. Plasma concentrations of  all amino acids present 
in casein immediately increased after intraileal protein delivery. The estimated amino 
acid digestion and absorption efficiency was comparable to a previous study showing 
that intrajejunal infusion of  an amino acid mixture resulted in very rapid and efficient 
absorption (53).  Recently it was also shown that protein digestion and absorption is 
accelerated after Roux-Y gastric bypass (RYGB) (54). These and other results of  studies 
investigating the effects of  RYGB support the hypothesis that the distal small intestine 
is able to sense and process nutrients resulting in efficient digestion and absorption of  
nutrients and activation of  satiation. 
RYGB is a surgical procedure were nutrients are shunted to the more distal parts of  the 
small intestine. This surgery is the most effective bariatric surgery procedure, resulting 
in weight loss which is maintained for at least 20 years. Moreover, this intervention is 
effective in reducing obesity related comorbidities such as type II diabetes and overall 
mortality (55, 56). The exact mechanism of  how RYGB exerts its beneficial effects is 
not completely understood. It is hypothesized that these effects are a result of  increased 
nutrient exposure of  the distal small intestine. This is supported by the findings that 
RYGB results in increased density of  GLP-1, PYY, CCK immuno-reactive cells 
coupled with increased expression of  encoding preproglucagon (57), and also increased 
postprandial plasma levels of  GLP-1, PYY and CCK (58-60). Additionally, there are 
studies suggesting that post RYGB surgery, both taste preferences and the activity of  
brain areas involved in food rewarding shift towards a pattern normally seen with more 
healthy foods (61-66).These results, together with the results presented in this thesis all 
contribute to the idea that there are several mechanisms in the distal small intestine that 
respond to fluctuations in nutrient levels making digestion and absorption as efficient as 
possible,  resulting in increased satiation and improved insulin sensitivity (67-69). 
Taken together, the most effective strategy for weight management so far is RYGB, 
but this intervention is only applied to patients with severe obesity and (or) severe 
risk factors or comorbidities. The data presented in this thesis show that ileal nutrient 
delivery could be a promising strategy for future weight management strategies. 
Recommendations for future research 
Although ileal nutrient delivery has been shown to be a promising strategy for weight 
management strategies, more studies are needed to confirm its practical value and to 
investigate the underlying mechanisms behind the ileal brake as a target for weight 
management. By improving our understanding of  the mechanisms by which the ileal 
brake operates, it may be possible to develop strategies that target its activation. However, 
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approaches or strategies other than intraileal infusion are needed to deliver (non)
nutritional stimuli to the ileum. In this paragraph suggestions and recommendations for 
future research are presented focusing on the ileal brake as a potential target for weight 
management. 
To better understand how various (non-)nutritional stimuli result in GLP-1 release it 
would be interesting to investigate which specific serotonin receptor(s) is(are) responsible 
for serotonin-induced GLP-1 release. When this is known it may offer potential targets 
for nutritional or pharmacological approaches to stimulate GLP-1 release. However, it 
should be noted that there are already several pharmacological anti-obesity approaches 
available but none of  these have been shown to be as effective as RYGB. One such anti-
obesity drug is liraglutide, a GLP-1 analogue that recently has been approved.  When 
combined with a restriction of  500 kcal/day and with increased physical activity (≥150 
min/wk), this drug results in weight loss of  6% (70). Comparable to this effect most 
anti-obesity drugs available so far claim to achieve 3-5% weight loss after 3 months 
(71) or claim to contribute to weight maintenance after a (very) low caloric diet  (72). 
Although a loss of  <5% of  body weight may already improve health, safety and costs 
need to be considered as well. The disadvantage of  using these anti-obesity drugs is 
that while mostly aiming to target 1 specific process involved in food intake regulation, 
so-called off-target effects often lead to several side-effects. It would therefore be 
more interesting to investigate if  nutritional approaches that stay more close to normal 
physiology, such as ileal nutrient delivery, can result in weight loss. Indeed there is 
evidence that foods that are less easily digested, such as “slow foods”, are more satiating 
and have potential to reduce the risk on obesity and type II diabetes (73).  
To develop effective weight management strategies that target ileal brake activation there 
are still some issues to solve. First, the most optimal conditions to activate the ileal brake 
should be further investigated. One such condition is selection of  the most optimal 
food compound(s) or food mixture to activate the ileal brake. So far only the effects 
of  single nutrient stimuli on the ileal brake have been studied. Since there are various 
mechanisms operating in the ileum sensing different nutrients or non-nutritional stimuli 
(e.g. rebaudioside A), it may be possible that combinations induce stronger effects on 
satiation as compared to single (non-)nutrient stimuli. A previous study showed that 
the combination of  sucralose and pea protein increases GLP-1 and CCK release more 
in comparison to these stimuli alone from both STC-1 cells and human duodenal 
biopsies (74). However, up to now there are no in vivo studies that compare the effects 
of  intraileal infusion of  nutrient combinations with  that after single nutrient infusions. 
Another condition which should be taken into account is the gastric load at the time 
the ileal brake is activated. In our human studies it was shown that when the stomach 
was still partially filled just before ileal brake activation the decrease in food intake was 
130 kcal. By contrast, this difference was 90 kcal if  the stomach was empty just before 
ileal brake activation. More studies show the importance of  gastric distension in the 
Ch
ap
te
r 8
GENERAL DISCUSSION 
153
regulation of  appetite and food intake (75-77). Therefore, gastric distension and thus 
the timing of  ileal nutrient delivery, should be taken into account in order to achieve the 
most optimal effects of  ileal brake activation on energy intake. 
Second, the data presented in this thesis show the effects of  single intraileal infusions 
whereas data about the long term effects of  ileal brake activation are still lacking. The 
efficacy of  repeatedly targeting the ileum with undigested macronutrients or other food 
compounds remains to be investigated. Future studies should investigate whether the 
reduction of  approximately 80-130 kcal after a single intraileal infusion is effectively 
limiting overall daily energy intake and whether this does not result in compensation of  
these kcal during a day. In addition, the effects on safety of  repeatedly targeting the ileum 
should be investigated. However, based on literature describing patients undergoing 
RYGB it seems unlikely that repeatedly targeting the ileum results in adverse effects 
such as malabsorption (68).
Third, future studies should investigate whether stimulation of  the ileal brake is 
effective in overweight and obese subjects as well. There are some contradictory results 
on food suppressing effects of  intraduodenal nutrient infusion in lean compared to 
obese subjects. One study showed a less pronounced suppression of  food intake 
after intraduodenal lipid infusion in obese subjects (78), whereas others did not find 
differences in appetite-suppressing effects of  intraduodenal protein infusion between 
lean and obese subjects (16).  Since there are no studies known that compare the effects 
of  intraileal delivery of  macronutrients in lean and obese subjects, future studies should 
investigate if  ileal brake activation efficiently reduces energy intake in overweight and 
obese subjects as well. 
Fourth, in our studies macronutrients were delivered using an naso-ileal feeding catheter. 
This method is to invasive to apply daily for a longer period. Hence, non-invasive 
techniques need to be invented to deliver food compounds to the ileum. One such 
approach that has been suggested to active the ileal brake is by OlibraTM (Fabuless), which 
is an emulsified fat included in a yoghurt. However, results of  studies which investigated 
the effects of  OlibraTM are very inconsistent and mostly without affecting energy intake 
or body weight (79-85). One explanation for the lack of  efficiency of  OlibraTM may 
be the absence of  evidence that this fat emulsion reaches the ileum. Therefore, the 
feasibility of  reaching the ileum with relatively large amounts of  nutrients should be 
investigated. One such delivery technique would be microencapsulation. This technique 
may be applied to carry for example macronutrients that need to be protected from 
influences in the proximal GI tract to the ileum at which the macronutrient should be 
released (86). The advantage of  microencapsulation is that nutrients can be incorporated 
in a food product, for example a drink. For ileal nutrient delivery via microencapsulation 
the gastric emptying rate, and intestinal transit time should be considered as well. The 
intestinal transit time highly varies with gender, age, BMI, feeding status (fasted or fed) 
and the nutrient load (e.g. liquids or solid) (87). Therefore, the time between intake 
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of  the microencapsulated food compound and the next meal should be optimized in 
order to have the most optimal brake effects. There are two other research groups 
that successfully applied microencapsulation to deliver food components to the distal 
small intestine. They showed that whereas ileal delivery of  6 gram glutamine resulted 
in enhanced GLP-1 release, food intake inexpertly increased (88). In another study the 
short chain fatty acid propionate was delivered to the colon in the form of  an inulin 
proprionate ester. This resulted in increased PYY and GLP-1 release, a reduction of  
energy intake and prevention of  weight gain (89). Although more research is needed to 
investigate its efficiency, microencapsulation may be a tool to deliver macronutrients or 
other food compounds to the ileum. 
Overall, future research should investigate the most optimal conditions to activate the 
ileal brake. This includes timing of  ileal brake activation and activation by one single 
nutrient or (non-)nutritional nutrient mixtures. Furthermore, the efficacy of  ileal 
brake activation in overweight and obese people and of  repeatedly targeting the ileal 
brake should be investigated. Besides these aspects, non-invasive techniques, such as 
microencapsulation, to deliver (non-)nutritional stimuli to the ileum should be further 
developed.
Concluding remarks
The data presented in this thesis show that macronutrient delivery to the ileum results 
in activation of  satiety signals and reduction of  energy intake. Besides direct nutrient-
receptor interaction, the ileum efficiently senses (non-)nutritional stimuli via serotonin 
mediated processes resulting in GLP-1 release. Together these results show that cells 
in the intestinal epithelium of  the ileum efficiently sense undigested native (non-)
nutritional stimuli resulting in efficient digestion, absorption, activation of  satiety 
signals and finally a reduction of  energy intake. Conclusively, this demonstrates that 
ileal delivery of  (non-)nutritional stimuli has potential as a weight management strategy. 
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There is a clear need to develop preventive strategies for overweight. Worldwide, in 
2014, more than 1.9 billion adults were overweight of  which 600 million were obese. 
Also in the Netherlands this number was strikingly high; in 2014, 43.2% of  the adults 
were overweight, of  which 12.3% were obese. The only effective weight loss treatment 
so far is bariatric surgery. This surgery does not only result in long term weight loss, 
but also in improved metabolic health. Studies on bariatric surgery have suggested that 
signals from the small intestine contribute to the beneficial effects of  this treatment. 
However, bariatric surgery is only applied when people are extremely obese (BMI >35 
kg/m2). Although it is well known that excessive energy intake and an inactive life style 
result in overweight, developing preventative strategies that help people to maintain a 
healthy body weight have proven difficult so far. For this reason, there is a clear need 
for other non-surgical weight management strategies to prevent people from excessive 
energy intake. These strategies may be invented by addressing how targets in the small 
intestine activate satiety signals. The research presented in this thesis aimed to investigate 
small intestinal targets that may contribute to food intake regulation. 
Several receptors and transporters along the gastrointestinal tract detect and sense the 
presence of  macronutrients. As a result a number of  hormones including glucagon 
like peptide-1 (GLP-1), peptide YY and cholecystokinin are released. These hormones 
activate satiation and satiety and are therefore called satiety hormones. For the research 
presented in this thesis it was investigated in chapter 2 and chapter 3 which (non-)
nutritional stimuli stimulate GLP-1 and PYY release.  Furthermore, we investigated 
if  serotonin is involved in sensing these (non-)nutritional stimuli and if  serotonin 
contributes to GLP-1 release.
Once released from the small intestine, GLP-1, PYY and CCK can act in a paracrine 
fashion to neighboring cells, in a neural fashion via receptors located on vagal nerve 
endings or act in an endocrine fashion  via the blood. In chapter 4 we investigated the 
contribution of  neural and endocrine signaling to food intake regulation. This was done 
by evaluating if   CCK and GLP-1 activate satiation via their receptors located at vagal 
nerve endings or via receptors elsewhere in the body. 
When macronutrients are delivered to the distal parts of  the small intestine they can 
activate the so-called intestinal brake mechanism. We investigated if  ileal nutrient delivery 
resulted in the strongest effects on satiation. In chapter 5 it was investigated if  the ileal 
brake is stronger in activating satiation compared to the duodenal and jejunal brake, 
and in chapter 6 we investigated if  all macronutrients that are delivered to the ileum 
increase satiation. Finally, in chapter 7 we investigated if  protein that is delivered to the 
ileum is efficiently digested and absorbed and does not result in adverse effects such as 
malabsorption. The main findings, methodological considerations and interpretation 
of  these findings are discussed in chapter 8, as well as implications and directions for 
future research. 
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Is serotonin involved in (non-)nutritional induced GLP-1 release?  
It was found that all macronutrients, including lipid (safflower oil), protein (casein) and 
carbohydrate (sucrose), stimulate GLP-1 and PYY release from ileal tissue segments. 
On top of  these macronutrients a natural non-caloric sweetener (rebaudioside A) was 
found to stimulate GLP-1 and PYY release as well.  Although some macronutrient-
receptor interactions were known to result in GLP-1 release, such an interaction was not 
described for all macronutrients and non-nutritional stimuli. Therefore, we investigated 
the hypothesis that an additional serotonin-mediated mechanism is involved in (non-)
nutritional-induced GLP-1 release.  We found that serotonin is released upon protein 
and fat stimulation. Additionally, inhibiting the reuptake of  serotonin reuptake resulted 
in enhanced GLP-1, PYY and CCK release. Furthermore, we found that serotonin 
stimulates GLP-1 release from ileal tissue segments and from enteroendocrine cells 
via a serotonin receptor mediated process. This was the first study that showed that 
serotonin mediates nutrient-induced GLP-1 release from ileal tissue segments.   
Do CCK and GLP-1 activate satiation in a neurocrine or an endocrine 
fashion?
How CCK and GLP-1 receptors present on the vagal nerve contribute to satiation was 
investigated by studying ad libitum food intake using vagotomized pigs and by blocking 
CCK and/or GLP-1 receptors. Food intake increased after CCK receptor blockade 
in both vagotomized and sham-operated pigs, suggesting that interruption of  the 
abdominal vagal nerve does not contribute to satiation. Blocking the GLP-1 receptors 
did not affect food intake in both groups. Although interruption of  the vagal nerve 
did not affect food intake, it did increase gastrointestinal transit time and affected the 
postprandial responses of  glucose, insulin, CCK and GLP-1. These results showed that 
GLP-1 and CCK receptors present on the vagal nerve contribute less to satiation in 
comparison to GLP-1 and CCK receptors elsewhere in the body. However, these results 
also showed the importance of  the vagal nerve for the gastrointestinal transit of  food. 
Ileal brake activation; a strong and safe effect on satiation? 
In this thesis it has been shown that ileal delivery of  small amounts of  all macronutrients 
result in activation of  satiety signals and in a reduction of  food intake. Moreover, it was 
found that the ileal brake has stronger effects on satiation as compared to the duodenal 
and jejunal brake. Ileal delivery of  undigested native protein resulted in decreased energy 
intake and increased GLP-1 plasma concentrations compared to placebo.
Bypassing the proximal parts of  the gastrointestinal tract (mouth, stomach, duodenum 
and jejunum) did not affect the digestion and absorption of  protein. Undigested casein 
protein, delivered to the ileum, was efficiently digested and absorbed as amino acids. 
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Additionally ileal protein delivery did not activate immune responses, nor gastrointestinal 
complains, suggesting that ileal protein delivery is safe. 
Concluding remarks 
Altogether the data presented in this thesis show that all macronutrients delivered to 
the ileum result in activation of  satiety signals and reduction of  energy intake. Ileal 
stimulation resulted in the strongest activation of  satiety signals and energy intake 
reduction compared to duodenal or jejunal stimulation. Besides direct nutrient-receptor 
interaction, the ileum senses (non-)nutritional stimuli via serotonin mediated processes 
resulting in GLP-1 release. Conclusively, these results demonstrate that ileal delivery of  
(non-)nutritional stimuli has potential as a weight management strategy.
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Overgewicht en obesitas zijn beide een 
wereldwijd probleem. Volgens het Centraal 
Bureau voor de Statistiek had in 2014 meer 
dan 43.8% van de Nederlandse bevolking 
overgewicht en van deze mensen had 
12.3% obesitas. Obesitas is een groot 
probleem voor de samenleving omdat 
obesitas het risico verhoogt op allerlei 
ziekten zoals diabetes type II, hart- en 
vaatziekten en zelfs sommige vormen van 
kanker. Het is daarom van groot belang 
dat er methodes worden ontwikkeld om 
overgewicht en obesitas te voorkomen. 
De meest voorkomende oorzaken van 
overgewicht en obesitas zijn een inactieve 
leefstijl en een overmatige voedselinname. 
Er zijn weinig succesvolle methodes om 
overmatige voedselinname te voorkomen. 
Door te onderzoeken hoe voedselinname 
door het lichaam wordt gereguleerd kunnen er methodes ontwikkeld worden om 
overmatige voedselinname te beperken en daardoor overgewicht en obesitas te 
voorkomen. 
Een belangrijk deel van de voedselinname wordt gereguleerd door de dunne darm. Dit 
blijkt, onder andere uit studies waarbij mensen een ‘gastric bypass’ operatie ondergaan. 
Op basis van dit onderzoek zijn een aantal processen in de dunne darm onderzocht die 
relevant zijn bij de voedselinname regulatie, zij zijn verantwoordelijk voor het stoppen 
met eten tijdens de maaltijd (verzadiging). Wanneer bekend is hoe deze processen 
werken, kunnen er voedingsmiddelen worden ontwikkeld die verzadiging activeren en 
daarmee overmatig eten kunnen voorkomen (hoofdstuk 1). De onderzochte processen 
zijn; het zogenaamde ‘intestinal brake’ mechanisme, de activatie van de nervus vagus en 
de rol van het signaalmolecuul serotonine. 
Het maagdarmkanaal bestaat uit de slokdarm, maag, dunne darm en de dikke darm. De 
dunne darm bestaat uit drie delen. De twaalfvingerige darm (duodenum), de nuchtere 
darm (jejunum) en de kronkeldarm (ileum). Gedeeltelijk verteerde voedingsmiddelen 
komen in contact met de wand van de dunne darm en zo kunnen ze uiteindelijk in 
het lichaam worden opgenomen. De meeste voedingsstoffen worden al in het eerste 
en tweede deel van de dunne darm opgenomen. In het maagdarmkanaal zitten allerlei 
sensoren die de aanwezigheid van voedingsstoffen waarnemen. Als gevolg van deze 
waarneming, worden er hormonen uitgescheiden die zorgen voor een verzadigd gevoel, 
en dus de verdere voedselinname tijdens een maaltijd remmen. Deze hormonen zijn 
Wat is obesitas?
Volgens de 
Wereldgezondheidsorganisatie 
(WHO) is obesitas een aandoening 
waarbij vet zich zodanig overmatig 
in het lichaam opstapelt, dat dit 
aanleiding geeft tot
gezondheidsrisico’s.
Wanneer de ‘Body Mass Index’ 
(BMI), welke gedefinieerd is als 
de verhouding tussen lengte en 
gewicht (kg/m2), gelijk is aan of  
hoger is dan 25, dan is er sprake 
van overgewicht. Er is sprake van 
obesitas wanneer iemand een BMI 
heeft gelijk aan of  hoger dan 30.
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onder andere glucagon like peptide-1 (GLP-1), peptide YY (PYY) en cholecystokinin 
(CCK). 
In hoofdstuk 2 is er onderzocht welke voedingsstoffen de afgifte van GLP-1, PYY en 
CCK stimuleren. Uit dit onderzoek blijkt dat wanneer het ileum in contact komt met 
macronutriënten zoals vet (saffloer olie), eiwit (caseïne eiwit) en koolhydraat (sucrose) 
of  zelfs met een calorie-loze zoetstof  (rebaudioside A), de afgifte van GLP-1 en PYY 
gestimuleerd wordt.  
Verder blijkt uit het onderzoek beschreven in hoofdstuk 3 dat serotonine, een 
signaalmolecuul aanwezig in het ileum, betrokken is bij de in hoofdstuk 2 bestudeerde 
macronutriënt-geïnduceerde afgifte van GLP-1. Uit hetzelfde onderzoek blijkt dat 
serotonine gestimuleerde GLP-1 afgifte gemedieerd wordt door een serotonine receptor. 
Nadat GLP-1, PYY en CCK worden uitgescheiden kunnen deze hormonen op een aantal 
manieren een verzadigd gevoel opwekken. Dit kan door; 1. processen in  naastliggende 
cellen te activeren (paracrien), 2. zenuwen te activeren (neuraal) of  3. processen ergens 
anders in het lichaam te activeren via het bloed (endocrien). In hoofdstuk 4 wordt 
onderzocht in welke mate  neurale en endocriene signalering bijdragen aan verzadiging 
in het varken. De resultaten van deze studie laten zien dat CCK verzadiging activeert via 
endocriene signalering, en in mindere mate door neurale signalering via CCK receptoren 
op de nervus vagus. 
      
Ileal brake activatie: de maag, duodenum en het jejunum overslaan 
om minder te eten?  
Het laatste proces dat is onderzocht is het zogenaamde ‘intestinal brake’ mechanisme. 
De ‘intestinal brake’ wordt geactiveerd wanneer er onverteerde voedingsstoffen in 
het duodenum, jejunum of  ileum terecht komen. Activatie van het ‘intestinal brake’ 
mechanisme zorgt voor verhoogde verzadiging en een geremde passage en vertering 
van voedsel. Dit komt onder andere omdat er verzadigingshormonen zoals CCK, GLP-
1 en PYY worden uitgescheiden. Wij hebben onderzocht of  activatie van de ‘ileal brake’ 
sterkere effecten heeft op verzadiging vergeleken met activatie van de ‘duodenal brake’ 
of  de ‘jejunal brake’. Dit is onderzocht in gezonde vrijwilligers door eiwit (caseïne) 
of  een controle behandeling (water) in het duodenum, jejunum of  ileum te spuiten 
(infuseren) met behulp van een slangetje (sonde). Uit deze studie blijkt dat  eiwitinfusie 
in het ileum, grotere effecten heeft op verzadiging en afgifte van het hormoon GLP-1 
vergeleken met eiwit infusie in het duodenum of  jejunum (hoofdstuk 5). 
In hoofdstuk 6 is onderzocht of  de ‘ileal brake’ door alle soorten macronutriënten 
(vet, eiwit en koolhydraat) kan worden geactiveerd. Deze vraag is onderzocht 
door de hoeveelheid voedselinname te meten na infusie van verschillende soorten 
macronutriënten in het ileum. Er zijn voor deze studie gelijke hoeveelheden (51.7 kcal) 
vet (saffloer olie), eiwit (caseïne) of  koolhydraat (sucrose) in het ileum geïnfuseerd. De 
resultaten van deze studie laten zien dat ileale infusie van zowel vet, eiwit als koolhydraat 
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zorgen voor een verminderde voedselinname, die in alle drie de gevallen even groot is. 
Hieruit blijkt dat ileale infusie met alle soorten macronutriënten verzadiging activeert en 
voedselinname verlaagd in gezonde vrijwilligers. 
Wanneer macronutriënten in het ileum worden geïnfuseerd worden er belangrijke 
verteringsstappen overgeslagen. Daarom hebben we onderzocht of  het eiwit (caseïne) 
dat in het ileum wordt geïnfuseerd wordt verteerd en opgenomen (hoofdstuk 7). Uit 
dit onderzoek blijkt dat ileale infusie van onverteerd eiwit efficiënt wordt verteerd en 
opgenomen. Verder laten de resultaten van dit onderzoek zien dat ileale infusie van 
onverteerd eiwit niet leidt tot een immuun respons. Samen met de bevinding dat de 
vrijwilligers geen klachten hadden voor, tijdens of  na de infusies suggereren deze 
resultaten dat infusie van onverteerd eiwit in het ileum niet leidt tot nadelige effecten.  
Algemene discussie
Tot slot wordt een kort overzicht gegeven van de belangrijkste bevindingen van dit 
proefschrift (hoofdstuk 8). Ook worden de voor- en nadelen van de gebruikte 
onderzoeksmethoden besproken, en worden de gevonden resultaten vergeleken met 
eerdere bevindingen in de wetenschappelijke literatuur. Ook worden in dit hoofdstuk 
suggesties gedaan voor vervolgonderzoek evenals suggesties over hoe de belangrijkste 
bevindingen uit dit proefschrift te gebruiken om overmatig eten te voorkomen.  
 
Het onderzoek in dit proefschrift heeft laten zien dat het introduceren van kleine 
hoeveelheden onverteerde macronutriënten in het ileum een succesvolle strategie kan 
zijn om mensen minder te laten eten, omdat: 
1. Macronutriënten in het ileum efficiënt worden waargenomen: alle soorten 
macronutriënten die worden afgeleverd in het ileum stimuleren GLP-1 afgifte. Dit 
gebeurt onder andere via serotonine gemedieerde processen. 
2. Eenmalige toediening van kleine hoeveelheden onverteerde macronutriënten in het 
ileum niet leidt tot nadelige effecten.  
3. Aflevering van macronutriënten in het ileum sterkere effecten op verzadiging en 
voedselinname heeft in vergelijking met aflevering van macronutriënten in het 
duodenum of  in het jejunum. 
4. Aflevering van relatief  kleine hoeveelheden macronutriënten (51.7 kcal) resulteren 
in  een afname in voedselinname (80 -130 kcal). 
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